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ABSTRACT
Dendrites and the dendritic spines of neurons play key roles in the connectivity of the
brain and have been recognized as the locus of long-term synaptic plasticity, which is correlated
with learning and memory. The development of dendrites and spines in the mammalian central
nervous system is a complex process that requires specific molecular events over a period of
time. It has been shown that specific molecules are needed not only at the spine’s point of
contact, but also at a distance, providing signals that initiate a cascade of events leading to
synapse formation. The specific molecules that act to signal neuronal differentiation, dendritic
morphology, and synaptogenesis are tightly regulated by genetic and epigenetic programs. It has
been shown that the dendritic spine structure and distribution are altered in many diseases,
including many forms of mental retardation (MR) such as Rett syndrome, and can also be
potentiated by neuronal activities and an enriched environment. Because dendritic spine
iv

pathologies are found in many types of MR, it has been proposed that an inability to form normal
spines leads to the cognitive and motor deficits that are characteristic of MR. Epigenetic
mechanisms, including DNA methylation, chromatin remodeling, and the noncoding RNAmediated process, have profound regulatory roles in mammalian gene expression. My
dissertation research focused on two aspects of epigenetic mechanisms, Mecp2-DNA
methylation pathway and noncoding microRNAs that regulate the development and maturation
of dendrites and spines. It is well known that Rett Syndrome, a severe postnatal childhood
neurological disorder is mostly caused by mutations in the MECP2 gene. My studies focused on
the role of MeCP2-mediated epigenetic regulation in postnatal brain development in a Mecp2deficient mouse model. I found that, while Mecp2 was not critical for the production of
immature neurons in the dentate gyrus (DG) of the hippocampus, the newly generated neurons
exhibited profound deficits in neuronal maturation, including delayed transition into a more
mature stage, altered expression of presynaptic proteins, and reduced dendritic spine density.
Furthermore, I found that cultured neurons and brains lacking Mecp2 exhibited altered
expression of microRNAs. My studies demonstrate that one brain-enriched microRNA, miR137, has a significant role in regulating neuronal maturation by translational regulation of Mind
bomb1. Despite extensive efforts to understand the molecular regulation of dendrite and spine
development, epigenetic and non-coding RNA pathways have only recently been considered. In
this thesis, I will first summarize the literature on epigenetic mechanisms that regulate the
development and maturation of dendrites and spines, and discuss some general methodologies as
well as recent technological advances in biology and neurosciences. I will then present my own
data to show how epigenetic alterations could result in the morphological and phenotypic
abnormalities that are a fundamental characteristic MR, such as Rett syndrome.
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CHAPTER 1:
Neuronal Dendrites and dendritic spines in development and
disease
(Chapters 1-3 were published in a recent review article (Smrt and Zhao, 2010))

1.1 Introduction to neuronal dendrites and dendritic spines

Santiago Ramon y Cajal, the founder of neuroscience and Nobel Prize winner, was the
first to propose in the late 19th century that the nervous system is made up of individual neurons
that are able to communicate with neighboring cells through long projecting axons and highly
branched dendrites. He first described dendritic spines in 1891 as “the tips of charge or points of
reception of impulses, their retraction would result in the individualization or disaggregation of
neurons. The awake state would correspond to the swelling and lengthening of spines, while the
resting state would correspond to the retraction of these appendages” (Cajal, 1891).
Cajal’s observations were based on Golgi staining and a light microscope over 100 years
ago. To date, significant advances in biology have confirmed that dendritic spines can undergo
long-term modifications, such as changes in number and shape, in response to novel experiences,
suggesting that dendritic spines are the locus of long-term synaptic plasticity associated with
memory storage in the brain (Segal, 2005). In light of advances in genetic and molecular tools,
scientists still ponder why dendrites and dendritic spines become grossly impaired in individuals
faced with mental retardation (MR) and neuropathology.
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The brain is composed of a complex network of neurons that communicate with each
other through specialized cell junctions called synapses (Figure 1.1A,B). Most of these synaptic
junctions are chemical synapses, in which a chemical neurotransmitter is released by the axon of
the presynaptic neuron. The neurotransmitter can diffuse into the synaptic cleft (space between
synaptic contact), where it can act on the corresponding neurotransmitter receptors on the
postsynaptic neuron (Figure 1.1B). The synapses are typically found on the dendritic shaft,
located on stubby spines and filipodia (long, thin dendritic protrusions), and are characterized by
the clustering of certain proteins on the pre- and postsynaptic sites of contact. Dendritic spines
have been classified into many types based on their shape. The most common types of spines in
the central nervous system (CNS), and also the primary focus of pathological studies, are the
following: mushroom-like spines with a bulbous head attached to the dendrite by a narrow neck,

Figure 1.1: Schematic diagram of a mature neuron and synapse. A: A mature neuron has elaborate processes that
are composed of multiple dendrites and one axon. Dendrites contain a large number of dendritic spines that form
contacts, or synapses, with other neurons. The synapses are typically found on the dendritic shaft, located on
stubby spines and filipodia. B: A neuronal synapse is the point of contact between two neurons, a presynaptic
neuron and a postsynaptic neuron. It is characterized by specific synaptic proteins located on the pre and
2
postsynaptic sites.

Figure 1.2: Common dendritic spine types in the
CNS. Three types of dendritic spines are commonly
found in the CNS. A: the long and thin filipodia spine
with no head enlargement; B: the mushroom-like
spine with a bulbous head attached to the dendrite by
a narrow neck; and C: the short and stubby spine with
no neck. It is believed that long, thin spines are
mostly immature spines, and they develop into the
more mature mushroom-like spines.

short and stubby spines with no neck, and long and thin spines with no head enlargement (Fiala
et al., 2002). It is believed that long, thin spines are mostly immature spines, and they develop
into the more mature mushroom-like spines (Figure 1.2). During development, dendrites start out
with no spines, and during synaptogenesis and neuronal maturation, filipodia emerge from the
dendrites and form nascent synapses with axons (Fiala et al., 1998; Fiala et al., 2002). Mature
synapses are gradually formed on mushroom-like spines that have a well-defined head (Harris
and Kater, 1994), and the density of mature spines increases along the dendrite as the neuron
matures and forms functional connections with the surrounding brain circuitry (Zhao et al., 2006)
(Figure 1.3). More about the specific molecular machinery found in the mature excitatory
synapse will be discussed in the next section.

1.2 Activity-dependent modulation of gene expression controls dendrite
and spine development

Glutamatergic neurons in the mammalian brain have elaborate dendrites covered with
dendritic spines. These spines function as the primary sites of excitatory synaptic input for the
neuron (Alvarez and Sabatini, 2007). The formation of an excitatory synapse in the CNS during

3

Figure 1.3: The stages of morphological development of dendrites and dendritic spines. A: Immature neurons
have shorter dendrites, and these dendrites have no spines. B: During synaptogenesis and neuronal maturation,
neurons develop a more complex dendritic arbor, and these dendrites begin to form spines. Some of these spines
start to receive input from the axons of other neurons. C: Mature neurons have elaborate dendritic trees and a high
density of mature spines. These neurons form functional connections with other neurons and participate in the
brain circuitry.

development is initiated by the contact between the presynaptic axon and the postsynaptic
dendrite, followed by the recruitment of pre- and postsynaptic proteins to the site of contact, and
the stabilization of these interactions. Dendritic development and synapse formation are highly
influenced by neuronal activities. Spine pruning occurs during early postnatal development,
characterized by an experience-dependent loss of spines that selectively maintains spines of
4

active synapses resulting in the appropriate maturation of neuronal circuitry (Grutzendler et al.,
2002).
A major area of research in neurodevelopment is how neuronal activity-dependent
modulation of gene expression affects dendritic development and synapse formation. It has been
shown that dendritic and spine morphogenesis depends on proper neuronal development and
activation of glutamate receptors, which maintain appropriate connections between neurons
(Parrish et al., 2007b). Activation at the synapse leads to calcium influx into the dendrites of the
postsynaptic neuron, which regulates the dendritic outgrowth of postsynaptic neurons. Calcium
not only functions locally at the site of entry, but also leads to changes in gene transcription in
the nucleus. Calcium influx through the NMDA receptor or voltage-sensitive calcium channels
(VSCCs) during development can activate many signaling pathways, such as the calciumsensitive calcium/calmodulin kinases (CaMKs) known to be important for signal transduction in
neurons. For example, activated CaMKII regulates the number of AMPA receptors at the
synapse and the complexity of neuronal dendrites by influencing actin cytoskeleton (Dillon and
Goda, 2005). In cultured neurons, CaMK activity initiates signaling to the nucleus, where
activation of cAMP response element binding protein (CREB) leads to activity-dependent gene
expression and subsequent dendritic morphological changes (Redmond et al., 2002; Wayman et
al., 2006). Thus, intrinsic gene expression programs can be modified by neuronal activity to
modulate spine morphogenesis and dendritic development (Cohen and Greenberg, 2008).

1.3 Dendritic spine pathology
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Because spines are the key sites of synaptic input, altered spine morphology associated
with pathological conditions may have a dramatic impact on the properties of the individual
neuron, the neural networks, and mental function as a whole. In fact, dendritic spine distribution
and structure is abnormal in many diseases and injuries, as well as many forms of MR (Figure
1.4). Thus, it has been proposed that the cognitive and motor deficits observed in MR may result
from altered spine development and function. Understanding the effect of altered spines in
pathological conditions will provide researchers with a better understanding of how spines
contribute to normal synaptic conditions during development and learning in the adult brain.

Figure 1.4: Pathological changes in spine density. Common pathological alterations in dendritic spines are altered
spine density and abnormal spine shapes. A: Healthy neuronal dendrites contain spines with a typical variation of
spine types. B: Reduced spine density is common in many cognitive and developmental disorders, such as Rett
syndrome. C: Increased spine density with abnormally increased long and thin types of spines is commonly found
in patients with fragile X syndrome.

As summarized in Table 1, morphological dendritic spine abnormalities are found in
many types of pathological conditions, including MR such as is seen in autism spectrum disorder
(Persico and Bourgeron, 2006), Rett syndrome (Zhou et al., 2006), and fragile X syndrome
(Bagni and Greenough, 2005). Spine abnormalities are also found in schizophrenia (Lewis et al.,
2003b), depression, stress (Pittenger and Duman, 2008), drug addiction (Robinson and Kolb,
2004), epilepsy, and neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s
disease (Day et al., 2006), and Huntington’s disease (Spires et al., 2004).

Table 1.1: Spine pathology related to genetic mutations and mental retardation.
6

Disorder
Rett syndrome

Genetic abnormality
MECP2 mutation

Fragile X syndrome

FMR1 protein deficiency

Angelman syndrome

Chromosome 15q11-q13,
UBE3A

Prader–Willi syndrome

Chromosome 15q11-q13

Down’s syndrome

Chromosome 21 trisomy

Lafora disease
Patau syndrome

EPM2 mutation
Chromosome 13 trisomy

Tuberous sclerosis

Mutations of TSC1 or TCS2
genes

Niemann–Pick disease

Deficiency of
sphingomyelinase

Potocki–Lupski syndrome
Smith–Magenis syndrome

Duplications of 17p11.2
Chromosome 17p11.2, RAI1
mutations
7q11.23 (CYLN2, LIMK1,
FZD9)

Williams–Beuren
syndrome

22q11.2 deletion
syndrome and DiGeorge
syndrome

Spine pathology
Reduced spine
density, reduced
dendritic complexity
and maturation
Increased spine
density, abnormal
spine morphology
Reduced spine
density, abnormal
spines, small RNA
pathway
Autism, reduced
cognitive ability
Reduced spine
density, reduced
dendritic complexity

Reduced spine density
Abnormal spine
morphology
Reduced spine
density, abnormal
spine morphology
Reduced spine
density, reduced
dendritic complexity
Autism
Autism, abnormal
brain anatomy
Reduced brain
volume, altered spine
morphology

Deletion of 22q11.2, DGCR8

miRNA pathway,
autism, smaller
spines, smaller
dendrites

Reference
(Amir et al., 1999;
Belichenko et al., 1994;
Moretti et al., 2006; Smrt
et al., 2007)
(Comery et al., 1997;
Hinton et al., 1991; Irwin
et al., 2001; Wisniewski et
al., 1991)
(Ding et al., 2008; Lalande
and Calciano, 2007; Miura
et al., 2002)
(Battaglia, 2005; Sahoo et
al., 2008)
(Ferrer and Gullotta, 1990;
Marin-Padilla, 1972;
Marin-Padilla, 1976;
Suetsugu and Mehraein,
1980; Takashima et al.,
1981; Takashima et al.,
1994)
(Busard et al., 1987)
(Marin-Padilla, 1972)
(Machado-Salas, 1984)

(Higashi et al., 1993;
Sarna et al., 2003; Walkley
and Baker, 1984)
(Potocki et al., 2007)
(Elsea and Girirajan, 2008;
Slager et al., 2003)
(Berg et al., 2007;
Hoogenraad et al., 2002;
Lim et al., 2007; Meng et
al., 2002; Zhao et al.,
2005)
(Gothelf et al., 2007;
Kobrynski and Sullivan,
2007; Lee and Lupski,
2006; Stark et al., 2008)

Aberrant dendritic spine development includes a broad range of changes in spine
morphology and structure, such as increases or decreases in spine density, altered spine size or
shape, dendritic beading with subsequent loss of spines, and ectopic spines in abnormal locations
(Fiala et al., 2002). Since the shape and structure of a spine are closely associated with its
function, the presence of abnormal spine morphology in many of these diseases suggests that the
7

resulting cognitive phenotype is a result of dysfunctional spines. Understanding the effect of
altered spines in pathological conditions will provide researchers with a better understanding of
how spines contribute to normal synaptic conditions during development and learning in the
adult brain.
The spine pathogenesis among various types of MR is strikingly similar. These
observations suggest that various genetic and epigenetic deficits related to MR may be the result
of abnormal dendrites and spines leading to the disruption of neural homeostasis and the ability
of the brain to return to a set point following perturbation (Ramocki and Zoghbi, 2008).
Interestingly, many of the MR susceptibility genes encode proteins that regulate neuronal
dendrite and spine development. This suggests that the molecular factors involved in behavioral
and cognitive processes function in a tightly regulated homeostatic fashion. More specifically,
single genes or noncoding RNAs do not encode specific cognitive processes, but instead encode
biological processes. It is when a particular biological process, such as synaptic transmission, is
disrupted during development that we can appreciate the resulting numerous neurological
phenotypes.
Despite the fact that several protein pathways have been identified as critical players in
spine development and pathology, the molecular pathogenesis of aberrant spine morphology in
these diseases has yet to be clearly and comprehensively elucidated. It is apparent that complex
programs of gene expression work to shape the developing nervous system. In this review, we
will discuss the roles of epigenetic mechanisms in this important process. Revealing the roles of
signaling factors and epigenetic gene regulators in dendritic spine pathologies will provide us
with a better understanding of dendritic and spine disease and offer new approaches to treating
neurodevelopmental disorders.
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CHAPTER 2:
Epigenetic regulations are critical for neuronal dendritic
development

2.1

Introduction to epigenetic regulation

In eukaryotic cells, genomic DNA exists in the form of chromatin and is tightly
associated with histones and other chromatin proteins. Epigenetic regulation is defined as
heritable changes in gene expression that are not coded within the DNA sequence itself.
Epigenetic modulation of the genome involves three interacting systems, DNA methylation,
histone modification (Egger et al., 2004; Li and Zhao, 2008), and noncoding RNA-mediated
processes (Li and Zhao, 2008) (see Table 2). Recent literature has demonstrated that the
phenotype of the cell is not only dependent on the genotype, but also the epigenotype. For
example, DNA methylation within promoter regions (e.g., CpG islands) can result in heritable
silencing of gene expression and has likely evolved as a host defense mechanism against viral
sequences (Bestor and Tycko, 1996; Yoder et al., 1997). This type of epigenetic modulation can
imprint dynamic environmental changes on a fixed genome, resulting in a stably transmitted
alteration of phenotype, and has long been proposed to be an epigenetic silencing mechanism of
fundamental importance (Holliday and Pugh, 1975; Riggs, 1975). The epigenotype shows far
greater plasticity than the genotype during normal development, and disruption of these systems
can lead to inappropriate expression or silencing of genes, resulting in “epigenetic diseases.”
This section will review the epigenetic mechanisms that regulate dendrite and spine development
and related diseases.
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Table 2.1: Summary of epigenetic modifications and their direct effects on gene expression.
Epigenetic
Target
Direct Effect on gene
modification
expression
DNA methylation
CpG dinucleotides
Repression
H3 (K4,K36,K79)

Activation

Histone methylation

H3 (K9, K27), H4(K20)

Repression
Activation

Histone acetylation

H3 (R17,R23), H4(R3)
H3 (K9,K14,K18,K56), H4
(K5,K8,K13,K16)
mRNA

microRNA

2.2

Activation
Repression

DNA methylation

DNA methylation involves covalent modification of cytosine at position C5 in CpG
dinucleotides. Over 70% of CpG dinucleotides in the mammalian genome are methylated, and
most DNA methylation occurs at CpG dinucleotides. The exception is CpG islands, defined as
more than 500 base pairs of sequence composed of 55% GC content. CpG islands are found in
the promoters and the first exon of about 40% of the mammalian genes, and they are normally
kept free of DNA methylation by mechanisms that are still unclear (Takai and Jones, 2002).
Methylation of CpG islands is associated with stable heritable transcriptional silencing (Jones
and Baylin, 2002). The methylation of CpG dinucleotides is catalyzed by several DNA
methyltransferases (DNMTs). The de novo establishment of DNA methylation relies on
DNMT3a and 3b and cofactor DNMT3L, whereas the maintenance of DNA methylation depends
on DNMT1, which specifically recognizes semi-methylated DNA and methylates the remaining
strand (Bestor, 2000; Jaenisch and Bird, 2003; Robertson et al., 2000). Mammalian DNA
methylation has been implicated in a diverse range of cellular functions, including tissue-specific
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gene expression, cell differentiation, cell fate determination, genomic imprinting, and X
chromosome inactivation (Bird, 2002b). Here we focus on the function of DNA methylation in
neurodevelopment.
Deletion of DNMT1 in neural progenitor cells leads hypomethylation in neurons and
subsequent abnormalities in synaptic maturation and function (Golshani et al., 2005; Hutnick et
al., 2009). Although deletion of DNMT1 in neuronal precursors at E9-E10 leads to normal
development through birth, it adversely affects neuronal survival after birth, resulting in death of
the mice (Fan et al., 2001). Recently, Feng et al. have shown that DNMT1 and DNMT3a
regulate synaptic function in neurons (Feng et al., 2010). Feng’s group made use of conditional
mutant mice that lacked Dnmt1, Dmnt3a, or both specifically in post-mitotic forebrain neurons
of the postnatal mice. Their findings suggest that DNMT1 and DNMT3a are required for
synaptic plasticity and learning and memory, likely due to their functions in maintaining DNA
methylation and controlling gene expression in post-mitotic neurons. Although these studies
provide sufficient evidence that DNMTs and DNA methylation are critical for neuronal
development, the function of DNA methylation in post-mitotic neurons of the adult brain is still
for the most part unknown. DNMT1 is highly expressed in neurons, and the deletion of DNMT1
from post-mitotic neurons of postnatal brains leads to neuronal death (Fan et al., 2001),
suggesting that DNMT1 may have other roles in addition to its methyltransferase activity. In
fact, DNMT1 has been shown to form a complex with HDACs and participates in transcriptional
repression (Jaenisch and Bird, 2003; Robertson et al., 2000), suggesting that DNMTs may have
complex roles in transcriptional regulation. Researchers have yet to identify specific genes
affected by Dnmt deficiency, which impacts synaptic function, as well as learning and memory.

11

Despite the magnitude of literature on DNMTs and DNA methylation, much less is
known about DNA demethylation. It has been proposed that the steady-state methylation of a
particular gene is a dynamic equilibrium between methylase and demethylase activities. It has
been found that MBD2 has DNA demethylase activity (Bhattacharya et al., 1999; Detich et al.,
2002). It has also been proposed that Gadd45a erases DNA methylation marks by DNA repairmediated DNA demethylation (Barreto et al., 2007). More recently, Gadd45b was found to be
important for the activity-induced demethylation of promoters and the expression of
corresponding genes critical for adult neurogenesis, such as Bdnf and Fgf-1 (Ma et al., 2009). It
was also shown that demethylation can take place in the absence of DNMT1 and DNMT3a in
vivo (Feng et al., 2010). Although researchers have yet to elucidate the mechanisms of active
DNA demethylation in the brain, it has been proposed that DNA oxidation and repair are
possible mechanisms underlying this process.
DNA methylation represses gene transcription either through directly blocking the access
of transcription factors to their binding sites or through indirectly recruiting methyl-CpG binding
proteins (MBDs). The MBD protein family consists of a growing number of DNA-binding
proteins with the ability to recognize methylated CpGs in the genome. The MBD family includes
at least MBD1, MBD2, MBD3, MBD4, MECP2, and Kaiso (Klose and Bird, 2006). In a sense,
MBDs translate genomic CpG methylation into gene expression changes; therefore, these
proteins are the central components of the DNA methylation pathway. DNA methylation is
important in mammalian brain development (Chahrour and Zoghbi, 2007). One of the best
examples of this occurs in Rett syndrome (RTT), an X-linked dominant pervasive
neurodevelopmental disorder caused by de novo mutations in methyl-CpG binding protein 2
(MeCP2) (Amir et al., 1999). Mecp2 is thought to be involved in the structural conformation of
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chromatin. Once MeCP2 is bound to Methylated DNA, MeCP2 recruits a complex of chromatinremolding enzymes that help to condense the DNA surrounding the MeCP2 binding site, and
silence transcription (Bird, 2002b; Chahrour and Zoghbi, 2007). Mutations in MeCP2 lead to
Rett Syndrome, a severe neurodevelopmental disorder. As discussed below, extensive evidence
suggests that Mecp2 plays an important role in dendritic development and neuronal maturation
(Smrt et al., 2007).

2.3

Histone code

Histones are abundant nuclear proteins. Eukaryotic genomic DNA wraps around histones,
which form the basic unit of chromatin, the nucleosome that consists of ~147 base pairs of DNA
wrapped around a core histone octamer (~1.65 turns). Each histone octomer includes two copies
of H2A, H2B, H3, and H4 histones, and all of them can undergo different types of posttranslational modifications, such as acetylation, methylation, and phosphorylation (Lachner et
al., 2003). The types and sites of histone modifications, the so-called “histone code,” have a
significant impact on chromatin structure and gene expression.
Chromatin is present in two states: heterochromatin and euchromatin. Heterochromatin is
in a condensed state that is repressive for gene transcription. When the chromatin is in an open
state, called euchromatin, genes can be transcribed. Chromatin remodeling is a mechanism that
alters the chromatin structure and functions to modulate DNA-protein interactions and gene
activity without changing genomic DNA sequences. The chromatin structure and maintenance
are not only critical for gene expression, but also for many cellular processes, such as
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chromosome segregation during mitosis and X-chromosome inactivation (Grewal and Elgin,
2007).
Recent genome-wide studies have demonstrated that histone modifications, as well as
recruitment of other chromatin proteins, can be used as markers for gene expression state.
Among histone modifications, lysine acetylation and methylation are the most characterized
markers. For example, methylation of a histone at lysine 4 (H3K4), H3K36, or H3K79 is
correlated with open chromatin and generally active gene transcription, whereas methylation of
H3K9, H3K27, or H4K20 is correlated with condensed chromatin and gene inactivation (Krogan
et al., 2003; Santos-Rosa et al., 2002; Schubeler et al., 2004). Additionally, mono-, di-, and
trimethylation at the same lysine residues lead to different levels of gene activation or repression
and are involved in distinct cellular pathways (Barski et al., 2007). Histone acetylation leads to
less condensed chromatin structure and can be used to mark transcriptionally active regions. On
the other hand, histone hypoacetylation is associated with more condensed heterochromatin and
is used to mark transcriptionally inactive regions (Grewal and Elgin, 2007). Additionally,
histones are subject to a number of other modifications, including phosphorylation,
ubiqutinylation, etc. (Lachner et al., 2003). Thus, post-translational modifications of histones
demonstrate a high degree of diversity and complexity and reflect the importance of the “histone
code” in gene expression regulation.
The enzymes that catalyze histone modifications are critical components of the
epigenome and play important roles during neurodevelopment. For example, studies of histone
acetylation have focused on two opposing enzymes, histone acetyltransferases (HAT) that
catalyze acetylation, and histone deacetylases (HDAC) that catalyze deacetylation. Transcription
activators can either recruit HATs or utilize their own internal HAT domains (for example CREB
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binding protein, CBP) to catalyze histone acetylation to promote active chromatin structure.
Conversely, transcription repressors can recruit HDACs that lead to histone deacetylation and
gene repression. The opposing activities of HATs and HDACs are important for gene
transcription regulation and therefore are tightly regulated during development. Alteration of
these processes leads to developmental disorders, such as Rubinstein-Taybi syndrome, which
results from heterozygote mutations of CBP. It is thus not surprising that HDAC inhibitors, such
as VPA, have been developed and used to treat diseases, including psychiatric disorders (Phiel et
al., 2001). VPA has been shown to increase neuronal differentiation in hippocampal neural
progenitors (Hsieh et al., 2004). More recently, VPA has been shown to alter the morphology of
motor cortex neurons in a rat model of autism (Snow et al., 2008) and affect neurite outgrowth in
mouse neuroblastoma cells (Yamauchi et al., 2008; Yamauchi et al., 2009). Another HDAC
inhibitor, trichostatin A (TSA), has also been shown to increase neuronal differentiation of
neural stem cells (NSCs) and enhance the dendritic length and complexity of NSC-derived
neurons (Balasubramaniyan et al., 2006). More recently, it was found that the neuronal abundant
HDAC2 suppresses synapse formation and dendritic spine development of hippocampal neurons
through its negative regulation of multiple neuronal genes. The authors demonstrated that
HDAC2 functions to suppress synaptic plasticity and memory formation (Guan et al., 2009).
Another histone modification enzyme in the spotlight is enhancer of zeste homolog 2
(Ezh2), a H3-K27 histone methyltransferase and a part of the Polycomb group (PcG) protein
complexes. PcG proteins and Ezh2 are important for neurogenesis and stem cell function in the
brain (Lee et al., 2006; O'Carroll et al., 2001). PcG proteins are known in to function in
maintaining the bivalent chromatin state in stem cells (Boyer et al., 2006; Lee et al., 2006). For
example, genes in embryonic stem cells related to differentiation contain both activating
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(methylated-H3K4) and repressing (trimethylated-H3K27) chromatin markers (Azuara et al.,
2006; Bernstein et al., 2006). This bivalent chromatin state is believed to “prime” genes for
expression, but “hold them in check” at the same time, therefore control the balance between
proliferation and differentiation in embryonic stem cells (Bernstein et al., 2007). Recently PcG
proteins have been shown to regulate dendritic arborization in Drosophila sensory neurons in a
cell-autonomous manner (Parrish et al., 2007a; Parrish et al., 2007b). We have recently found
that Ezh2 expression is controlled by the crosstalk between MeCP2 and microRNAs (Szulwach
et al., 2010), suggesting that aberrant regulation of histone methyltransferase could be involved
in the mammalian neuronal development and pathogenesis of neurodevelopmental disorders.
Together, these studies provide evidence that histone modification and chromatin
structure modulation play significant roles in the regulation of neuronal development and the
formation of dendrites and spines.

2.4

Noncoding RNAs

Of the human genome, only about 2% is comprised of coding genes, whereas more than
80% of the genome is transcribed into RNA. Mounting evidence points to important roles for
noncoding RNAs in gene expression regulation and cell phenotype determination (Li and Zhao,
2008). MicroRNAs (miRNAs) are a class of small noncoding RNAs that are transcribed from the
genome. Experimental evidence indicates that miRNAs function to modulate gene expression at
the post-translational level by partial base-paring with the seed sequence located in the 3’UTR of
the protein-coding mRNAs, leading to repression of translation efficiency or cleavage of the
target mRNA (Filipowicz et al., 2008). miRNAs are expressed in many different tissues,
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particularly in the brain. The expression levels and patterns of miRNAs in the brain are
dynamically regulated, suggesting that they play important roles in neuronal development
(Barbato et al., 2008; Bushati and Cohen, 2007). One of the most studied brain specific miRNAs
is miR-9. This miRNA has been of particular interest because it plays an important role in
neurogenesis (Krichevsky et al., 2006), zebrafish brain patterning (Leucht et al., 2008), and its
expression levels increase as neuronal precursors differentiate into the neurons. It was shown that
miR-9 and miR-124 repress BAF53a, a process important for neural stem cell (NSC)
proliferation and post-mitotic dendritic outgrowth (Yoo et al., 2009). Additionally, miR-9
regulates the expression of orphan nuclear receptor (Tlx), a gene important for self renewal of
NSCs (Shi et al., 2004). Additionally, Tlx also regulates expression of miR-9, demonstrating a
regulatory loop that functions to regulate neurogenesis (Zhao et al., 2009). Tlx is also targeted by
Let-7b (Zhao et al., 2010), a member of the let-7 miRNA family. The let-7 miRNA family was
one of the first families of miRNAs found to regulate stem cell function (Liu and Zhao, 2009a;
Rybak et al., 2008; Schwamborn et al., 2009). Additionally, let-7 is known to affect self-renewal
and differentiation and it has been shown to interact with the 3’UTR of high mobility group A2
(HMGA2), a known target of let-7. Together, let-7 and HMGA2 regulate the expression of
p16Ink4a partially responsible for aged-dependent decline in self-renewal ability of brain NSCs
(Nishino et al., 2008).
It has been shown previously that miRNAs are important for a number of cellular
processes, such as differentiation, apoptosis, metabolism, and dendritic development (Brennecke
et al., 2003; Chang et al., 2004; Chen et al., 2004; Johnston and Hobert, 2003; Poy et al., 2004).
Loss of important components of the miRNA pathway, such as Dicer and DGCR8, can alter the
proliferation and differentiation of stem cells (Kanellopoulou et al., 2005; Wang et al., 2007).
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Additionally, miRNAs have been demonstrated to play a role in the modulation of proliferation
and differentiation of different stem cell types (Ivey et al., 2008; Szulwach et al., 2010).
One of the most exciting recent discoveries in neuroscience is that miRNAs have a role in
synaptic plasticity. Learning and memory in the brain requires the synapse to undergo long-term
modifications. It is believed that these changes require the local translation of factors important
for synaptic function (Sutton and Schuman, 2005). Local protein synthesis at the dendritic spine
involves transport of mRNAs to the dendritic compartment; however, we know little about how
translation at the synaptic compartment is regulated. In Drosophila melanogaster, it has been
shown that mRNAs important for synaptic plasticity are targets of the miRNA pathway (Ashraf
et al., 2006). The authors have analyzed the brains of RISC mutants and demonstrated that
protein translation of neuronal CaMKII is increased in dicer-, armitage-, or aubergine-mutant
brains. At the same time, Schratt et al. were able to directly link a specific miRNA to dendrite
and spine development in mammalian neurons (Schratt et al., 2006). First, they showed that miR134 is localized in the dendrites of cultured mouse hippocampal neurons and is in dendritic
spines that are apposed to synapsin-positive presynaptic terminals. Next, they found that
overexpression of miR-134 leads to decreased spine size, whereas inhibition of endogenous miR134 leads to increased spine size. Therefore miR-134 may act as a negative regulator of dendritic
spine maturation. Recently, the same group found that miR-138 is important for dendritic
patterning and spine morphogenesis. miR-138 is highly enriched in the brain and is localized in
the dendrites. The authors revealed that miR-138 negatively regulates dendritic spine size in rat
hippocampal neurons by controlling the protein translation of APT1 (Siegel et al., 2009). In
addition, brain-specific miR-124 is localized at presynaptic terminals of Aplysia and regulates
synaptic plasticity by regulating the transcription factor CREB (Rajasethupathy et al., 2009).
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Recently, a neuronal activity-dependent miRNA, miR-132, was shown to regulate dendritic
development by targeting a Rho family GTPase-activating protein, p250GAP (Wayman et al.,
2008). We have demonstrated that neuron-enriched miR-137 has a significant impact in vivo and
in vitro on the maturation and dendritic morphogenesis of young hippocampal neurons by
regulating the translation of Mib1, a ubiquitin ligase known to be important for neurogenesis and
neurodevelopment (Smrt et al., 2010). Overall, these reports demonstrate that miRNAs have the
capacity to modulate the expression of mRNAs important for dendrite and spine development
(Figure 3.1). The identification of these specific miRNAs that are important for dendritic
development and synaptic plasticity are critical for our understanding of miRNAs in the CNS.
New methods for detecting and quantifying miRNA at dendritic spines and synapses will help
untangle the role of miRNAs in dendritic spine development and synaptic plasticity (see review
(Schratt, 2009)).

2.5

Epigenetic diseases that affect dendritic spine development

Cognitive functions like learning and memory are extremely complex and require a
precise balance of epigenetic and regulatory mechanisms. Extensive data support the link
between epigenetic dysregulation of gene expression and neurodevelopmental disorders (Table
1). In this section, we will focus on two of the best-characterized epigenetic disorders with
known dendritic pathology, Rett syndrome and fragile X syndrome.
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2.6

Rett syndrome

Rett syndrome (RTT) is a neurodevelopmental disorder and an autism spectrum disorder.
RTT is one of the most common forms of MR in young females. RTT patients develop normally
until 6-18 months of age, and thereafter experience a myriad of neurological deficits, including
seizures, ataxia, and stereotypical hand movements. RTT is caused by loss-of-function mutations
in MECP2, an X-linked gene encoding the MeCP2 protein, one of the MBDs. MeCP2 is a central
player in epigenetic regulation by binding methylated DNA and recruiting factors, such as
histone deacetylases, leading to the repression of gene expression (Amir et al., 1999; Bird,
2002b) (Figure 3.1).
Extensive evidence supports the role of MeCP2 in neuronal maturation (Hagberg et al.,
1983a; Smrt et al., 2007). The neurological symptoms of RTT appear after a seemingly normal
embryonic development, suggesting that MeCP2 is not required for early developmental
neurogenesis. However, MeCP2 expression coincides with a period of synaptogenesis (Akbarian
et al., 2001a; Shahbazian and Zoghbi, 2002b; Zoghbi, 2003), suggesting that MeCP2-dependent
epigenetic modulation of gene expression is important for the maturation and maintenance of
neurons during brain development. Several mouse models have contributed to our understanding
of the function of MeCP2 in neuronal and dendritic spine development (Bienvenu and Chelly,
2006; Chahrour and Zoghbi, 2007; Smrt et al., 2007). Expression studies in these animal models
indicate that MeCP2 expression steadily increases during neuronal maturation, and is low or
absent in immature neurons (Kishi and Macklis, 2004). Both RTT patients and Mecp2 mutant
mice have excess immature neurons in the olfactory epithelium, and reduced transition of
immature neurons into mature neurons (Matarazzo et al., 2004; Smrt et al., 2007). Additionally,
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human postmortem tissues show less complex dendritic arborization, smaller soma size,
decreased dendritic spine density (Figure 1.4B), and lowered levels of the dendritic cytoskeletal
protein MAP2 in RTT brains (Armstrong, 2002; Kaufmann and Moser, 2000a). On the other
hand, exogenous Mecp2 expression leads to increased neurite complexity in cultured neurons
(Jugloff et al., 2005; Smrt et al., 2007). Consistent with human pathology, adult Mecp2 mutant
mice have smaller soma sizes and less complex dendrites in layer II/III pyramidal neurons in the
cortex (Kishi and Macklis, 2004). Using retroviral labeling of new cells, we have shown that
Mecp2-deficient mice have reduced dendritic spine density and exhibit delayed maturation of
newborn dentate granule neurons (Smrt et al., 2007). On the other hand, both we and others have
shown that exogenous MeCP2 expression can lead to increased neurite complexity in cultured
neurons (Jugloff et al., 2005; Smrt et al., 2010), further suggesting an important role for MeCP2
in dendritic development.
Extensive efforts have been devoted to the identification of downstream effectors of
MeCP2, but only a handful of them have been verified, including BDNF, DLX5, and DLX6
(Chahrour and Zoghbi, 2007; Tudor et al., 2002). Since these known targets cannot fully explain
the deficits associated with MeCP2 deficiency, the identification of additional MeCP2 effector
genes is needed to paint a full picture of the pathogenesis of RTT. Recently, epigenetic
regulation of noncoding RNAs by MeCP2 has been suggested as a novel mechanism for
understanding the pathogenesis of Rett syndrome. It was found that the miR-184 transcript is
imprinted and exclusively expressed on the paternal allele and that MeCP2 binds upstream of
miR-184 before neuronal depolarization, and releases after depolarization in an activitydependent manner (Nomura et al., 2008). However, the miR-184 expression level is decreased in
Mecp2 KO brains, which contradicts the authors’ finding. It is possible that miR-184 is indirectly
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regulated by MeCP2. In fact, we have found that miR-184 is directly regulated by MBD1 (Liu et
al., 2010). We have shown that MeCP2 can directly regulate the expression of a subset of
miRNAs in primary neural progenitor cells isolated from postnatal brains. One of these miRNAs,
miR-137, modulates NPC proliferation and differentiation by regulating protein translation of
Ezh2, a histone H3K27 methyltransferease (Szulwach et al., 2010). In developing neurons, miR137 represses dendrite and spine morphogenesis by targeting another neurodevelopmental factor,
MIB1 (Smrt et al., 2010). Therefore, it is conceivable that MeCP2 regulates neuronal dendrite
and spine development through noncoding RNAs. Functional crosstalk between the DNA
methylation pathway and small regulatory RNA could be an important and novel mechanism
regulating mammalian neurodevelopment (Figure 3.1).

2.7

Fragile X syndrome

Fragile X syndrome (FXS) is the most common cause of inherited MR and is attributed to
mutations in the X-linked FMR1 gene. Epigenetic mechanisms have been implicated in the
molecular mechanisms of the disease (Graff and Mansuy, 2009). Typically, fragile X syndrome
is caused by the expansion of a polymorphic CGG repeat in the 5’ untranslated region (UTR) of
the gene. If the CGG expansion reaches more than 200 repeats in female carriers, it is considered
a full mutation. As a result, the repeat, the upstream CpG island, and the surrounding sequence
become hypermethylated, and the gene is silenced (Oberle et al., 1991). One distinct
characteristic of patients with FXS is that they have many more dendritic spines than normal
individuals (Figure 1.4C), and their spines are longer and thinner, resembling immature spines
(Hinton et al., 1991; Irwin et al., 2001). It has been suggested this is due to misregulated
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development and elimination. This phenotype is also seen in the mouse model of FXS (Comery
et al., 1997; Greenough et al., 2001; Hinton et al., 1991; Irwin et al., 2001; Nimchinsky et al.,
2001). During dendritic spine development, synapses may be formed in excess numbers.
Therefore, maturation and pruning are needed to establish the final synaptic pattern. In FXS, the
activity-dependent events that lead to removal of excess or inappropriately placed synapses do
not occur (Galvez et al., 2003).
Fragile X mental retardation protein (FMRP) is an RNA-binding protein, part of the
heterogeneous nuclear ribonucleoproteins (hnRNPs), which function in many aspects of mRNA
metabolism and biology, including nuclear export of mRNA and subcellular localization (Van de
Bor and Davis, 2004). FMRP is part of a large protein complex that is involved in the
transportation and translation of mRNA in neurons. Studies have shown that abnormal spines in
FXS are associated with impaired neuronal plasticity; therefore, it has been suggested that FMRP
may function to transport coding and noncoding RNA to the synapse and participate in local
protein synthesis in dendrites (Figure 3.1). Local protein synthesis in dendrites modulated by
FMRP can potentially influence biochemical pathways or signaling cascades involved with spine
morphogenesis, such as Rac1, MAP1B, CamKII, calbindin, and cadherins (Grossman et al.,
2006; Penagarikano et al., 2007). The mechanism by which FMRP regulates translation of
synaptic factors at the dendritic spine is still under investigation. It has also been shown that the
bidirectional transport of the FMRP-mRNA complex between the soma to the dendrites and
spines is driven by neuronal activity (Antar et al., 2004; Antar et al., 2005; Ling et al., 2004),
indicative of multiple roles for FMRP in the activity-dependent regulation of gene expression at
the dendritic spine.
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It has been suggested that FMRP can associate with miRNAs and regulate the expression
of a subset of target synaptic mRNAs (Fiore et al., 2008; Jin et al., 2004; Penagarikano et al.,
2007; Vanderklish and Edelman, 2005) (Figure 3.1). Recently, it was shown that a number of
microRNAs, including miR125b and miR-132, can associate with FMRP in the mouse brain.
While these miRNAs have opposing effects on dendritic spine morphology, knockdown of
FMRP ameliorates the effects of overexpressing these microRNAs on spine morphology. The
FMRP-associated miRNA 125b was found to target glutamate receptor subunit NR2A,
suggesting FMRP-associated miRNAs may have a profound impact on synaptic plasticity, as
well as on the pathophysiology of FXS (Edbauer et al., 2010). Although there is supporting
evidence that FMRP collaborates with miRNAs to suppress the expression of genes important
for dendritic spine morphology and synaptic plasticity, the details of how miRNA and FMRP
interact are unclear. One proposed interaction is that miRNA and mRNA could act as the
“kissing complex” RNA structure that has previously been proposed to bind the KH2 domain of
FMRP (Bassell and Warren, 2008).
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CHAPTER 3:
Methods for studying the epigenetic regulation of dendrite and
spine development

3.1

Genetic and molecular methods

Significant advances in genetics and molecular biology have made a profound impact on
our understanding of neurodevelopment and disease. Here we will summarize a few important
methods.

3.1.1 Drosophila genetics
Drosophila neurogenetics was born in Seymour Benzer’s lab at Caltech in the mid-1960s,
when he proposed that genes can control behaviors in the fruit fly (Benzer, 1967). Benzer’s
trainees went on to isolate the shaker (sk) gene, which is a member of the transient receptor
potential (trp) ion channel family (Papazian et al., 1987). A number of classical studies of brain
functional genetics involved the use of loss-of-function approaches in Drosophila (Hotta and
Benzer, 1970; Lin et al., 1998; Lush et al., 1998; Min and Benzer, 1999).
Many neurologic as well as other human diseases can be modeled using Drosophila to
characterize genetic, epigenetic, and cellular pathways that lead to the disease state. Drosophila
genetics are appealing to biologists because the tools of this trade are relatively simple and
behavioral paradigms are well characterized, providing an extremely powerful method to go
from mutant phenotypes to genotypes (forward genetics). Thus, the use of Drosophila models of
human disease has grown rapidly and significantly contributed to our understanding of the
25

human pathogenesis. The molecular and cellular pathways in Drosophila are generally
considered to be highly conserved with vertebrates; approximately 75% of human genes known
to be associated with disease correspond to a Drosophila ortholog (Reiter et al., 2001).
Drosophila can be used to conduct assays ranging from genetic screens to drug target validation.
For example, genetic modifier screens can identify proteins and genes that interact with
pathways associated with pathology (Egger et al., 2004). Additionally, flies are excellent subjects
for high-throughput drug screening libraries and are responsible for the identification of mGluR5
as a drug target for treating fragile X syndrome (Chang et al., 2008; Marsh and Thompson,
2006).
Drosophila has been used to understand the genetic pathways implicated in fragile X
syndrome. The Drosophila genome contains the gene Drosophila fragile X-related (dfxr or
dfmr1), which is homologous to FMR1 (Wan et al., 2000) and contains all the functional motifs
related to FMRP. It was found that Drosophila genetics could be used to show dFXR plays a role
in neuronal development, including synaptic formation, axonal growth, and dendritic
development (Dockendorff et al., 2002; Lee et al., 2003; Michel et al., 2004; Morales et al.,
2002; Zhang et al., 2001).
Drosophila has been used for studying epigenetic regulation related to histones and
miRNAs. For example, dFMR1 is important in the microRNA (miRNA) pathway (Caudy et al.,
2002; Ishizuka et al., 2002; Yang et al., 2007) and has been shown to modulate miR-124a levels,
which are important for dendritic branching in Drosophila (Xu et al., 2008). However, CpG
methylation is essentially absent in Drosophila, making it an invalid model for studying
mammalian DNA methylation.
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3.1.2 Genetic mouse models
Genetic manipulation of the mouse genome along with the characterization of mutant
phenotypes has made a profound impact on our understanding of the pathophysiology of many
human diseases. Mice and humans share 99% of their genes and have similar physiological and
biochemical features, making genetic mouse models a powerful tool to study human disease
(Rosenthal and Brown, 2007). This section will briefly describe the most common mouse models
used to study Rett syndrome and fragile X syndrome, both implicated in abnormal spine
development.

The MeCP2 mouse
To model Rett syndrome and related disorders in mice, three mouse models were
generated with different Mecp2 genetic alterations. One of these models is the Mecp2 conditional
KO mouse, which lacks either exon 3 or both exons 3 and 4 of the Mecp2 gene (Chen et al.,
2001a; Guy et al., 2001). These conditional knockout mice develop normally during the first 3-6
weeks of life, and thereafter develop motor dysfunction, hind limb clasping, and breathing
irregularities. Mutant brains show reduced brain weight and more densely packed neurons, but
do not show neuroanatomical abnormalities. The female mice, which are heterozygous for the
Mecp2 mutation (Mecp2+/-), show behavioral phenotypes that are less severe and with a later
onset.
Another mouse model was generated by truncating Mecp2 at amino acid 308. This
truncation resulted in a hypomorphic allele that contains a truncated C-terminal region,
reminiscent of Rett patients found with C-terminal deletions (Shahbazian et al., 2002a). These
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mice have many similarities with the conditional knockout model described above, but have a
less severe phenotype that leads to longer longevity.
The third mouse model involves a two-fold overexpression of human MeCP2 that leads
to an initial increase in synaptic plasticity and contextual learning; however, by 20 weeks of age
the mice develop progressive neurological phenotypes, including motor abnormalities, hind limb
clasping, and seizures, and they die by 1 year of age (Collins et al., 2004). This is also seen in the
clinic, where duplication of MECP2 in human male patients causes severe MR. Moreover,
selective overexpression of MeCP2 in post-mitotic neurons, under the tau promoter, lead to a
progressive neurological phenotype in mice (Luikenhuis et al., 2004).
In yet another mouse model, deletion of Mecp2 specifically in post-mitotic neurons using
a CaMKII Cre transgene results in a phenotype resembling the Mecp2-/y knockout. This suggests
that dysfunction of brain-specific MeCP2 leads to the neurological phenotype observed in Rett
syndrome (Chen et al., 2001a; Gemelli et al., 2006). Additionally, when Mecp2 is expressed in
post-mitotic neurons under the tau promoter in null mice, the Rett phenotype is rescued, further
supporting this idea (Luikenhuis et al., 2004). Taken together, these studies demonstrate that
perturbations in the homeostatic balance of MeCP2 expression can result in aberrant neurological
functioning.

The fragile X mouse
FMR1 is highly conserved between humans and mice (Ashley et al., 1993). The FMR1
knockout mouse was generated by disrupting exon 5 of the FMR1 gene by homologous
recombination. This resulted in the absence of normal FMRP protein (Bakker et al., 1994). These
mice show cognitive and anatomical impairments that are related to those seen in human
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patients, making the fragile X knockout mouse an important model to study the function of
FMRP. The fragile X knockout mouse displays distinct phenotypes, such as hyperactivity,
special learning deficits, macroorchidism, and altered dendritic spines (Bakker et al., 1994;
Kooy, 2003). Among the similarities between the human pathology and the mouse model is
cognitive function. It has been found that FMR1 KO mice have special learning deficits when
challenged with the Morris water maze and radial arm maze (Bakker et al., 1994; Kooy, 2003;
Kooy et al., 1996; Mineur et al., 2002), two tests generally considered to reflect problems in
hippocampal functioning (Logue et al., 1997; Morris et al., 1982). We found that FMR1 KO
mice exhibit impaired hippocampal neurogenesis, which may contribute to the deficits in
hippocampus-dependent learning (Luo et al., 2010). Among structural abnormalities in the
mouse model, FMR1 KO mice show macroorchidism due to increased Sertoli cell proliferation
(Slegtenhorst-Eegdeman et al., 1998). No gross neuroanatomical differences are observed in
human patients or fragile X mouse brains (Bakker et al., 1994); however, it is well appreciated
that patients and mice have long, thin immature spines with increased spine density in dendrites
of the cortex (Comery et al., 1997; Irwin et al., 2001). FRM1 KO mice also show a propensity
for epileptic seizures. Seizures occur in fragile X patients (Hull and Hagerman, 1993) and can be
elicited by auditory stimuli in knockout mice (Chen and Toth, 2001). Epileptic seizures in fragile
X are likely due to dendritic spine abnormalities in mice and patients. Fragile X mice have been
used for developing therapeutic treatments, though the results are still controversial.
Pharmalogical approaches have been proposed to compensate for the loss of FMRP (Kooy, 2003;
Penagarikano et al., 2007). More work is required for a better understanding of the mechanism of
how FMRP regulates mRNA translation, and how FMRP functions in activity-dependent local
protein synthesis in the dendrite.
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3.1.3 Isolation and RNA content analysis of synaptoneurosomes

Synaptoneurosomes are small vesicle structures that are prepared by subcellular
fractionation of brain homogenate. These structures are known to be enriched in dendritic spines
(Lugli et al., 2008). It has been shown that polyribosomes, as well as many mRNAs, are present
in dendrites and are recruited into dendritic spines (Bourne et al., 2007; Ostroff et al., 2002).
Gene chip analysis of PSD fraction-associated mRNAs shows that mRNAs encoding many
postsynaptic proteins are highly concentrated in PSD fractions (Suzuki et al., 2007). In addition,
synaptoneurosomes also contain a large number of miRNAs. To characterize microRNA
expression at the synapse, Lugli and collaborators isolated synaptic fractions from the mouse
forebrain and analyzed microRNA expression using microarrays; enriched microRNAs were
subsequently confirmed by qRT-PCR (Lugli et al., 2008). Lugli et al. found that a number of
microRNAs were highly enriched in synaptoneurosomes and are predominately associated with
PSDs. Their study further supports the role of miRNAs in protein synthesis at the synapse. It is
likely that synaptosomes contain other types of RNAs and perhaps even DNA. With the
development of next-generation sequencing, more synaptosome RNAs will be revealed,
providing a better picture of the regulatory network governing dendrite and spine development.

3.2

Histological methods

3.2.1 The Golgi method
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The Golgi method was discovered by Camillo Golgi and published in 1873 (Golgi,
1873); however, it was popularized by Ramon e Cajal, who modified the method to study a
myriad of species and tissues during many developmental periods, including the brain (De Carlos
and Borrell, 2007). Since then, the application of the Golgi technique in neurosciences has been
used to study morphological abnormalities in dendrites that are typical in diseases associated
with MR. The pioneers of Golgi impregnations to study dendrites in MR were Huttenlocher
(Huttenlocher, 1970; Huttenlocher, 1974) and Purpura (Purpura, 1975), who relied on postmortem and biopsy material. Using the Golgi method, Parpura found cortical pyramidal neurons
to have shorter and less complex dendritic branches in individuals with unclassified MR
(Purpura, 1974). This dendritic “dysgenesis” was also observed in individuals with
chromosomopathies and genetic disorders associated with MR (Ferrer et al., 1984; MarinPadilla, 1972) (see Figure 1.4). Golgi impregnation in Rett syndrome post-mortem tissue showed
a reduction in the dendritic arborization of cortical neurons throughout life in RTT patients
(Armstrong et al., 1995). Similar results were obtained using this method in an animal model of
RTT lacking MeCP2 (Kishi and Macklis, 2004). In fragile X syndrome, Golgi preparations
showed long dendritic spines (Hinton et al., 1991), and the FMR1 knockout mouse also shows
spine dysgenesis (Comery et al., 1997).

3.2.2 Lipophilic dye
Lipophilic dyes are fluorescent substances that can be microinjected into a single cell and
visualized using a confocal microscope to study neuronal morphology in both animals and
humans (Belichenko et al., 1994). This method offers advantages over the Golgi method because
that experimenters can select the neuron(s) that are to be infused with the dye and perform digital
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3-D reconstruction of dendritic morphology with laser confocal imaging, instead of the
traditional light microscope with Camera-Lucida method. Belichenco’s group used the dye
Lucifer Yellow and confocal microscopy to reconstruct the 3-D morphology of neurons in the
prefrontal, motor, and temporal areas of RTT brain tissue. They showed reduced apical dendritic
morphology and spine density, as well as dendritic segments lacking spines, which they called
“naked dendrites,” in pyramidal neurons of the frontal cortex (Belichenko et al., 1997a;
Belichenko et al., 1994). Belichenko and his colleagues used this method to study the
morphology of neurons in a number of diseases and injuries associated with spine pathology
(Belichenko et al., 1997a; Belichenko et al., 2004; Belichenko et al., 1994; Johansson and
Belichenko, 2002).

3.2.3 The single-cell genetic approach
The use of retrovirus-mediated gene delivery, also known as the single-cell genetic
approach, has made it possible to study the morphology and functional properties of newborn
neurons throughout their lifetime (Gage, 2002; van Praag et al., 2002). Newborn neurons in the
adult hippocampus have been used as a model to study neuronal development, because they
recapitulate many features of embryonic hippocampal development (Song et al., 2005). When
using the retroviral approach, newborn cells in the hippocampus are infected with retrovirus,
causing them to express a live reporter, such as green fluorescent protein (GFP), throughout the
cell, including the dendritic processes spines. This allows researchers to conduct a temporal
analysis of the dendrite and spine development of newborn neurons by direct visualization of
living newborn cells (Zhao et al., 2006). We used the single-cell genetic approach in an animal
model of RTT to investigate the role of Mecp2 in developing neurons of the adult hippocampus
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(Smrt et al., 2007). We found that four-week-old new neurons in adult Mecp2 knockout animals
showed reduced dendritic spine density, a characteristic feature of immature neurons suggesting
that newborn dentate granule neurons lacking Mecp2 have impaired maturation. Using a similar
approach, we demonstrate that miR-137 overexpression inhibits dendritic morphogenesis (Smrt
et al., 2010). These data are consistent with similar findings using other methods described in
this section to study dendritic spines under pathological conditions and support the idea that
abnormal dendrite and spine development is the common point of vulnerability leading to the
neurological deficits in diseases associated with MR.

3.3

Conclusions
In first 3 chapters, I have discussed the role of epigenetics in dendritic and spine

morphogenesis. Since Cajal’s epic contributions to neuroscience in the late 19th and early 20th
centuries, contemporary science and advances in genetic and molecular tools have enabled
researchers to look deeper into the underlying mechanisms of dendritic and synaptic
development. The advent of epigenetic research has provided much new knowledge and also
opened up more questions regarding the role of gene expression regulation in neurodevelopment.
My focus as a researcher has been to use our arsenal of tools and knowledge of molecular
biology and genetics to understand how dendrites and dendritic spines become grossly impaired
in individuals faced with MR and neuropathology.
Recent studies have shown that mutations in the epigenetic machinery lead to many
forms of MR disorders. Synaptic plasticity, as well as learning and memory, are believed to
depend on proper neuron-neuron communication, and identification of the genes involved in
synaptic development is crucial to understanding these human disorders.
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The important challenge for both scientists and clinicians is to identify the molecular
basis for cognitive and behavioral symptoms in order to design adequate pharmacological
treatments. A number of epigenetic-based therapeutic methods have been proposed as treatments
for epigenetic-associated diseases. Many pharmacological agents have been discovered that alter
methylation patterns on DNA and histones, many of which are being extensively tested in vitro
and in clinical trials (Egger et al., 2004). However, epigenetic reagents, such as HDAC or DNA
methylation inhibitors, have met with concerns about the specificity of the drug’s action.
MicroRNAs have recently been identified as promising candidates for the treatment of diseases,
such as heart disease and cancers. The challenge is to identify the specific miRNA(s) that could
be considered treatment targets and to deliver that miRNA or miRNA inhibitor precisely to the
target cells with high efficiency and without side effects. The next chapter will state the goal of
my dissertation research and how I will explore the link between epigenetics, miRNA, and
disease such as Rett Syndrome.

Figure 3.1. Epigenetic regulation of biogenesis and functions of miRNA in the neuron. Transcription of miRNA,
which can be regulated by epigenetic machinery, leads to the production of miRNA transcripts (pri-miRNAs), which are
cleaved in the nucleus and exported into the cytoplasm as pre-miRNAs. The pre-miRNA is processed by the RNase
Dicer and is likely associated with other accessory proteins, such as FMRP, to form an intermediate miRNA duplex. The
leading strand of the miRNA duplex can then associate with the miRNA-induced silencing complex (miRISC), and then
pair with sequences located on the 3’UTR of target mRNAs. This leads to translational repression of the target mRNA.
This example illustrates the effect of miRNA-mediated translational repression of proteins important for
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dendritic spine function.

CHAPTER 4:
Goal of my Thesis Dissertation
The goal of this thesis is to determine how epigenetic factors influence the key
characteristics of neuronal maturation in developing neurons. Despite the fact that several protein
pathways have been identified as critical players in spine development and pathology, the
molecular pathogenesis of aberrant spine morphology in epigentic diseases such as Rett
syndrome has yet to be clearly and comprehensively elucidated. The scientific studies I
conducted focus on how epigenetic mechanisms that are known to regulate gene expression,
including DNA methylation, chromatin remodeling, and noncoding RNA-mediated processes
may play a role in regulating the development and maturation of dendrites and spines.
In Chapter 5, I investigated the role of MeCP2-mediated epigenetic regulation in
neurogenesis and neuronal maturation of the hippocampus in postnatal brains (Smrt et al, 2007).
Using the Mecp2-deficient mouse mutant, we found that MeCP2 was not critical for the
production of immature neurons in the dentate gyrus (DG) of the hippocampus. However, the
newly generated neurons exhibited pronounced deficits in neuronal maturation, including
delayed transition into a more mature stage, altered expression of presynaptic proteins, and
reduced dendritic spine density. Furthermore, analysis of gene expression profiles of isolated DG
granule neurons revealed abnormal expression levels of a number of genes previously shown to
be important for synaptogenesis. Our studies suggest that MeCP2 plays a central role in neuronal
maturation, which might be mediated through epigenetic control of expression pathways that are
instrumental in both dendritic development and synaptogenesis. The data collected in this study
suggest that Mecp2 is not critical for the early stages of neurogenesis, but is important for
neuronal maturation in the postnatal brain.
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It has been shown that epigenetic factors such as MeCP2 have a profound effect on
normal brain and dendritic development (Chahrour and Zoghbi, 2007); however, how epigenetic
factors such as MeCP2 regulate brain development and neuronal maturation is unclear due to the
challenges of identifying the downstream targets by classical gene expression analyses
(Bienvenu and Chelly, 2006). Despite extensive effort to understand how MeCP2-deficiency
leads to abnormal neuronal development, relatively few genes have been confirmed to be
regulated by MeCP2, and the MeCP2-targeted gene(s) responsible for the pathogenesis of Rett
syndrome have yet to be elucidated. To understand the function of MeCP2 in dendritic and
dendritic spine development, I investigated non-coding miRNAs as the potential downstream
effectors of MeCP2. In a paper I co-authored (Szulwach et al., 2010), we show that MeCP2
epigenetically regulates a number of specific miRNAs in adult brain-derived neural stem cells
(NSCs) under both proliferating and neuronal differentiating conditions. One of the miRNAs is
miR-137. MeCP2 was found to bind directly to the genomic region proximal to miR-137, and
absence of MeCP2 binding to this region correlated with an altered chromatin state and enriched
miR-137 expression (Szulwach et al., 2010). This study suggests that the crosstalk between
MeCP2-mediated epigenetic regulation of gene expression and miRNA pathways can function to
modulate adult neurogenesis. In separate experiments done in the adult mouse brain and primary
neurons, we show that miR-137 is significantly upregulated in the absence of MeCP2
(APPENDIX A). Thus, because MeCP2 can alter expression of specific miRNAs, including
miR-137, we proposed that altered expression of miRNAs may contribute to the dendrite and
dendritic spine pathogenesis observed in Rett Syndrome.
In Chapter 6, I demonstrate that miR-137 is a brain-enriched microRNA that has a
significant role in regulating neuronal maturation in vivo and in vitro (Smrt et al, 2010).
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Overexpression of miR-137 inhibited dendritic morphogenesis, phenotypic maturation, and spine
development both in brain and cultured primary neurons. Similarly, a reduction in miR-137 had
opposite effects. Our research group produced a luciferase construct containing the 3’UTR of
Mib1, which I used to show that miR-137 targets the MIB1 protein through the conserved target
site located in the 3’ untranslated region of Mib1 mRNA. Exogenously expressed MIB1 partially
rescued the phenotypes associated with miR-137 overexpression suggesting that a novel
miRNA-mediated mechanism involving miR-137 and MIB1 can function to regulate neuronal
maturation and dendritic morphogenesis during development. I used the “single-cell genetic
approach” in newborn neurons of the adult hippocampus and found reduced dendritic complexity
and spine density; however, since the single-cell genetic approach specifically targets
proliferating cells prior to neuronal differentiation, I also confirmed that overexpression of miR137 has the same effect on postmitotic cultured hippocampal neurons. Both overexpression and
inhibition of miR-137 have significant but opposite effects on dendritic complexity. Therefore,
my data indicate that proper expression of miR-137 is required for the normal dendritic
development of hippocampal neurons.
Chapter 7 expands the discussion of the previous chapters. In Chapter 7, I summarize the
significance of my thesis research, address specific concerns and limitations regarding my
research, define specific steps that I have taken to address many of those concerns, and propose
additional experimental procedures that may function to strengthen my previous findings.
Finally, I discuss potential future directions of this project based on my current findings.
In summary, the results of my dissertation research demonstrate that epigenetic
regulations, particularly those involving MeCP2 and epigenetically controlled noncoding
microRNAs, are important modulators for normal development of neuronal dendrite and
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dendritic spines. My data show how alterations in epigenetic and non-coding RNA-mediated
processes may result in morphological and phenotypic abnormalities of neurons that are a
fundamental characteristic for many forms of MR, such as fragile X, autism, and Rett syndrome.
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5.1

ABSTRACT
It is well known that Rett Syndrome, a severe postnatal childhood neurological disorder

is mostly caused by mutations in the human MECP2 gene. However, how deficiencies in the
MeCP2 protein contribute to the neurological dysfunction of Rett Syndrome is not clear. We
aimed to resolve the role of MeCP2-mediated epigenetic regulation in postnatal brain
development using a Mecp2-null mutant mouse model. We found that, while MeCP2 was not
critical for the production of immature neurons in the dentate gyrus (DG) of the hippocampus,
the newly generated neurons exhibited pronounced deficits in neuronal maturation, including
delayed transition into a more mature stage, altered expression of presynaptic proteins, and
reduced dendritic spine density. Furthermore, analysis of gene expression profiles of isolated DG
granule neurons revealed abnormal expression levels of a number of genes previously shown to
be important for synaptogenesis. Our studies suggest that MeCP2 plays a central role in neuronal
maturation, which might be mediated through epigenetic control of expression pathways that are
instrumental in both dendritic development and synaptogenesis.
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5.2

Introduction
Rett Syndrome (RTT) is a neurodevelopmental disorder that affects one of every 15,000

female births. RTT patients develop normally until 6 to 18 months of age, but then regress
rapidly experiencing a wide range of neurological defects, such as seizures, ataxia, and
stereotypical hand movements. Individuals affected by RTT often survive into adulthood, and
while some symptoms stabilize, others may worsen (Hagberg et al., 1983b; Hagberg and WittEngerstrom, 1986; Kriaucionis and Bird, 2003). In most cases, RTT can be linked to loss-offunction mutations in the X-linked human MECP2 gene (Amir et al., 1999), which encodes a
methylated-CpG binding protein that recruits additional factors such as histone deacetylase to
repress transcription (Bird, 2002a). Several lines of Mecp2 mutant mice (KO) have been
generated and these mice develop similar symptoms to those seen in RTT patients and have been
widely used to study the etiology of human RTT (Chen et al., 2001b; Guy et al., 2001; Pelka et
al., 2006; Shahbazian et al., 2002a). Nevertheless, the neurodevelopmental pathways and specific
genes targeted by the disruption of this epigenetic regulatory control have not been determined.
Recent experimental evidence indicates that MeCP2 may play a vital role in neuronal
maturation (Bienvenu and Chelly, 2006). A critical step in the process of neuronal maturation is
synaptogenesis, which coincides with the increased expression of MeCP2 in developing neurons
(Akbarian et al., 2001b; Zoghbi, 2003) (Shahbazian and Zoghbi, 2002a), suggesting that
epigenetic modulation of gene regulation during this period might be critical for brain
development. In fact, postmortem analysis has demonstrated reduced numbers of axonal and
dendritic processes, decreased dendritic spine density, and lowered levels of the dendritic
cytoskeletal protein MAP2 in RTT brains (Armstrong, 2002; Kaufmann and Moser, 2000b).
Consistent with human pathology, pyramidal neurons in the cortex of adult Mecp2 null mutant
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(KO) mice were found to have smaller soma and less complex dendrites, though the morphology
and density of dendritic spines were not determined in this study (Kishi and Macklis, 2004).
Exogenous MeCP2 expression could also lead to increased neurite complexity in cultured
neurons (Jugloff et al., 2005), further suggest a role of MeCP2 in dendritic development.
However, in another study, analyses of Golgi-stained cortical and subcortical neurons of Mecp2
truncation mutant mice (Mecp2y/308) did not reveal significant abnormalities in either dendritic
arbor or spine density (Moretti et al., 2006). The discrepancy between these results could be due
to differences in either the model systems analyzed or the methods used. Abnormalities in
dendritic spines have been found in several developmental disorders [reviewed by (Fiala et al.,
2002)]. Therefore it is critical to clarify whether Mecp2 mutations affect spine development by
monitoring the maturation of single neurons in a well defined cell population in order to
understand the function of MeCP2 in neural development and the etiology of RTT.
Unlike most other brain regions, neurogenesis in the adult dentate gyrus (DG) persists
throughout life. In adult mice, newborn DG neurons develop properties similar to mature granule
neurons after approximately 4-8 weeks of differentiation. The properties of newborn neurons in
the adult DG recapitulate embryonic hippocampal development (Song et al., 2005), providing a
unique model system for studying the generation and maturation of neurons in postnatal brains
(Gage, 2002). The hippocampus also provides a logical framework to study the pathogenesis of
MeCP2 deficiency because the morphological maturation, functional properties, and molecular
mechanisms of the hippocampus have been extensively characterized due to their potentially
critical roles in learning and memory (Nicoll and Schmitz, 2005; Ziv and Garner, 2004), and
because Mecp2 KO mice have been shown to have impaired long-term potentiation and

42

depression, impaired excitatory neurotransmission, and altered expression of neurotransmitter
receptors in hippocampal neurons (Asaka et al., 2006; Moretti et al., 2006; Nelson et al., 2006).
MeCP2 has been found to be expressed in neural stem cells (NSCs) (Jung et al., 2003;
Namihira et al., 2004). While MeCP2 was shown to be involved in embryonic neurogenesis in
Xenopus, studies have indicated that this is not the case in mice (Kishi and Macklis, 2004;
Stancheva, 2003). Recent evidence has revealed that adult NSCs are different from embryonic
NSCs in both the cellular environment they encounter and in their intrinsic genetic and
epigenetic properties (Cheng et al., 2005; Zhao et al., 2003). Moreover, deletion of Mecp2related Methyl-CpG binding protein 1 (Mbd1) specifically affects postnatal, but not embryonic,
neurogenesis (Zhao et al., 2003), suggesting that postnatal neurogenesis may be particularly
vulnerable to altered epigenetic regulation. Therefore, analyzing postnatal neurogenesis in the
absence of MeCP2 will provide critical information for understanding the function of this
protein.
In this study, we have determined that MeCP2 is not critical for the early stages of
neurogenesis. In contrast, we show that immature neurons in the DG of KO mice exhibit deficits
in their ability to transition into later mature stages of development. This deficit results in adult
Mecp2 KO mice retaining characteristic features of immature brains, suggesting a stalled
maturation. At a single neuronal level in the postnatal hippocampus, MeCP2-deficient neurons
exhibited a reduced number of dendritic spines. By analyzing gene expression profiles of a
homogeneous population of DG neurons isolated from KO brains, we have found that the
expression levels of several genes encoding proteins that are likely to be involved in
synaptogenesis were altered. Together, these data suggest that MeCP2 is critical for the
maturation of young neurons, possibly through regulating synaptogenic factors.
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5.3 Materials and Methods
Animals: All animal procedures were performed according to protocols approved by the
University of New Mexico Animal Care and Use Committee. The Mecp2 KO mice
(Mecp2tm1.1Jae) used in this study were created by deleting exons 3 containing the MBD domain
of Mecp2 (Chen et al., 2001b). These mice have been bred over 40 generations on to ICR
background. They start to show neurological symptoms between 5 and 7 weeks of age and die
before 10 weeks of age. For histological analyses, mice were euthanized by intraperitoneal
injection of sodium pentobarbital. Mice were then perfused with saline followed by 4% PFA.
Brains were dissected out, post-fixed overnight in 4% PFA, and then equilibrated in 30%
sucrose. Forty-µm brain sections were generated using a sliding microtone and were stored in 20oC freezer as floating sections in 96-well plates filled with cryoprotectant solution (glycerol,
ethylene glycol, and 0.1M phosphate buffer, pH 7.4, 1:1:2 by volume).

Statistical analyses: All statistical analyses were performed using unpaired, two-tailed, Student’s
t-test and in all figures, the data bars and error bars indicate mean ± standard error (s.e.m).

Isolation and in vitro analyses of adult NSCs: Isolation of adult NSCs was performed based on
the published method (Zhao et al., 2003). Briefly, forebrains without olfactory bulb and
cerebellum (4 mice/ genotype, age- and sex-matched) were dissociated mechanically followed by
enzymatic digestion using PPD (2.5 U/ml papain, 1U/ml DNAseI, and 200 mg/100 ml Dispase
II) in DMEM high glucose (Cellgro, Herndon, VA). After filtering through a 70-µm cell strainer
(BD Falcon, San Jose, CA), a single cell suspension was loaded onto 50% percoll. The NSCs
were separated from other cells by ultracentrifugation at 127 krpm for 30 min at 20oC using a
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SW41 rotor (Beckman, Fullerton, CA). The fraction containing NSCs (immediately above the
red blood cell layer in the gradient) was collected, washed with PBS, and plated in N2 medium
(DMEM/F12 1:1 containing N2 supplement (Invitrogen, Carlsbad, CA) supplemented with 20
ng/ml FGF-2 and 20 ng/ml EGF in a 5% CO2 incubator. Cell proliferation analyses were
performed as described (Lie et al., 2005). Briefly, BrdU was added to the culture medium at 5
µM for 16 hours, followed by fixation using 4% PFA. Cells were then stained with antibodies
against BrdU (1:500, Accurate Chemicals, Westbury, NY) and Ki67 (1:1000, NovoCastra
Laboratories, Newcastle upon Tyne, UK) and 10 µg/ml DAPI. The percentage of BrdU+ cells or
Ki67+ over total DAPI+ cells indicates the percentage of cells that are proliferating. For in vitro
differentiation analysis, cells were incubated in N2 media containing 1 µM forskolin, 1 µM alltrans retinoic acid and 0.5% FBS for 7 days. Cells were then fixed by 4% PFA, followed by
immunocytochemical analysis as described previously (Zhao et al., 2003). Primary antibodies
used were: rabbit anti-type III β-tubulin (1:4000, Covance, Berkeley, CA), RIP (1:50,
Hybridoma Bank, Iowa City, Iowa), s-100

(1:1000; Sigma-Aldrich, St Louis, MO), and all

secondary antibodies (Jackson ImmunoResearch, West Grove, PA) were used in 1:250 dilution.
Cell phenotypes were analyzed using an Olympus BX51 Research microscope equipped with
epifluorescence, an optronics microfire digital color camera, and StereoInvestigator software
(MicroBrightField). Cell counting was performed using an optical fractionator sampling design
and formula (Gundersen et al., 1988). Four independent experiments (each had triplicates), using
similar passages of cells, were performed for in vitro proliferation and differentiation assays.

In vivo neurogenesis analyses: In vivo neurogenesis analyses were performed essentially as
described previously (Zhao et al., 2003). Briefly, in 8-week-old mice (11 WT and 8 KO), BrdU
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(50mg/kg) was injected daily for 7 consecutive days to increase the amount of labeling. In 4week-old mice (6 WT and 9 KO), BrdU was injected once daily for 4 consecutive days. Mice
were then euthanized 1 day post-injection to assess proliferation (and early survival) of labeled
cells. For cell survival analysis, mice injected at 4 weeks of age (6 WT and 9 KO, 1 injection/day
for 4 days) were euthanized 4 weeks post-injection. For immunohistological analysis, 1-in-6
serial floating brain sections (240 µm apart) were performed based on the published method
(Zhao et al., 2003). The primary antibodies used were: rat-anti-BrdU (1:500; Accurate
Chemicals), mouse anti-NeuN (1:5000; Chemicon International, Temecula, CA), rabbit anti-S100

(1:500; Sigma), and chicken anti-Mecp2 (1:5000, a generous gift from Dr. Janine LaSalle

University of California, Davis). Fluorescent secondary antibodies were used at 1:250 dilutions
(donkey, Jackson ImmunoResearch). After staining, sections were mounted, coverslipped, and
maintained at 4oC in the dark until analysis. BrdU-positive cells in the granule layer were
counted using unbiased stereology (StereoInvestigator, MicroBrightField) with a 5-µm guard
zone as described elsewhere (Zhao et al., 2003). DG volume and cell density determinations
were performed as described (Zhao et al., 2003). Phenotype analysis of BrdU+ cells was
performed as described previously (Zhao et al., 2003). Briefly, 50 BrdU+ cells in the DG were
randomly selected and their phenotypes (double labeling with either NeuN, S100β, or neither)
were determined using a Zeiss LSM510 laser scanning confocal microscope. The data were
analyzed using a Student’s t-test (Graphpad software, www.graphpad.com).

Quantification of mature, immature, and “transitioning neurons” in the DG: This procedure was
performed based on the published method (Brown et al., 2003). Briefly, 40-µm thick coronal
tissue sections containing hippocampus were stained with antibodies against DCX (1:1000, goat,
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Santa Cruz), NeuN, and DAPI. The immunofluorescence signals were captured using a spinning
disk confocal microscope (Nikon Eclipse TE2000-U, 40x oil,1.2 NA). Quantification was done
by a person who was blind to the genotypes of the mice. The numbers of NeuN-/Dcx+,
NeuN+/DCX+, NeuN+/DCX-, and cells were quantified by examining z-stacks taken at 1-um
intervals using MetaMorph imaging software (Molecular Devices Inc., Sunnyvale, CA). A total
of 5 WT and 6 KO mice for the 4-week time point and 8 WT and 5 KO mice for the 8-week time
point were used. Three z-stacks were taken from each animal and 6 image planes per optical
stack were used for quantification.

Immunohistological analyses and quantification of synaptophysin: Staining and analyses of
synaptophysin immunoreactivity were performed according to published method (Li et al.,
2002). Briefly, 40-µm thick brain sections were incubated in primary antibody against
synaptophysin (rabbit, 1:100; Zymed, San Francisco, CA), followed by biotinylated secondary
antibody (donkey anti rabbit IgG; 1:250; Jackson ImmunoResearch), then incubated in ABC
reagent (VECTASTAIN ABC Kit, Vector Laboratories) and detected by diaminobenzidine
(DAB Substrate Kit, Vector Laboratories, Burlingame, CA). The sections were then thoroughly
washed, mounted, air dried, and coverslipped with Permount (Biomedia Corp., Foster City, CA).
Sections incubated with normal rabbit IgG instead of a primary antibody (Sigma-Aldrich) were
used as negative controls. Optical density analysis of synaptophysin staining was performed by
placing 10 circles in each region using Image-J software, as described elsewhere (Li et al., 2002).
To categorize the clustered staining pattern, 63X (Zeiss Axioscope, NA = 1.4) images of brain
sections were used. Images were captured at 1300 pixels x 1030 pixels using Slidebook software
(Intelligent Imaging Innovations, Denver, CO). Using Image-J (NIH) image analysis software, a
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threshold value was determined for positive staining and remained the same throughout the data
analysis. Large clusters were determined to be clusters greater than 300 pixels2 and were
quantified using the “Analyze Particles” function of Image-J. Sections with 0-5 “large clusters”
in the molecular layer of the hippocampus were placed into category 1, and sections with greater
than 5 “large clusters” were placed into category 2. The experimenter was blind to the genotypes
of the sections. The number of large clusters in each category was counted for each genotype and
age group and the data were used to create Figure 5.3e.

Retroviral grafting. Production of CAG-eGFP retrovirus and in vivo grafting into the DG of
mice were performed as described elsewhere (Zhao et al., 2006). Briefly, CAG-eGFP plasmid
was co-transfected with packaging plasmids pCMV-gag-pol and pCMV-Vsvg into HEK293T
cells and the medium containing virus was collected, filtered, and concentrated using
ultracentrifugation. For in vivo grafting, 4-week-old mice were anesthetized with isofluorane and
virus (1.5 μl with titer greater than 5X105/µl) was injected stereotaxically into the DG using the
following coordinates relative to bregma: anteroposterior, -(1/2) x d mm; lateral, -1.8 mm (if d >
1.6) or -1.7 mm; ventral, -1.9 mm (from dura). Four weeks after injection, mice were deeply
anesthetized with pentobarbital and perfused with saline followed by 4% PFA.

Immunohistochemistry and dendritic spine density analyses: 1-in-3 floating brain sections
containing eGFP+ cells (120 µm apart, approximately 8 brain sections) were used for
immunohistological staining using a protocol described elsewhere (Zhao et al., 2003). The
primary antibody used was rabbit anti-GFP (Invitrogen, Eugene, OR). Briefly, for spine
quantification, a minimum of 12-15 images of dendritic fragments were taken at 25-100 μm from
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the cell body of each eGFP+ neuron using a confocal microscope with an oil immersion objective
(100x; NA = 1.3; Zeiss). Z-stacks at 1 µm intervals were taken and merged for a maximum
intensity projection. For quantification of dendritic spines, protrusions were counted along 10 μm
long dendrite segments measured using Image-J software (NIH Image). The “dendritic spine
density” result was calculated as number of spines per 10 μm length of dendrite. A minimum of
40 dendritic fragments (10-μm each) from a minimum of 4 eGFP+ neurons were quantified from
each animal. At least 3 animals from each genotype were analyzed and the final results were
compared using a Student’s t-test. The apposition of immunostained presynaptic boutons with
eGFP-expressing postsynaptic spines was determined according to a published method
(Belichenko et al., 2004). Briefly, the presynaptic terminal (synaptophysin+) and postsynaptic
spine (eGFP+) were defined as apposed when there was an overlap between pre- and
postsynaptic elements, or when these elements were separated by no more than one pixel (0.1
µm).

Laser Capture Microdissection (LCM) and gene expression analyses: LCM, amplification by in
vitro transcription, and probe labeling were performed using a highly reproducible protocol that
has been adapted and optimized to analyze gene expression profiles using as little as 5ng total
RNA (Phillips and Eberwine, 1996) (Dr. FH Gage, unpublished). Briefly, 4 KO and 4 WT mice
(8 weeks of age) were used. Brains were rapidly removed from the cranium and flash-frozen in
OCT mounting medium (TissueTek, Sakura Finetek, Torrance, CA) in a dry ice-isopentane
slurry and stored at –80oC. The day before LCM, 12 µm sections of brain were generated,
stained with cresyl violate, and dehydrated. The granule cell layers of DG were captured using
an Arcturus PixCelII LCM microscope (Arcturus Bioscience Inc., Mountain View, CA). An
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example is shown in Figure 5.5. LCM was performed at a power level between 25 and 45 mV,
between 2 and 20 ms duration, and at a median spot size setting. A minimum of 30 brain sections
(less than half of the sections generated from each brain) were used to capture sufficient DG
neurons for this study. Captured tissue was dissolved in cell lysis buffer in the MicroRNA kit
(Stratagene, San Diego, CA) for 2 to 5 minutes immediately after capturing. Total RNA was
isolated from cell lysate using a MicroRNA kit (Stratagene), and approximately 20 ng total RNA
was obtained. Half of the sample was used to quantify RNA using a Ribo Green kit (Invitrogen).
Finally, 10 ng total RNA was amplified using 3 rounds of a MessageAmep kit (Ambion, Austin,
TX). During the last round, RNA was labeled with biotin (Enzo kit, Affymetrix, Santa Clara,
CA), purified, and quantified. Biotin-labeled cRNA (30 µg) was fragmented and hybridized to
Affymetrix U430 arrays (Affymetrix). Analysis of microarray data was performed using three
distinct software programs as described in our previous publication (Barkho et al., 2006).
Briefly, the data were pre-processed using the Affymetrix Microarray Analysis Suite (MAS) 5.0
and subsequently analyzed using dChip (Li and Wong, 2001), Drop Method (Aimone and Gage,
2004), and the algorithms of RMA (Irizarry et al., 2003; Tusher et al., 2001). The combination of
these methods has been shown to reduce both false positives and false negatives (Aimone et al.,
2004; Barkho et al., 2006). Specifically, for dChip, we selected genes that passed with 90%
confidence and had a fold change greater than 1.2. For the Drop method (the PM-only, and PMMM are considered as one method), we selected genes that passed with a confidence of 70%. For
RMA, a fold change had to meet the criteria of being greater than 1.2 and have a false discovery
rate (FDR) less than 30%. The FDR value used for RMA was based on the Significance for
Analysis of Microarrays software (SAM) (Tusher et al., 2001). Only genes identified by all three
software programs were included as differentially expressed genes and are listed in Table 5.1.
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Real time quantitative PCR: Real time quantitative PCR was performed as described (Barkho et
al., 2006; Zhao et al., 2001). Briefly, the cDNA was synthesized using MessageAmep kit,
(Ambion) for LCM samples. PCR primers were designed using PrimerExpress software (Applied
Biosystems, Foster City, CA) and ordered from IDT Inc. (CA). The primer sets were first
evaluated by standard PCR to determine that single PCR products of the predicted size were
generated. A typical Real Time PCR reaction mix contained 1X SYBR Green Master Mix
(Applied Biosystems), 100 nM of each oligonucleotide primer and 10 ng cDNA in a total volume
of 25µl. The reaction was carried out in an ABI 7700 System (Applied Biosystems). Each
condition was acquired in at least triplicate, and data analysis was performed according to the
protocol provided by Applied Biosystems. Standard curves were generated using a pre-made
pool of mouse brain and spinal cord total RNA. The amount of mRNA for tested genes was
calculated according to the standard curve for that particular primer set. Finally, the relative
amount of the tested message was normalized to the level of an internal control message,
hypoxanthine phosphoribosyl transferase (HPRT).

5.4

RESULTS

5.4.1 Early postnatal neurogenesis appears normal in MeCP2-deficient mice
We have previously found that mice deficient for Mbd1, a MeCP2-related protein, exhibited
reduced adult hippocampal neurogenesis both in vivo and in vitro (Zhao et al., 2003). Because
RTT manifests at 6-18 months of age in patients, well after primary neurogenesis, we asked
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whether a lack of functional MeCP2 causes deficits in postnatal neurogenesis that might be
linked to neurological symptoms comparable to those seen in RTT patients. We compared neural
stem/progenitor cells (NSCs) isolated from 6-week-old male KO and wild type (WT) mice. At
this age, the majority of KO mice have developed characteristic neurological signs of disease as
previously reported (Chen et al., 2001b; Guy et al., 2001). Using bromodeoxyuridine (BrdU)
incorporation as a measure of proliferation index, we found that KO NSCs proliferated at a rate
that was indistinguishable from WT control cells (Fig 1A and 1B, p=0.41). Moreover, KO and
WT cultured NSCs also differentiated into similar numbers of neurons (Fig 5.1C and 1D,
p=0.43) and astrocytes (data not shown), indicating that there was no marked impairment in the
proliferation or differentiation potential of MeCP2-deficient NSCs in culture.
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Figure 5.1. Mecp2 KO mice exhibit a normal early stage of postnatal neurogenesis even though immature
neurons have an abnormal morphology. (A) For cell proliferation analyses, NSCs isolated from 6-week-old
KO and WT brains were cultured in the presence of BrdU to label dividing cells. BrdU-labeled cells were
detected by immunocytochemistry (red, BrdU; blue: DAPI nuclear staining; scale bar=10 µm). (B) Quantitative
analyses of BrdU-labeled cells indicated no significant difference in cell proliferation between KO and WT NSCs
in vitro (p=0.41, n=3, t-test). (C) Mecp2 KO NSCs can differentiate into neurons (TuJI+, red) and astrocytes
(S100b+, green) (blue: DAPI nuclear staining); scale bar=10 µm. (D) There was no significant difference in
neuronal differentiation between KO and WT NSCs in vitro (p=0.43, n=3 t-test). (E) Example of a brain section
stained with antibodies to NeuN (green) and BrdU (red) for in vivo neurogenesis analyses. Neither 4-week-old
(F) nor 8-week-old (G) KO mice exhibited significant deficits in the number of BrdU+ cells at either 1 day postBrdU injection (F and G) or 4 weeks post-BrdU injection (H). At 4 weeks post-labeling, BrdU+ KO cells
differentiated into similar numbers of new neurons (I) compared to WT mice. Low magnification (J-M, scale
bar=100 µm) and high magnification (N-S, scale bar=10 µm) images of DG stained with antibodies against
Mecp2 (red nuclear staining) and DCX (green). Note that Mecp2 staining is absent in KO brains (L, M, Q-S). (NS) DCX+ immature neurons in KO brains have disorganized morphologies compared to those in WT brains
(arrowhead in P), with abnormal orientation of the processes of many DCX+ neurons (arrowhead in S). The
dotted lines in N-S indicate the boundary of the granule cell layer. m, molecular layer, g, granule cell layer, and
h, hilar region.

To examine postnatal neurogenesis in vivo, we assessed proliferation, survival, and
differentiation of NSCs in the hippocampus of young mice. In the rodent hippocampus, granule
cells of the DG develop postnatally, becoming morphologically mature at about 4 weeks of age,
which corresponds roughly to the second year in humans (Seress et al., 2001; Seress and
Mrzljak, 1992), when RTT symptoms first become apparent. Newborn cells were distinguished
by incorporation of BrdU administered through intraperitoneal injections into either 4 week-old
juvenile or 8-week-old young adult mice. Quantitative histological analysis at one day after the
last BrdU injection showed no difference between KO and WT mice either at 4 or 8 weeks of age
(Fig 5.1E-G). This finding suggested that, as found in cultured NSCs, the NSCs in KO mice
proliferate normally in the DG of developing and mature mice. In a separate group of mice, longterm survival and differentiation of BrdU-labeled cells were examined by analyzing labeled cells
4 weeks after BrdU injections. We found that the numbers of BrdU-labeled cells that survived
from 4 weeks to 8 weeks were also similar in both KO and WT mice (Fig 5.1H, p=0.13).
Moreover, the percentage of BrdU-labeled cells co-labeled for either the neuronal marker NeuN
(Fig 5.1I) or astrocyte marker GFAP (data not shown) did not differ significantly between KO
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and WT mice. Furthermore, neither the cell density nor the volume of the DG of KO mice was
significantly different from WT mice (data not shown). Finally, to investigate whether there was
a difference in the population of transient migrating neuroblasts or immature neurons, we
quantified the number of cells stained with doublecortin (DCX), a microtubule associated protein
(Brown et al., 2003) Francis et al., 1999; Gleeson et al., 1999; Magavi et al., 2000). Again, we
found no difference between the number of DCX-positive cells in the DG of KO and WT mice
(Fig 5.1J-S). Taken together, these in vitro and in vivo results strongly suggest that the lack of
MeCP2 does not impair the proliferation, survival, or differentiation of neural progenitors during
this early stage of postnatal hippocampal neurogenesis.

5.4.2 Impaired maturation of MeCP2-deficient neurons
Despite the overall similar numbers of immature neurons in the DG of KO and WT mice,
we noticed clear abnormalities in the neurite outgrowth from MeCP2-deficient immature neurons
(Fig 5.1R and S). In the DG of WT mice, the cell bodies of the DCX+ neurons were typically
located in the subgranular zone (SGZ) of the DG adjacent to the hilar region, with their processes
perpendicularly extended through the granule cell layer (GCL) and exited into the opposite
molecular layer (Fig 5.1N-P, arrowhead) (Brown et al., 2003; Rao et al., 2005; Rao and Shetty,
2004). In contrast, the processes of most DCX+ neurons in the DG of Mecp2 KO mice were
found to traverse nearly parallel along the hilar boundary of the DG (Fig 5.1Q-S, arrowhead).
This morphological difference might reflect impaired maturation because since horizontal and
short processes are characteristic features for new neurons at early stage of differentiation
(Esposito et al., 2005; Ge et al., 2006; Zhao et al., 2006). Because the majority of the DG granule
neurons are generated during postnatal development, we exploited the possibility that this deficit
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was widespread in the developing DG. We therefore compared the ratio of NeuN+ mature and
DCX+ immature neurons in the DG of Mecp2 KO and WT mice at two different ages: when the
DG had just past the peak of primary cell genesis (4 weeks of age) and when DG had reached the
adult level of maturity (8 weeks of age) (Fig 5.2A-G) (Mullen et al., 1992). Furthermore, we
quantified the number of cells positive for both NeuN and DCX to distinguish the cells that were
transitioning from an immature to a mature phenotype and to provide an additional index of this
developmental maturation process (Fig 5.2E-G).
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Figure 5.2. Immature neurons in the DG of Mecp2 KO mice have delayed transitioning to mature stage.
(A-D) Confocal images showing DG of the hippocampus labeled with antibodies against NeuN (A, green,
mature neurons), DCX (B, red, immature neurons), and DAPI (C, blue, nuclear dye). Scale bars=100 µm. (D)
Merged image of A-C. (E-G) Higher magnification images of granule neurons and examples of neurons that are
NeuN+DCX- (asterisk) and NeuN+DCX+ (arrowhead). Scale bars=10 µm. (H) Quantitative analyses indicate the
percentage of mature neurons (NeuN+DCX-, white bar), immature neurons (DCX+NeuN-, light gray) and
“transitioning neurons” (NeuN+DCX+, dark gray) in 4-week-old and 8-week-old mice. (I) Age-dependent
changes in the proportion of “transitioning neurons” over total neurons are significantly different between KO
and WT mice (p<0.0001), (J) The percentage of “transitioning neurons” among total DCX+ neurons are also
significantly different between WT and KO mice at both 4 and 8-weeks-old. While WT mice exhibited an agedependent decrease in the proportion of “transitioning neurons” over total DCX+ neurons, KO mice displayed
an increase (p<0.0001), suggesting more neurons are stalled at the transitioning stage in the KO brains.

Quantitative analysis of confocal images was used to determine the percentage of neurons in
each maturation stage (Fig 5.2A-G, DCX+/NeuN-; DCX+/NeuN+; DCX-/NeuN+) in both the KO
and WT DG. The results summarized in Figure 5.2H show that whereas neither 4- nor 8-weekold Mecp2 KO mice displayed significant differences in the percentage of mature or immature
neurons compared to WT mice, the DG of 8-week-old Mecp2 KO mice had a significantly higher
percentage of “transitioning neurons” (p<0.001). In fact, comparison of the number of
“transitioning neurons” (DCX+/NeuN+) among total neurons showed that maturation from
juvenile (4 weeks) to young adult (8 weeks) was accompanied by a 75 % decrease in the
percentage of “transitioning neurons” in normal WT brain but only a 44% reduction in the KO
brains (Fig 5.2I, p<0.0001). In addition, comparison of the number of “transitioning neurons”
(DCX+/NeuN+) and total immature neurons (both DCX+/NeuN- and DCX+/NeuN+) showed that
maturation from a juvenile (4 weeks) stage to a young adult (8 weeks) stage was accompanied, in
the normal WT brain, by a 28.5% decrease in the percentage of “transitioning neurons” among
the total population of DCX+ neurons (Fig 5.2J). However, the age-dependent reduction of this
subpopulation of double positive “transitioning neurons” among total immature neurons did not
occur in MeCP2-deficient mutants; but rather there was a 26.9% increase in the percentage of
these neurons during this developmental time period (Fig 5.2J, p<0.0001). This finding may
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indicate that the deficiency in MeCP2 may have led to DCX+/NeuN+ double positive
“transitioning neurons” being held up and failing to differentiate into more mature DCX-/NeuN+
neurons.

5.4.3 Impaired expression of developmentally regulated presynaptic proteins
in MeCP2-deficient hippocampus
Because synaptogenesis is a crucial step for the maturation and integration of newborn
neurons into the preexisting circuitry of the hippocampus, we investigated whether KO mice
have deficits in synapse formation. For this purpose, we used an antibody against synaptophysin,
a synaptic vesicle protein whose expression is known to reflect the distribution and density of
presynaptic terminals (Li et al., 2002). We focused on the molecular layer of the hippocampus,
where DG granule neuron dendrites receive input from perforant path axons from the entorhinal
cortex (Henze et al., 2000). Overall, no consistent difference was found in optical density
measurements of synaptophysin immunostaining between 4- and 8-week-old WT and KO mice
suggesting that the level of expression, and thus the number of nerve terminals, was not affected
by the lack of MeCP2. However, we did observe two patterns of synaptophysin
immunoreactivity in both WT and KO mice: highly distributed small positive spots (<300
pixels2, Fig 5.3C, arrowheads), and “large clusters” (>300 pixels2, Fig 5.3C and 3D, arrows) that
appeared to vary in density in different brain regions. To quantify the distribution of these large
clusters and determine whether they might differentiate between the synaptic density of WT and
KO hippocampus, we analyzed the number of “large clusters” (determined by Image-J
quantitative software) found in the molecular layer, where dendrites of granule neurons form
synapses. We found no significant difference in the number of large clusters in either 4-week-old
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or 8-week-old KO mice compared to their age-matched WT littermates (Fig 5.3E). However,
when WT mice mature from 4 to 8 week of age, there was an 82.6% decrease in the number of
large synaptic clusters in the molecular layer of the hippocampus (4-week, 18.29 ± 4.74, n = 14
mice; 8-week, 3.19 ± 1.10, n = 13 mice; P < 0.01), but such an age-dependent change was absent
in KO mice (P = 0.48), suggesting a failure in dispersing these large clusters into a more uniform
distribution of presynaptic terminals in the absence of functional MeCP2.

Figure 5.3. Mecp2 KO mice have altered presynaptic protein expression pattern. (A-C) Digitized brightfield micrographs show synaptophysin immunoreactivity in the adult and young mice. Scale bar=100 µm. (A)
The box indicates the region that is enlarged in C and D. (B) Sections were incubated with normal rabbit IgG,
instead of synaptophysin antibody, as a negative control. (C) Example of a brain section with small
synaptophysin positive spots (arrowheads) and two large clusters (arrows). scale bar=10 µm. (D) The output of
particle analysis of (C) produced by Image-J showing the two large clusters (arrows). (E) Number of large
clusters in 4- and 8-week-old WT mice (**P < 0.01) compared to 4- and 8-week-old KO mice. Note that WT
animals showed a clear age-dependent reduction in the density of large synapse clusters, whereas KO failed to
show this developmental change.
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5.4.4 Altered dendritic spine distribution in MeCP2-deficient mutant neurons
As neurons mature the density of dendritic spines increases (Ge et al., 2006; Zhao et al.,
2006). Consequently, reduced dendritic density is a common characteristic of the abnormal
synaptic development seen in a variety of neurological disorders (Fiala et al., 2002). To clarify
the current discrepancy in the literature and determine whether Mecp2 mutations affect dendritic
spine development, we decided to analyze the morphology of individual MeCP2-deficient
neurons in vivo. Because the persistent, albeit low level, of postnatal neurogenesis in the DG
allowed us to trace the maturation of single new neurons, we performed detailed morphological
analyses to investigate the maturation of these newly generated neurons in the MeCP2-deficient
mice. Recombinant retroviruses, which are only capable of infecting dividing cells, have been
previously used to label and follow the differentiation of NSCs in postnatal DG (Ge et al., 2006;
van Praag et al., 2002; Zhao et al., 2006). We therefore injected recombinant retrovirus
expressing enhanced green fluorescence protein (eGFP) under a chicken actin promoter (CAGeGFP) (Zhao et al., 2006) into 4-week-old KO and WT mice and analyzed the morphology of
new neurons after 4 weeks, a time when labeled new neurons would be expected to develop the
dendritic morphology of fully mature neurons (Ge et al., 2006; van Praag et al., 2002; Zhao et
al., 2006) (Fig 5.4A). As shown in Figure 5.4B-E, whereas most of the eGFP+ neurons expressed
the mature neuronal marker NeuN, a few of them also expressed DCX, indicating NSCs that had
not yet reached a fully matured state. To quantify the density of synapses, we counted the
number of spines within each 10-μm segment of dendrites imaged by high-resolution confocal
microscopy. Quantitative analyses indicated that the spine density of eGFP+ neurons in the DG
of Mecp2 KO mice was significantly reduced compared to WT mice (Fig 5.4J, WT= 13.46 ±
0.31, KO= 11.41 ± 0.11; P < 0.005).
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Figure 5.4. Newly matured neurons in Mecp2 KO hippocampus have reduced dendritic spine density and
abnormal distribution. (A) Schematic diagram demonstrating stereotaxic grafting of CAG-eGFP retrovirus into
the DG of 4-week-old KO and WT mice to label dividing neuroprogenitors in the germinal zone of the DG. At 4
weeks post grafting, many eGFP+ cells had differentiated into NeuN+ (B, C, D, arrowheads) and/or DCX+ (E)
new neurons. (F, G) High resolution image of dendrites of eGFP+ neurons were used to quantify the density of
dendritic spines (number of spines/10 µm dendrites) to generate the data in (H-J). (G) High magnification view
of the box in F. Scale bars in F and G=10 µm. (J) New neurons in KO brains had reduced dendritic spine density
(P<0.005, n=3 t-test). (H, I) Frequency distribution data indicate higher variation in spine density in KO mice (I)
than in WT mice (H), indicating an uneven distribution of spine density. (K) Z-stack confocal image showing
apposition of presynaptic terminal marker synaptophysin (red, arrow) with eGFP+ spines of new neurons. (L)
Quantitative analyses indicating that similar percentages of eGFP+ spines were apposed to presynaptic terminals
in both WT and Mecp2 KO mice (p=0.33, n=3, t-test)

Because the formation of functional synapses requires apposition of presynaptic terminals and
postsynaptic spines, we asked whether the postsynaptic spines of eGFP+ neurons in the DG of
KO mice were adjacent to synaptophysin-positive presynaptic terminals. As shown in Figure
5.4K and L, similar percentages of eGFP+ spines in WT and Mecp2 KO mice were apposed to
synaptophysin–positive presynaptic terminals. These data indicate that, at the single neuron
level, while newly matured neurons in MeCP2-deficient mice are able to form synaptic contacts,
the number of these synapses is greatly diminished.

5.4.5 Altered gene expression of synaptic proteins in MeCP2-deficient DG
granule neurons
To investigate the molecular mechanisms that might underlie the deficits in dendritic
spine development in the DG of MeCP2-deficient mice, we investigated differential gene
expression in the granule cells of the DG isolated by LCM from 8-week-old Mecp2 KO and WT
mice (Fig 5.5A-C). Relative levels of gene expression were determined by hybridization to
mouse U430 gene array (Affymetrix) and the data were analyzed using three independent
software packages based on distinct algorithms (see Materials and Methods). This bioinformatic
strategy of using a combination of different analyses reduces the selection of both false positives
and negatives as candidate genes (Barkho et al., 2006). Only genes that were identified by all
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three algorithms, as differentially expressed genes, were listed in Table 5.1. We found that the
expression of 13 genes was significantly changed in the Mecp2 KO DG granule neurons
compared to WT controls. Consistent with the function of MeCP2 as a transcription repressor, 12
of the 13 differentially expressed genes displayed increased expression in the KO neurons. The
Mecp2 gene was not on the list because a truncated mRNA corresponding to the 3’ coding region
of Mecp2, where Affymetrix probe sets hybridize, was expressed in KO neurons. Among the
identified differentially expressed genes, Prefoldin 5 is involved in actin and tubulin folding and
cytoskeleton formation (Hartl and Hayer-Hartl, 2002; Nolasco et al., 2005), and Syndecan 2 has
been shown to be critical for synaptogenesis (Ethell et al., 2001; Ethell and Yamaguchi, 1999).
We have confirmed that the expression levels of both Syndecan 2 and Prefoldin 5 mRNA were
higher in KO neurons using Real time PCR analyses (Fig 5.5D-E). Alteration of either of these
proteins could potentially affect dendritic development and neuronal morphology.
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Figure 5.5. Gene expression analyses of LCM-isolated DG neurons indicate altered expression of genes
related to synaptogenesis. (A-C) Bright field images demonstrate the process of isolating DG granule neurons
from cresyl violet-stained brain sections using LCM. (C) Isolated neurons (dark) were melted into the cap during
the LCM procedure and used for RNA isolation. (D-E) Real time PCR analyses confirmed the differential
expression of two of the candidate genes, Syndecan 2 and Prefoldin 5. The fold changes determined by real time
PCR are consistent with those determined by microarray analyses (p<0.05; n=3 experiments with 4
mice/genotype).

5.5 Discussion

With the identification of MECP2 as the gene responsible for RTT, it becomes critically
important to understand the role of MeCP2 in postnatal neural development. In this study, we
provide strong evidence that while the lack of MeCP2 does not affect the production of NSCs, it
does significantly impair subsequent steps in the maturation of neurons. First, we determined that
the expression of specific markers defining the transition from immature to mature neurons was
delayed in MeCP2-deficient NSCs. Second, we showed that the age-dependent shift in the
expression pattern of synaptophysin in the molecular layer of the hippocampus did not occur in
Mecp2 KO brains. Third, using single neuronal labeling, we found that there were striking
defects in the development of dendritic spines and synaptogenesis in DG of KO mice. Finally,
the expression levels of several genes that are likely to be important for synaptogenesis, such as
Prefoldin 5 and Syndecan 2, were found to be significantly altered in the DG of the hippocampus
in Mecp2 KO mice. This finding points toward a potential mechanism for the epigenetic effects
mediated by ablating MeCP2 control of gene expression.
The important role of MeCP2 as an epigenetic regulator at later stages of neural
differentiation, in contrast to that reported for Xenopus (Kishi and Macklis, 2004; Stancheva,
2003), is consistent with the normal development of the brain until birth both for RTT patients
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and Mecp2 KO mice. While our results demonstrate clearly that the initial generation of new
neurons in the DG was not altered, later steps in synapse formation were significantly perturbed.
Although further efforts to examine the effects on early stages of neurogenesis in the SVZ could
be useful, our studies, together with those of Kishi and Macklis (Kishi and Macklis, 2004),
strongly support the view that MeCP2 is not critical for the production of new, immature neurons
in either the embryonic or postnatal mammalian brains.
The progressive acquisition of protein markers followed by the loss of their expression
provides a well-defined system to measure the development and differentiation of newborn
neural progenitor cells. During normal development, DCX is expressed transiently in immature
neurons, and co-expression of DCX and NeuN (DCX+NeuN+) marks the end of the early
immature neuronal stage. Subsequently, the expression of NeuN, but not DCX, is the hallmark of
matured DG neurons (Brown et al., 2003). It seems likely that the age-dependent decrease in the
DCX+NeuN- immature population and increase in DCX-NeuN+ mature population that we
observed in both control WT and Mecp2 KO mice are due to both the decrease in cell
proliferation and the increase in total number of granule neurons that occurs from 4 to 8 weeks of
age. DCX+NeuN+ “transitioning neurons” can be detected as early as 12 days post-differentiation
in the DG, and reach their highest level about three days later (Brown et al., 2003). The lower
percentage of “transitioning neurons” observed in 4-week-old Mecp2 KO mice compared to WT
mice could result from delayed maturation of DCX+NeuN- immature neurons into the
“transitioning neuron” stage. The WT adult DG had a lower percentage of “transitioning
neurons” than young mice, indicating that the DG is more mature; however, this reduction is
much attenuated in adult KO mice, suggesting that more immature neurons either become
“stuck” or stay longer in the “transitioning neuron” stage and thus their transition into a mature
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stage is delayed. This hypothesis is consistent with previous reports indicating a greater
percentage of immature neurons in the olfactory epithelium of Mecp2 KO mice (Matarazzo et al.,
2004), and with histone H3 lysine-9 acetylation and methylation patterns seen in MeCP2deficient RTT human brains that correspond to an arrest at the transitioning stage of neuronal
maturation (Kawasaki et al., 2005). Future studies will be needed to define how MeCP2
regulates the expression of genes critical for this transitioning stage.
Synaptophysin staining has been widely used to indicate the numbers and distribution of
neuronal synapses in mammalian brains (Li et al., 2002). However, while most studies have
focused on determining the level of expression, we observed two distinct staining patterns (small
positive spots and large clusters) in the developing mouse brain. These synaptophysin patterns
change in a regulated manner in WT mice, with young brains exhibiting more large clusters than
adult brain. The presence of large clusters could, therefore, correlate with immature stages of
neuronal plasticity, when synaptophysin may not be well distributed to synaptic sites. If this is
the case, the persistence of clustered synaptophysin staining in adult Mecp2 KO mice would be
consistent with the notion that newborn neurons are “stalled” from further maturation in the
absence of MeCP2. This stalling might be due to deficits in the neuronal transport mechanism or
abnormalities in cytoskeleton structure in the absence of functional MeCP2 protein. In fact, we
have found that the expression levels of several cytoskeleton-related factors are altered in Mecp2
mutant DG neurons (Table 5.1). Interestingly, we also observed that clustered synaptophysin
staining was retained in the stratum lucidum of the hippocampus, which contains the terminals of
CA3 neurons (data not shown). Further analyses of other brain regions should shed light on
whether the lack of MeCP2 as an epigenetic factor leads to a general impairment of synaptic
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development, as reflected by synaptophysin staining, and results in global deficits in neuronal
maturation throughout the brain.
Dendritic spine density is a morphological indicator of neuronal maturation in
hippocampal granule cells, and reduced spine density is correlated with impaired maturation of
DG neurons (Zhao et al., 2006). Abnormalities in the morphology and density of dendritic spines
have been found both in RTT patients and other neural developmental disorders, such as Down’s
syndrome, Fragile X syndrome, and Autism (Fiala et al., 2002), however whether Mecp2
mutations affect dendritic development in animal models is currently not clear. To clarify the
current controversy between human and mouse studies (Belichenko et al., 1997b; Kishi and
Macklis, 2004; Moretti et al., 2006), we used a retrovirus to mark single newborn neurons on the
DG. Our findings of the reduced dendritic spine density in newly generated neurons in the DG
are thus consistent with similar findings in human pathologies, suggesting that this abnormal
dendritic development may be a common point of vulnerability that leads to the neurological
deficits caused by these genetic disorders. Further experiments analyzing the dendritic
morphology of eGFP+ neurons at earlier time points will help to define how MeCP2 regulates the
development of dendritic spines. The apposition of postsynaptic and presynaptic terminal
components is a prerequisite for a functional synapse. Although we did not observe a significant
difference in the percentage eGFP+ spines apposed to presynaptic terminals distinguished by
synaptophysin, the evaluation of impairments in the number of functional synapses and potential
abnormalities in synaptic transmission will require future electrophysiological analyses.
Remarkably, the altered morphology seen in DCX+ immature neurons, including abnormal
orientation of the processes (Fig. 5.1), was not found in GFP+ new neurons at 4-week postlabeling. This phenomenon might be due to the preferential death of morphologically altered
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immature neurons or, alternatively, the abnormal orientation might correspond to a characteristic
of an immature stage of neuronal maturation within the first week of differentiation. New
neurons display horizontal processes, or short processes similar to those seen in Mecp2 KO
brains and develop vertical processes during later stages of development (Esposito et al., 2005;
Ge et al., 2006; Zhao et al., 2006). Further analyses of viral-labeled cells at early stages of
neuronal differentiation will confirm this hypothesis.
Despite extensive effort, only a few genes, including Brain-Derived Neurotrophic
Factor (Chen et al., 2003b; Martinowich et al., 2003), DLX5 and 6 (Horike et al., 2005), and
inhibitor of differentiation (ID1, 2, 3, and 4) genes (Peddada et al., 2006) have been shown to be
regulated by MeCP2. Therefore, the identification of additional genes that are either directly or
indirectly regulated by MeCP2 in neurons is a critical step forward in delineating what role this
epigenetic regulator of gene expression plays in the development of the brain, as well as other
tissues. Several of the candidate genes we identified are involved in cytoskeleton structure
formation, such as Prefoldin 5, Arpc3, Syndecan 2, etc (Table 5.1). Prefoldin 5 is involved in
actin and tubulin folding. Mutations of prefoldins result in an abnormal cytoskeleton (Hartl and
Hayer-Hartl, 2002). Syndecan 2 is a transmembrane heparin sulfate proteoglycoprotein that
binds extracellular matrix components and growth factors and is expressed at the mature
dendritic spines of hippocampal neurons. Like that of MeCP2, the expression of Syndecan 2
coincides with dendritic spine maturation (Ethell and Yamaguchi, 1999). Exogenous Syndecan 2
expression induces increased dendritic spine formation, whereas blocking Syndecan 2
phosphorylation by the EphB2 receptor results in reduced spine density (Ethell et al., 2001).
Further mechanistic analyses will determine whether these genes are targets of MeCP2 and
functional consequences their altered expression in Mecp2 KO neurons
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In summary, our data indicate that MeCP2 is not critical for the early stages of
neurogenesis, but is important for neuronal maturation in the postnatal brain. The fact that adult
Mecp2 KO brains are more similar to immature WT brains than to mature WT brains suggests
that MeCP2 is critical for regulating the transition of neurons from immature to mature stages.
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Table 5.1. Genes that are expressed at different levels in hippocampal granule neurons of Mecp2
KO mice.
Gene Symbol

Gene Description

Genes expressed at higher levels
Pfdn5
Prefoldin 5
1110013I11Rik
RIKEN cDNA 1110013I11 gene
Uchl1
Ubiquitin carboxy-terminal hydrolase
L1
Sfxn3
Sideroflexin 3
AL024345
expressed sequence AL024345
5031401C21Rik
RIKEN cDNA 5031401C21 gene
Osbpl9
Oxysterol binding protein-like 9
Zipro1
Zinc finger proliferation 1
Arpc3
Actin related protein 2/3 complex,
subunit 3
Sdc2
Syndecan 2
1500011H22Rik
RIKEN cDNA 1500011H22 gene
1110020P15Rik
RIKEN cDNA 1110020P15 gene
Genes expressed at lower levels
Hmgb1
High mobility group box 1

dChip Fold
Change*
(Range)

Drop
Confidence#
(Range)

Gene Bank IDs

1.61
2.58
1.53

94.5 - 99.0%
99.80%
83.6 – 90.9%

NM_020031.1
BF608615
NM_011670.1

1.34
1.42
1.42
1.36
1.58
1.49

85.7 - 87.6%
76.2 - 85.7%
98.0 - 98.4%
87.6 - 89.3%
97.5 - 99.2%
2.5 - 83.6%

NM_053197.1
AV295157
AW537061
AI875733
AI326272
BC013618.1

1.49
1.37
1.44

60.5 - 85.7%
26.7 - 83.6%
63.9 - 83.6%

NM_008304.1
BC019498.1
BF681728

-1.46

83.6 - 87.6%

C78183

Note: * Reference fold changes were obtained by dChip analysis; #, Confidence values were
obtained by Drop analysis; the ranges are the maximum and minimum if multiple probe sets
were returned.
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6.1

ABSTRACT

A final step of neurogenesis is the maturation of young neurons, which is regulated by
complex

mechanisms

and

dysregulation

of

this

process

is

frequently

found

in

neurodevelopmental disorders. MicroRNAs have been implicated in several steps of neuronal
maturation including dendritic and axonal growth, spine development, and synaptogenesis. We
demonstrate that one brain-enriched microRNA, miR-137, has a significant role in regulating
neuronal maturation. Overexpression of miR-137 inhibits dendritic morphogenesis, phenotypic
maturation, and spine development both in brain and cultured primary neurons. On the other
hand, a reduction in miR-137 had opposite effects. We further show that miR-137 targets the
MIB1 protein through the conserved target site located in the 3’ untranslated region of Mib1
mRNA. MIB1 is an ubiquitin ligase known to be important for neurodevelopment. We show that
exogenously expressed MIB1 could partially rescue the phenotypes associated with miR-137
overexpression. These results demonstrate a novel miRNA-mediated mechanism involving miR137 and MIB1 that function to regulate neuronal maturation and dendritic morphogenesis during
development.
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6.2

INTRODUCTION

In both embryonic and adult brains, neurogenesis is initiated from the neuronal fate
specification of neural stem cells. To function properly, new neurons have to integrate into
appropriate neural networks and establish correct communication with other neurons. A critical
step in development is neuronal maturation, which is characterized by dendritic and axonal
growth, synaptogenesis, neuronal and synaptic pruning, and modulations of neurotransmitter
sensitivities (Waites et al., 2005; Webb et al., 2001). The process of neuronal maturation is
regulated by complex mechanisms that are still unclear, and deficits in this step are evident in
many neurodevelopmental disorders such Rett Syndrome, Fragile X syndrome, and autism, etc
(Fiala et al., 2002).
MicroRNAs (miRNAs) are small non-coding RNAs that can modulate gene expression at
the post-translational level by targeting messenger RNA (mRNA), which leads to either reduced
translation efficiency or cleavage of the target mRNAs. miRNAs are known to be involved in
many cellular processes, such as proliferation, differentiation, apoptosis, and metabolism
(Carninci et al., 2005; Chang and Mendell, 2007; Gangaraju and Lin, 2009; Liu and Zhao,
2009b). Despite the fact that 70% of detectable miRNAs are expressed in the brain, where half
that number are either brain specific or enriched (Cao et al., 2006). There have been few
functional studies of miRNA in the nervous system. Recent evidence has shown that many
miRNAs act locally at the neuronal dendritic spines (Lugli et al., 2008; Smalheiser and Lugli,
2009). Both miR-134 and miR-138 are known to regulate dendritic patterning and spine
morphogenesis by regulating protein translation at the synapse (Fiore et al., 2009; Schratt et al.,
2006; Siegel et al., 2009). In addition, brain-specific miR-124 is localized at presynaptic terminal
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of Aplysia and regulates synaptic plasticity by regulating transcription factor CREB
(Rajasethupathy et al., 2009). Recently, a neuronal activity-dependent miRNA, miR-132, is
found to regulate dendritic development by targeting a Rho family GTPase-activating protein,
p250GAP (Wayman et al., 2008). Therefore, small noncoding miRNA pathways could be an
important and novel mechanism regulating mammalian neurodevelopment.
In this study we show that a neuron-enriched miRNA, miR-137, has a significant role in
the phenotypic maturation and dendritic morphogenesis of young neurons. We establish that
miR-137 regulates the translation of the mouse homolog of Drosophila Mind bomb 1 (MIB1), an
ubiquitin ligase known to be important for neurogenesis and neurodevelopment (Choe et al.,
2007; Itoh et al., 2003; Ossipova et al., 2009). Finally, we show that exogenously expressed
MIB1 can partially rescue the phenotypic deficits associated with miR-137 overexpression.
These data suggest that functional interaction between miRNA and MIB1 plays an important
modulatory role in neuronal development.

6.3

MATERIALS AND METHODS

Animals
All animal procedures were performed according to protocols approved by the University
of New Mexico Animal Care and Use Committee. Wildtype C57/B6 mice were used for in vivo
and in vitro studies. For histological analyses, mice were euthanized by intraperitoneal injection
of sodium pentobarbital. Mice were then perfused with saline followed by 4% PFA. Brains were

73

dissected out, post-fixed overnight in 4% PFA, and then equilibrated in 30% sucrose. Fortymicrometer brain sections were generated.

Isolation and differentiation of adult hippocampal neuroprogenitors
Adult hippocampal neuroprogenitors (A-94-NSCs) was characterized previously and
NSC proliferation and differentiation were carried out as described (Palmer et al., 1997). (Zhao
et al., 2003).

Relative quantification of mature miRNAs by Taqman miRNA real-time PCR
Mature miRNA expression was assayed using Applied Biosystems’ TaqMan microRNA
assays or individual TaqMan miRNA assays) were performed according to protocols provided by
the vendor (Lao et al., 2006). Detailed methods are provided in the Supplemental Data.
Undifferentiated A94 NSCs were run in parallel with lineage specific differentiated A94 NSCs
as paired samples. Data from the replicate experiments on undifferentiated A94 NSCs was then
pooled and a single analysis of miRNA expression in each NSC lineage relative to
undifferentiated NSCs was determined within the SDS v1.2 RQ manager to obtain the reported
values.

miRNA in situ hybridization
In situ hybridization on 10 µm thick serial cryosections was carried out as outlined
previously with a few modifications (Obernosterer et al., 2007). For hybridization 0.1 µl of 25
M DIG- or FITC-labeled LNA probe (Exiqon) was added to 100L hybridization buffer and
applied to the tissue at 50-60 oC overnight (~20°C below the predicted melting temperature (Tm)
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of probe:miRNA). Slides were mounted in Aquamount and visualized using confocal
microscopy. Detailed methods are provided in the Supplemental Data

Nucleic acid and expression constructs
Control miRNA (miR-Con), miR-137, anti-miR-137, and anti-miRNA control (anti-miRCon) were purchased from either GenePharma (Shanghai, China) or Ambion (AM17100,
AM17110, AM17000, and AM17010, Austin, TX). MIB1 expression plasmid was described
previously (Choe et al., 2007). Mib1 shRNA and non-silencing control was purchased from
Qiagen/SABiosciences (KM26177G). Lentivirus-sh-Control was created by cloning the
SureSilencing non-silencing control shRNA cassette into the HpaI and ClaI sites of lentiviral
vector. The generation and validation of this Lentivirus-sh-Control was described previously
(Barkho et al., 2008; Li et al., 2008). PCR based generation of the miR-137 shRNA driven by a
U6 Pol III promoter was done as described in our publications (Barkho et al., 2008; Li et al.,
2008). Detailed methods and sequences of primers are provided in the Supplemental Data.
Retroviral vector expressing both miR-137 and eGFP was engineered by deleting the original
HpaI and ClaI sites in the CAG-EGFP vector (Smrt et al., 2007; Zhao et al., 2006) and inserting
new HpaI and ClaI sites 5’-upstream from the CAG promoter. The sh-miR-137 or the sh-miRControl cassette were digested from Lentiviral vectors (see above) and inserted between the HapI
and ClaI sites of the retroviral vectors. The lentiviral and retroviral vectors expressing sh-miR137 or sh-miR-Control were then verified by sequencing.

Production of retrovirus expressing miR-137 and in vivo retroviral grafting
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Retrovirus production was performed as described previously (Smrt et al., 2007; Zhao et
al., 2006). Detailed methods are provided in the Supplemental Data.

Maturation analysis of retroviral labeled new neurons
Immunohistochemistry and confocal imaging analysis on floating brain sections were
carried out as described (Smrt et al., 2007). Floating brain sections containing eGFP+ cells were
selected for staining and matched by DG region. The primary antibodies used were chicken antiGFP (Invitrogen, #A10262), mouse NeuN (Chemicon, MAB377), and rabbit anti-doublecortin
(DCX, Cell Signaling, #4604). The secondary antibodies used were anti-chicken Alexa Fluor
488 (Invitrogen, #A11039), goat anti-mouse Alexa Fluor 647 (Invitrogen, #A21236), and goat
anti-rabbit Alexa Fluor 568 (Invitrogen, #A11036).
For dendritic branching analysis on 300 µm thick floating brain sections, GFP+ neurons
were imaged on a LSM 510 confocal with a 20x/oil objective. Z-stacks of GFP+ dendrites were
captured at 8μm intervals and the dendrites and the cell body of single GFP+ neurons were
analyzed by Neurolucida software (MicroBrightField, Inc.). Roughly 30-50 neurons per DG
were traced. Data were extracted for Sholl analysis, total dendritic length, branch number, and
dendritic end number for each GFP+ neuron. Neurons were selected for analysis based on
expression of GFP throughout the cell body and its processes. Cells were excluded if they exhibit
excessive overlapping with adjacent GFP expressing neurons, their morphology is not intact,
they have membrane varicosities, or they show signs of cell death such as compacted chromatin
structure revealed by DAPI staining.
For dendritic spine density analyses and quantification of stage-specific neuronal
markers, 1-in-3 of 40 µm floating brain sections containing eGFP+ cells (120 µm apart,
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approximately 8 brain sections) were used for immunohistological staining using established
protocols (Smrt et al., 2007). For the dendritic spine analysis above, the spine width was also
manually measured as the distance of a straight line drawn across the widest part of the spine
head using Image-J software (NIH Image).

Isolation of primary neurons from mouse embryos and transfection of cultured neurons
Hippocampal neurons were isolated from E17.5 fetal mice, and grown as described
previously (Tafoya et al., 2006; Washbourne et al., 2002). Hippocampal neurons from wildtype
E17.5 fetal mice were grown as dispersed mixed cell cultures, as established by the Wilson lab
(Washbourne et al., 2002). Hippocampal neurons were transfected on day 4 (DIV 4) as they are
undergoing dendritic and axonal morphogenesis during this time. Transfection was performed as
described (Tafoya et al., 2006). 48hours after transfection, the neurons were fixed and stained as
described below. Transfection efficiencies were 1-2%.

Morphological analysis of transfected neurons
Immunostaining of transfected neurons was performed as previously described (Barkho
et al., 2008; Li et al., 2008; Smrt et al., 2007; Zhao et al., 2003). The primary antibody used was
MAP2ab (mouse, 1:500, Sigma). The secondary antibody used was Cy3 (donkey anti-mouse,
1:500, Sigma). Low transfection efficiencies (1-2% neurons) permit imaging and quantification
of single GFP expressing neurons. GFP expressing neurons were imaged with an Olympus BX51
upright microscope with 20x/oil immersion lens, a motorized stage, and digital camera. Dendritic
traces were performed in real time using Neurolucida (MicroBrightField, Inc.) image analysis
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software. The axon is identified using Map2 staining where the only process not positive for
Map2 is the axonal process (Jugloff et al., 2005).

3’-UTR dual luciferase assays of miR-137 target mRNA
3’-UTR sequences of candidate mRNAs were PCR amplified directly from proliferating
aNSC first strand cDNA generated from 5 μg TRIZOL-isolated total RNA using oligo-dT
SuperScript III reverse transcription according to the manufacturer’s protocol (Invitrogen, Cat.
#1808-093). These primer sequences are available upon request. All primers were designed
incorporating XhoI and NotI restriction sites and 4 bp of extra random sequence to aid in
restricting digestion. XhoI- and NotI-digested PCR products were cloned into XhoI- and NotIdigested psiCHECK-2 dual luciferase vector (Promega, Cat# C8021) and were later transferred
by XhoI/NotI double digestion and T4 DNA ligation into a pIS2 renilla luciferase vector
modified with the addition of an XhoI restriction site and deletion of the SpeI restriction site.
miR-137 target site deletion was done using the QuickChange Site-Directed Mutagenesis Kit
(Stratagene, Cat. #2000518) to delete UUCGUUAU. Briefly, E17 hippocampal neurons were
cultured (as described above), and co-transfected by Lipofectamine 2000 with pIS2 Renilla
luciferase vector containing the Mib1 3’UTR, pIS0 firefly luciferase as a transfection control,
and miR-Con, miR-137, anti-miR-137, or anti-miR-Con. All co-transfections used a total of 1 μg
of plasmid DNA and 50ng of shRNA. At 48 h after transfection, the cell culture medium was
removed and cells were lysed with 20 μl of 1X passive lysis buffer at room temperature for 15
min and luciferase expression was detected using the Dual-Luciferase Reporter 1000 System
(Promega, Cat# E1980) per the manufacturer’s protocol. R-luc activity was normalized to F-luc
activity to account for variation in transfection efficiencies, and miR-137–mediated knockdown
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of R-luc activity was calculated as the ratio of normalized R-luc activity in the U6-miR-137shRNA treatments to normalized R-luc activity in the U6-neg-shRNA treatments. Luciferase
experiments were repeated at least three times.

Production of lentivirus and infection of E17 hippocampal neurons
Lentiviruses were produced as described previously (Barkho et al., 2008; Barkho et al.,
2006; Li et al., 2008). To study the effects of miR-137 on development of dendrites in cultured
neurons, 1:1 solution of virus containing supernatant and Neurobasal A medium (Invitrogen)
supplemented with 25 nM glutamate, 0.5 mM L- glutamine, and 1% antibiotics was added to the
neurons 1 day after plating. After 24hours, the medium was replaced with fresh virus containing
solution described above, and was incubated for an additional 24 hours. Infected neurons were
collected in cell lysis buffer for western blot analysis.

Western blot analysis
Protein samples were separated on SDS-PAGE gels and then transferred to PVDF
membranes (Millipore). Membranes were processed following the ECL Western Blotting
protocol (GE Healthcare, Cat #RPN2106). Anti-MIB1 antibody (M20a) (Choe et al., 2007) were
used at a 1:1000 dilution. HRP-labeled secondary antibodies were obtained from Sigma (A0545).
For loading controls, membranes were stripped and reprobed with the antibody against GAPDH
(Ambion AM4300).

Statistical analysis
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All statistical analyses were performed using unpaired, two-tailed, Student’s t-test. The
data bars and error bars indicate mean ± standard error mean. (s.e.m). Sholl analysis was
analyzed using a multivariate analysis of variance (MANOVA) using SPSS statistical software
(SPSS version 17, SPSS Inc., Chicago, Ill, USA).

6.4

RESULTS

6.4.1 miR-137 is enriched in neurons
To identify lineage specific miRNAs that may regulate development and function of
neurons in the postnatal hippocampus, we profiled mature miRNA expression in adult
hippocampal neuroprogenitors (A94-NSCs) differentiated into either neuronal or astrocytic
lineages and compared the miRNA profile in undifferentiated A94-NSCs (Supplemental Figure
S6.1A,B). We then quantitatively identified miRNAs that were enriched specifically in the
neuronal lineage relative to the astrocytic lineage (Figure 6.1A). Several miRNAs, particularly
miR-185, 27b, 182, 137, 29b, 132, and 146, showed enrichment in neurons, but not astrocytes or
undifferentiated NSCs; among these miRNAs, miR-137 was previously found to be enriched in
synaptosomes isolated from rat forebrains (Siegel et al., 2009; Silber et al., 2008). We further
confirmed that the expression levels of miR-137 increased during neuronal differentiation of
A94-NSCs (Figure 6.1B), and miR-137 expression levels were significantly higher in isolated
primary neurons compared with aNSCs (Figure 6.1C). The highly enriched expression of miR137 in the neuronal lineage suggests that it may have important functions in neuronal
development.
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Figure 6.1. miR-137 is enriched in neurons and is expressed in the dentate gyrus and the molecular layer of the
hippocampus. (A) Identification of lineage specific miRNAs in A94-NSCs. Plotted are the ratios of RQ values
determined by comparing A94-NSCs differentiated toward the neuron lineage to undifferentiated A94-NSCs
over RQ values determined by comparing A94-NSCs differentiated toward the astrocyte lineage to
undifferentiated A94-NSCs (Figure S1A and S1B). Ratios≥8 were set to a value of 8. ( B) miR-137 expression
during neuronal differentiation of A94-NSCs for 0.5, 1, 2, 3, and 4 days (miR-137 expression calibrated to
undifferentiated A94-NSCs, n=3, mean ± 95% CI). (C) Enrichment of miR-137 in E17 neurons as compared to
mouse primary aNSCs (miR-137 expression calibrated to mouse primary aNSCs, n=3, mean ± SEM). (D-E)
Hybridization with a miR-137-specific probe showed an enrichment of miR-137 within the DG and molecular
layer of the hippocampus compared with miR-1, which is expressed at low levels in the CNS (h, hilus; g, dentate
gyrus; m, molecular layer).

miR-137 is known to be expressed in the brain and enriched at the synaptic compartment (Siegel
et al., 2009; Silber et al., 2008).

We reasoned that if miR-137 is indeed a mediator of

neurodevelopment and function, it should be expressed in neurons of the adult hippocampus,
which is a region of the brain exhibiting significant plasticity and continuous production of new
neurons. Thus we chose to examine the cellular localization of miR-137 in the adult
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hippocampus. Hybridization with an miR-137-specific probe showed an enrichment of miR-137
within the dentate gyrus (DG) and molecular layer of the hippocampus compared with miR-1, a
miRNA that is expressed at low levels in the central nervous system (CNS) (Figure 6.1D and E).
Together, these data and the published literature (Siegel et al., 2009; Silber et al., 2008;
Smalheiser and Lugli, 2009) suggest that miR-137 may play functional roles in neurons, perhaps
during the formation of connectivity between neurons in the hippocampus.

6.4.2 miR-137 regulates dendritic development and phenotypic maturation of
new neurons in vivo
Recently, miRNAs were found to be expressed at the synapse and play an important role
in dendritic patterning and spine morphogenesis (Lugli et al., 2008; Schratt et al., 2006; Siegel et
al., 2009). To determine whether elevated miR-137 levels in neurons can affect neuronal
maturation and dendritic morphogenesis, we overexpressed miR-137 in newborn cells of the
adult DG using retrovirus-mediated gene delivery (Smrt et al., 2007). This method, referred to as
the single-cell genetic approach (Song et al., 2005; van Praag et al., 2002), makes use of
recombinant retroviruses capable of specifically infecting dividing cells (Figure 6.2A). Because
postnatal neurogenesis persists in the adult hippocampus, this method allows us to deliver a
transgene specifically to newborn cells in the DG and perform a detailed morphological and
phenotypic analysis on these newly generated neurons (Smrt et al., 2007; Song et al., 2005; Zhao
et al., 2006). Using stereotaxic microinjection surgery, we grafted retrovirus expressing both
eGFP and small hairpin miR-137 (sh-miR-137) into one hemisphere of the adult mouse DG, and
injected a retrovirus carrying nonsilencing small hairpin control (sh-Con) into the contralateral
hemisphere of the same animal (Figure 6.2A and B). At 4 weeks post-injection (4wpi), one
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cohort of injected animals was used to generate thick (300-µm) sections, which preserves the
dendritic arborization of eGFP-positive neurons and enables extensive morphological analysis.
Individual eGFP-expressing neurons in these sections were imaged using confocal microscopy.
To precisely evaluate the dendritic complexity of eGFP+ neurons, we reconstructed the eGFP+
dendritic arbor in 3 dimensions, rather than the traditionally flattened 2 dimensions, for image
analysis using the Image Stack Module of Neurolucida analysis software (MicroBrightField,
Inc.) (Figure 6.2C and D, Supplemental Figure S6.2A and B). Since previous reports have
indicated that miR-137 has no affect on dendritic spine volume (Siegel et al., 2009), we
performed quantitative analysis using established parameters for assessing neuronal dendritic
development (Duan et al., 2007; Zhao et al., 2006). Sholl analysis indicated that miR-137overexpressing neurons exhibited significantly reduced dendritic complexity compared to shControl-expressing neurons (F (1,65) = 8.78, p = 0.004, multivariate analysis of variance)
(Figure 6.2E). In addition, miR-137-overexpressing neurons exhibited significantly reduced
average dendritic length (n = 3 animals, p < 0.05), number of nodes (branch points) (n = 3, p <
0.05), and number of dendritic endpoints (n = 3, p < 0.05) compared with young neurons
expressing sh-Control (Figure 6.2F-H).
Dendritic spine density increases as neurons mature, making the spine density a good
indicator of neuronal maturation (Ge et al., 2006; Zhao et al., 2006). On the other hand, altered
spine density is a common characteristic of abnormal synaptic development in a variety of
neurological disorders such as Fragile-X and Rett syndrome (Fiala et al., 2002; Smrt et al.,
2007). We therefore used another cohort of virus-injected animals to generate 40-µm thin
sections for dendritic spine analysis. To determine whether overexpression of miR-137 leads to
deficits in spine morphogenesis, we analyzed the dendritic spine density of newborn GFP-

83

expressing DG granule neurons at 4 weeks post-injection, a time at which labeled new neurons
are believed to exhibit the dendritic morphology of mature neurons (Ge et al., 2006; Smrt et al.,
2007; van Praag et al., 2002; Zhao et al., 2006). To maximize consistency of our analyses, we
focused on dendritic fragments 25-100 um from the cell body of each eGFP+ neuron. To
quantify spine density, we counted the number of spines protruding from the dendrite within
each 10-µm segment of dendrites. Quantitative analysis showed that miR-137-overexpressing
neurons exhibited a 17% reduction in dendritic spine density compared with sh-Controlexpression neurons (n = 3, p < 0.01) (Figure 6.2I-K). The widths of dendritic spines in miR-137overexpressing

neurons

were

no

different

from

(Supplemental Figure S6.3).
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Figure 6.2. miR-137 regulates dendritic development and phenotypic maturation of new neurons in vivo. (A) A
schematic diagram showing the retroviral vector used for in vivo miR-137 expression. miR-137 (sh-miR-137) or
control miR (sh-Con) was expressed as a short hairpin under U6 RNA Polymerase III promoter while eGFP was
expressed under a chicken β-actin (CAG) promoter. (B) Schematic diagram showing that control virus (sh-Con)
was injected into the left hemisphere, and retrovirus expressing miR-137 (sh-miR-137) was injected into the right
hemisphere. (C, D) Confocal z-stacks showing eGFP-expressing neurons at 4 weeks post-injection (4 wpi) with
representative traces from both the sh-Con (C) and sh-miR-137 condition (D) (scale bar = 50 µm). (E) Neurons
overexpressing sh-miR-137 show reduced dendritic complexity compared with controls, as determined by Sholl
analysis. (F-H) Neurons overexpressing sh-miR-137 show reduced dendritic length (F), number of nodes (branch
points, G), and dendritic ends (H). (I) Neurons overexpressing sh-miR-137 show reduced dendritic spine density.
(J) Confocal z-stacks showing eGFP-expressing dendrites (scale bar = 20 µm). (K) A representative dendritic
segment used for spine density analysis (* = p < 0.05)

New neurons in the DG express development stage-specific markers that define their
maturation

(Figure

6.3A)

(Ming

and

Song,

2005;

Zhao

et

al.,

2008).

Using

immunocytochemistry for doublecortin (DCX, an immature neuronal marker) and neuronal
nuclear antigen (NeuN, a mature neuronal marker) immunostaining, new neurons in the DG were
categorized into 3 subpopulations: immature neurons (DCX+ only), transitioning neurons
(DCX+ and NeuN+), and mature neurons (NeuN+) (Brown et al., 2003; Smrt et al., 2007). We
then determined whether new neurons overexpressing miR-137 had a developmental phenotype
that could be measured by the expression of stage-specific markers. Thus, we analyzed
retrovirus-labeled newborn neurons at 4 weeks post-injection, a time when many virus-labeled
cells have differentiated into mature neurons (Figure 6.3A-C). We found that miR-137overexpressing cells differentiated into fewer eGFP+ neurons (either DCX+eGFP+ and/or
NeuN+eGFP+ cells) in general compared with sh-Control-overexpressing cells (Supplemental
Figure S6.4). We then quantified the proportion of each type of neuron among total eGFP+
neurons. The results summarized in Figure 6.3D show that neurons overexpressing miR-137
displayed a significant difference in the proportion of immature vs. mature neurons compared
with neurons overexpressing control (sh-Con). Specifically, miR-137-overexpressing neurons
had an 80% decrease in the proportion of mature neurons (NeuN+, n = 3, p < 0.05) compared
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with control. Additionally, there was a

A

19% decrease in the proportion of
transitioning neurons (NeuN+/DCX+,
n = 3, p > 0.05) and a 62% increase in
the proportion of immature neurons
(DCX+, n = 3, p = 0.05) compared
with control. Therefore, this indicates
that elevated levels of miR-137 alter
the sequential events leading to the

B

eGFP

DCX

NeuN

Merge

development of a mature DG granule
neuron. Taken together, these in vivo
data suggest that increased expression
of miR-137 in newborn neurons results

C

in decreased dendritic development.

Figure 6.3. Overexpression of miR-137 leads
to altered neuronal maturation of new neurons
in vivo. (A) Illustration showing the stagespecific neuronal markers that can be used to
identify the maturation state of developing
DG granule neurons. (B, C) Confocal images
showing two representative eGFP-expressing
neurons in the DG: a relatively immature
eGFP neuron (B) expressed DCX (immature
marker) but not NeuN (mature neuron) and a
relatively mature eGFP+ neuron (C)
expressed NeuN but not DCX. (D) The miR137-overexpressing neuron population had
decreased proportions of NeuN+ only (blue)
mature neurons and of DCX+/NeuN+
(yellow) transitioning neurons, but increased
proportion of DCX+ only (red) immature
neurons compared with control (* = p <
0.05).

D
*

*
*
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6.4.3 miR-137 regulates neuronal dendritic development in vitro
Since retrovirus infects only dividing cells, overexpression of miR-137 in dividing
neuroprogenitors may affect initial neuronal differentiation, which might indirectly inhibit
neuronal maturation. To investigate whether miR-137 overexpression affects neuronal
maturation independent of its effect on the neuronal differentiation of neuroprogenitors, we
turned to a well-established in vitro cultured primary neuron system and used both gain-offunction and loss-of-function methods. Hippocampal neurons serve as a good model for studying
molecular mechanisms controlling dendritic and spine development, because they form elaborate
dendritic trees, functional synapses, and they can respond to both chemical and electrical
stimulations (Fletcher et al., 1994; Goslin and Banker, 1989; Okabe et al., 1998). We isolated
neurons from the hippocampi of E17.5 mouse embryos and plated them into serum-free medium
to limit astrocyte proliferation. To modulate miR-137 expression, we overexpressed miR-137
using two different gain-of-function assays. First, we expressed miR-137 as a small hairpin RNA
plasmid using a lentiviral vector that also expresses eGFP (Figure 6.4A) (Li et al., 2008).
Second, we cotransfected neurons with miR-137 synthetic double-stranded RNA and an eGFP
expression plasmid. Concurrently, we performed a loss-of-function assay to knock down
endogenous miR-137 in cultured hippocampal neurons using a 2’-O-methylated antisense
oligonucleotide.
At 48 hours post-transfection, eGFP-expressing neurons were imaged, and the
morphology of the soma, dendrites, and axons were manually traced and measured using
Neurolucida (MicroBrightField, Inc.) image analysis software (Figure 6.4B and C). Transfected
eGFP+ neurons had clearly identifiable dendrites and axons, and axons were distinguished from
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dendrites by two characteristics: axons are the longest among all processes and have negative
staining for MAP2, a somatodendritic marker (Jugloff et al., 2005). The morphology of cultured
hippocampal neurons is not as uniform as developing neurons in the DG of the hippocampus,
which may account for the variability we saw in neuronal morphometry. However, the
morphological differences between neurons expressing miR-137 and controls were apparent
(Supplemental Figure S6.5A, B). Neurons transfected with plasmid expressing sh-miR-137 had a
significantly reduced dendritic complexity (F(1,52) = 5.15, p < 0.05 multivariate analysis of
variance) (Figure 6.4D) and 23% reduction in total dendritic length (n = 3, p < 0.05) (Figure
6.4E) compared with sh-Control-transfected neurons. Consistent with this result, neurons
transfected with synthetic miR-137 also showed a 23% reduction in dendritic length and reduced
dendritic complexity compared with miR-Control-transfected neurons (n = 3, p < 0.01) (Figure
6.4F and G). On the other hand, neurons transfected with a specific inhibitor of miR-137 (antimiR-137) had increased dendritic complexity (F(2,51) = 3.58, p = 0.036 multivariate analysis of
variance) (Figure 6.4F) and a significant 25% increase in total dendritic length (n = 3, p < 0.01)
(Figure 6.4G) compared with control anti-miR (anti-miR-Con)-transfected neurons. The total
number of dendritic ends and nodes had a similar trend of a reduction in neurons transfected with
miR-137 and an increase in anti-miR-137-transfected neurons; although these differences did not
reach statistical significance (Supplemental Figure S6.4C and D). These loss-of-function and
gain-of-function data in primary neurons further support our in vivo observation that high levels
of miR-137 inhibit neuronal dendritic development.
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Figure 6.4. miR-137 is important for dendritic development in vitro. (A, B), E17 primary hippocampal neurons
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with controls. (E), Sholl analysis showing that neurons overexpressing miR-137 had reduced dendritic complexity
compared with controls, whereas neurons transfected with an anti-miR-137 had opposite effect. (F), Neurons
overexpressing miR-137 had reduced total dendritic length compared with neurons overexpressing miR-Control.
On the other hand, neurons transfected with anti-miR-137 showed increased dendritic length compared to neurons
transfected with anti-miR-Control. (G) A schematic diagram showing the lentiviral vector used for miR-137
expression. miR-137 (sh-miR-137) or control miR (sh-Con) was expressed as a short hairpin under U6 RNA
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6.4.4 Mind Bomb-1 is a Translational Target of miR-137
To determine how miR-137 affects dendritic morphology during neuronal development,
we first took a bioinformatic approach to identify the potential mRNA targets of miR-137. We
referenced TargetScan 4.1, PicTar, and miRanda to compile a set of potential candidate targets
(John et al., 2004; Krek et al., 2005; Lewis et al., 2003a). Next, we selected a subset of targets
for further analyses based on 3 criteria: conservation, context score of target “seed sequences,”
and known relevance to dendritic morphogenesis and neuronal development. Among the top
candidate miR-137 targets are a mouse homolog of Drosophila mind bomb 1 (MIB1), histone
H3K27 methyltransferase Ezh2, EphA7, and chromatin modulator NcoA3 (Table S1). We first
cloned the 3’-untranslated region (3’-UTR) of these four candidates containing the predicted
miR-137 target site from mouse cDNA into a Renilla luciferase (R-luc) reporter construct (see
Figure 6.5B for example). This allowed us to assess protein translation of these targets regulated
through their 3’-UTR. This 3’-UTR R-luc constructs along with a firefly luciferase (f-luc)
control plasmid were cotransfected into HEK 293 cells. We found that miR-137 could repress
the translation of luciferase through these 3’-UTR. Then we selected the expression plasmids of
the top two candidates, Mib-1 and Ezh2, to transfect into primary neurons. We found that MIB1,
but not EZH2, could promote dendritic morphogenesis, similar to the effect of anti-miR-137.
MIB1 was a particularly interesting candidate because it was previously shown to be enriched in
the postsynaptic compartment by mass spectrometry (Choe et al., 2007; Sheng and Hoogenraad,
2007). In addition, in our initial functional screening by overexpressing these candidate targets in
cultured primary neurons, MIB1 demonstrated the most dramatic effect on promoting neuronal
dendritic length (data not shown). We therefore decided to further investigate whether MIB1 is a
functional target of miR-137. To further test whether miR-137 could target Mib1, we cloned the
91

3’-untranslated region (3’-UTR) of Mib1 containing the predicted miR-137 target site, from
mouse cDNA into a Renilla luciferase (R-luc) reporter construct (Figure 6.5B). This allows us to
assess MIB1 protein translation regulated through its Mib1 3’-UTR. This 3’-UTR R-luc
construct along with a firefly luciferase (f-luc) control plasmid were cotransfected into cultured
primary neurons. We found that overexpression of miR-137 suppressed over 50% of the R-luc
activity in primary neurons at 48 hours post-transfection (n = 7, p < 0.001) (Figure 6.5C). On the
other hand, transfected anti-miR-137 led to a 28% increase in R-luc activity compared with the
anti-miR control (anti-miR-Con, n = 3, p < 0.05) (Figure 6.5D). To further validate the
interaction between miR-137 and its target Mib1 3’-UTR, we mutated the seed sequence of miR137 located within the Mib1-3’-UTR reporter (Figure 6.5,B lower panel). This mutation
substantially alleviated the miR-137-mediated suppression of luciferase activity, suggesting that
the action of miR-137 is specific to the miR-137 seed region within the Mib1-3’-UTR (n = 5, p <
0.001) (Figure 6.5E).
To investigate the effect of miR-137 on endogenous MIB1 expression in neurons, we
used the lentivirus expressing sh-miR-137 (Figure 6.4A) to infect cultured primary neurons.
Lentivirus transduction allows us to achieve relatively high expression efficiency (~50%) in
mouse primary neurons (Figure 6.5F). Neurons infected by sh-miR-137 expressing virus had a
13% decrease in endogenous MIB1 expression compared with neurons infected by control virus
(sh-Con, n = 3, p < 0.05) (Figure 6.5G). Taken together, these data suggest that miR-137
regulates the protein expression of MIB1 through the 3’-UTR of Mib1.
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Figure 6.5. Mib1 is a functional target of miR-137. (A) A miR-137 target site was found in the Mib1 3’
untranslated region (3’UTR) as predicted by TargetScan software. The Mutant Mib1 3’UTR used in B-E with
miR-137 site deleted is shown. (B) Schematic diagram showing the predicted seed region where miR-137 is
expected to bind the rLuc-Mib1 3’-UTR (upper), and the mutated version lacking the binding site for miR-137.
(C) Mib1-3’-UTR–dependent expression of a Renilla luciferase reporter gene (R-luc) was suppressed by miR137 over 50% in DIV6 primary neurons at 48 hours post-transfection (n = 7, p < 0.001). The 3’-UTR-dependent
Renilla luciferase (R-Luc) activities were normalized to control firefly luciferase (f-Luc) activities in the result of
miR-137 coexpression was calculated relative to the miR-Con in C-E. (D) The mutant Mib1-3’-UTR alleviated
the miR-137-mediated suppression of luciferase activity, suggesting that the action of miR-137 is specific to the
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Primary neurons infected with lentivirus expressing sh-miR-137 had reduced Mib1 protein expression compared
with neurons infected with lentivirus expressing sh-Con at 48 hours post-infection. (*, p < 0.05; ***, p < 0.001)
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6.4.5 Expression of MIB1 rescues the miR-137-mediated reduction in
dendritic complexity
Since we have confirmed that miR-137 targets MIB1, we performed additional
experiments to determine whether MIB1 could rescue the miR-137 overexpression-induced
reduction in dendritic complexity. We showed that overexpression of MIB1 led to significant
increases in both dendritic length (n = 5, 41% +/-0.12 SEM, p < 0.01) and dendritic complexity
(F(1,36) = 23.00, p < 0.001) compared with control vector-transfected neurons (Figure 6.6A and
B). On the other hand, using a specific small hairpin RNA (shRNA) against Mib1 (Supplemental
Figure S6.6), we also showed that acute knockdown of MIB1 led to a significant decrease in both
dendritic length (37.5% +/-0.09 SEM, n = 3, p < 0.05) and dendritic complexity (F(1,47) =
49.00, p < 0.001) compared with control shRNA-transfected neurons (Figure 6.6A and B). Then,
we cotransfected neurons with MIB1 expression plasmid and a synthetic miR-137 and show that
MIB1 overexpression partially rescued the miR-137-mediated reduction both in dendritic length
(n = 4, 6% difference between “Mib1+miR-137” and “Control GFP”, 33% difference between
“Mib1+miR-137” and “miR-137”) (Figure 6.6A) and in dendritic complexity (F(1,35) = 18.51, p
< 0.001) (Figure 6.6C). These data suggest that miR-137 regulates dendritic morphogenesis in
developing neurons, at least in part, by translational regulation of MIB1 (Figure 6.6D).
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6.5 DISCUSSION

The potential functions of miRNAs acting locally at the neuronal dendritic spines are just
beginning to be explored (Smalheiser and Lugli, 2009). Several miRNAs are found to be
localized and functioning in dendrites and synapses. Among them, miR-132 and miR-137 are
both enriched in dendritic spines, but whereas miR-132 represses spine volume, miR-137 shows
no effect on spine volume (Siegel et al., 2009). Therefore it is likely that individual miRNAs at
the synapse play specialized roles in dendritic morphogenesis and synaptic development.
Although the specific mechanisms underlying miRNA regulation of neuronal development are
not fully clear, current experimental evidence suggest that miRNAs can have functions during all
stages of neuronal development, including neural stem cell proliferation, neuronal fate
specification, neurite outgrowth, and spine development (Liu and Zhao, 2009a). In the case of
miR-137, we believe that it may play a dual role in neurogenesis. miR-137 is found to induce
differentiation of adult mouse neural stem cells as well as mouse oligodendroglioma-derived
stem cells and human glioblastoma multiform-derived stem cells (Silber et al., 2008). Studies
from our lab have shown that miR-137 also plays a role in the proliferation and differentiation of
adult neural stem cells by targeting histone H3K27 methyltransferase Ezh2 (Szulwach et al.,
2010). Interestingly, we found that miR-137 regulates dendritic morphogenesis by targeting
MIB1, not EZH2 (Supplemental Table S6.1). These studies suggest that miR-137 plays different
roles during the early and late stages of adult neurogenesis in the hippocampus. Additionally, our
ISH data (Figure 6.1) shows miR-137 expression is widespread in the DG, suggesting that miR137 may function in both developing and mature neurons. In fact, Siegel et al have found miR137 is one of the miRNAs enriched in the synpatosome postnatal mature neurons (Siegel et al.,
96

2009). Interestingly, double ISH/immunohistochemistry shows miR-137 overlaps with
presynaptic synapsin, indicating that miR-137 may also function in the pre-synaptic
compartment, in addition to the dendritic and postsynaptic compartment. It is well known that
local protein synthesis is important for synaptic transmission and plasticity. In mature neurons
miR-137 may regulate the translation of a subset of proteins that are important for neuronal
activity-dependent protein expression and synaptic plasticity, similar to what has been found for
miR-132 (Vo et al., 2005). Thus, an interesting question to pursue would be whether miR-137
can mediate neuronal activity-dependent dendritic development. It is also possible that miR-137
has effects on the maintenance and survival of neurons. One could speculate that miRNAs in the
dendrite may participate in the regulation of local protein translation and modify synaptic
plasticity at the synaptic compartment; however, a complete story of how miRNAs and their
dendritic target mRNAs regulate dendritic morphogenesis and synaptic development has yet to
be told and remains a critical area of future neurodevelopment studies.
The most challenging step in determining the function of miRNA is to identify their
downstream mRNA targets. Based on bioinformatic databases, we know that each miRNA can
have many potential mRNA targets, yet whether these predicted mRNA targets are functional in
the context of miRNA-mediated gene regulation remains to be determined. However, only a
small number of these predicted targets are true targets. In addition to MIB1, several additional
miR-137 targets are strongly associated with neuronal development and synaptic function
including Ezh2, EphA7, EphB2, NcoA3, Shank2, and Snap23. Even though some of these
predicted targets did not show obvious functional rescue in our initial screening, we cannot rule
out the possibility that miR-137 could function by modulating the translation of these genes to a
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lesser extent. Further experiments to identify additional miR-137 targets will give us a more
complete picture of miR-137 function during neurodevelopment
An interesting question to pursue would be whether miR-137 can mediate neuronal
activity-dependent dendritic development. Although neurons contain many potential targets of
miR-137, we chose to follow ubiquitin ligase MIB1, because mass spectrometry has shown it to
be enriched in the postsynaptic compartment (Choe et al., 2007; Sheng and Hoogenraad, 2007).
Mib1 was first cloned and studied in zebrafish (Itoh et al., 2003), and the loss of MIB1 led to
reduced lateral inhibition of Notch signaling, which in turn triggered changes in the number of
progenitors and neuronal differentiation during zebrafish CNS development (Itoh et al., 2003).
MIB1 is an E3 ubiquitin ligase and promotes ubiquitination and internalization of the Notch
ligand Delta, leading to Notch pathway activation. In mammals, the function of MIB1 is not fully
clear. In one study, MIB1 was found to activate the Notch pathway in embryonic mice, and Mib1
mutant mice exhibit deficits in neurogenesis and resemble mice lacking Notch signaling
components (Koo et al., 2005). MIB1 was also shown to be phosphorylated by PAR-1, resulting
in MIB1 degradation and stimulation of neuronal differentiation in mammalian neuronal
progenitors (Ossipova et al., 2009). Similarly, Notch activation by MIB1-positive newborn
neurons and intermediate progenitors in mice functions to ensure the maintenance of stem cell
properties of radial glia during neurodevelopment (Yoon et al., 2008). A recent study shows that
MIB1 inhibits dendritic development in cultured rat cortical neurons (Choe et al., 2007). The
precise role of MIB1 in mammalian dendritic development is unknown; however, the importance
of MIB1 in neuronal maturation is clearly demonstrated by both the published literature and our
data.
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The possible role of the E3 ubiquitin ligase MIB1 in neuronal maturation is intriguing,
albeit vastly speculative. The ubiquitin pathway is best known for its role in marking target
proteins for specific proteolysis by proteasomes; however, the ubiquitin pathway may also be
involved in regulating the abundance of postsynaptic receptors (Burbea et al., 2002). A neuronal
deficiency of UBE3A, an ubiquitin protein ligase involved in protein degradation, causes
Angelman syndrome, which is characterized by severe mental retardation. In recent studies,
UBE3A was found to localize to the synapse, and its deficiency resulted in abnormal dendritic
and spine morphology (Dindot et al., 2008; Lu et al., 2009). MIB1, on the other hand, seems to
be involved in protein trafficking rather than protein degradation (Itoh et al., 2003). It may
modify postsynaptic receptors or other regulatory molecules at the synapse and alter their
intracellular localization, hence its involvement in dendritic patterning in developing and mature
neurons. The fact that MIB1 can rescue the dendritic deficits associated with miR-137
overexpression further supports the positive effects of MIB1 on mammalian dendritic
morphogenesis and its role as one of the downstream effectors of miR-137. Understanding this
pathway may also shed light on the molecular mechanism underlying neurodevelopmental
disorders associated with neuronal dendritic deficits.

6.6 SUMMARY

Our goal is to understand how noncoding miRNAs regulate development and functions of
neurons. We have discovered a number of miRNAs that are enriched in neuronal lineage, relative
to either astrocytic lineage or undifferentiated NSCs. Here we show that one of these miRNAs,
miR-137, has an important modulatory role in dendritic morphogenesis during neuronal
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development both in vivo and in vitro. We find that overexpression of miR-137 using the
“single-cell genetic approach” in newborn neurons of the adult hippocampus results in reduced
dendritic complexity and spine density; however, since the single-cell genetic approach
specifically targets proliferating cells prior to neuronal differentiation, we also confirmed that
overexpression of miR-137 has the same effect on postmitotic cultured hippocampal neurons.
Both overexpression and inhibition of miR-137 have significant but opposite effects on dendritic
complexity. Therefore, our data indicate that proper expression of miR-137 is required for the
normal dendritic development of hippocampal neurons.
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Figure S6.1. A-B, Profile of mature miRNA expression in adult hippocampal neuroprogenitors (A94-NSCs)
differentiated into either neuronal or astrocytic lineages compared to undifferentiated progenitors. C, Double
ISH/immunohistochemistry to show miR-137 overlaps with pre-synaptic synapsin (h, hilus; g, dentate gyrus; m,
molecular layer).
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Figure S6.2. Sample traces of in vivo virus-infected neurons used for analysis in Figure 3.
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Figure S6.3. The widths of dendritic spines in miR-137overexpressing neurons were no different from sh-Control
overexpressing neurons at 4 weeks post-labeling.
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Supplemental Figure S6.4

Figure S6.4. Fewer miR-137-overexpressing cells differentiated
into neurons (both NeuN+ and DCX+) analyzed at 4 weeks post
viral labeling.
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Figure S6.6. Validation of Mib1 shRNA using
Western blotting. Mib1 expression vectors and
4 different Mib1 shRNA plasmids were cotransfected into HEK293 cells. The cell lysate
was analyzed for mouse Mib1 expression using
Western blotting. Among the 4 shRNAs tested,
number 3* showed the best knockdown
efficiency and was used for Figure 6
experiments.
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Supplemental Table S6.1
Table S6.1. Top candidate mRNA targets of miR-137.
mRNA
Targets

Luciferase
Activity
293
cells

Western
Blot

Dendritic
Complexity

Relevance

Hippo
Neurons
Notch signaling. Embryonic Development.
Dendritic development in hippocampal
neurons.

MIB1

Ezh2

N/A

N/A

EphA7

N/A

N/A

NCOA3

N/A

N/A

Nervous system development, stem-cell
proliferation and differentiation
N/A

Nervous system development, apoptosis,
proliferation. Synaptogenesis.

N/A

nuclear receptor coactivator. The protein
has histone acetyltransferase activity,
recruits p300/CBP-associated factor and
CREB binding protein as a multisubunit
coactivation complex.

Decreased
No Change

N/A Not Analyzed
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CHAPTER 7:
Summary and Critique

7.1 Summary
Dendrites and the dendritic spines of neurons are the key sites of synaptic input and
connectivity in the brain and have been recognized as the locus of long-term synaptic plasticity.
The development of dendrites and spines in mammals is a complex process that requires specific
molecular events that function to signal neuronal differentiation, dendritic morphology, and
synaptogenesis. These events are tightly regulated by genetic and epigenetic mechanisms,
including DNA methylation, chromatin remodeling, and the noncoding RNA-mediated process.
It has been shown that the altered spine morphology associated with pathological conditions can
affect the properties of an individual neuron, the neural networks, and mental function as a
whole. In fact, dendritic spine distribution and structure is abnormal in many diseases and
injuries, as well as many forms of mental retardation; however, spine characterizes can also be
potentiated by neuronal activities and an enriched environment. Understanding the pathways that
lead to altered spines in pathological conditions will provide researchers with a better
understanding of the conditions that contribute to normal dendritic spine and synaptic formation
during development and learning in the adult brain. Despite the fact that several protein
pathways have been identified as critical players in spine development and pathology, the
molecular pathogenesis of aberrant spine morphology in these diseases has yet to be clearly and
comprehensively elucidated. The goal of this thesis is to determine how epigenetic factors
influence the key characteristics of neuronal maturation in developing neurons of the adult
hippocampus to further elucidate the pathophysiology of abnormal spine morphogenesis in MR.
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In the previous chapters, I described how a Mecp2 mutant mouse model can be used to
investigate the role of MeCP2-mediated epigenetic regulation of hippocampal development
(Smrt et al., 2007). The data collected in this study showed that MeCP2 is not critical for the
early stages of neurogenesis, but is important for neuronal maturation and spine distribution in
the postnatal hippocampus. In a separate study, I showed that a brain-enriched microRNA, miR137, has a significant role in regulating neuronal maturation in vivo and in vitro by modulating
the expression of a MIB1 (Smrt et al., 2010). The data indicated that proper expression of miR137 is required for normal dendritic development of hippocampal neurons.
In summary, this research shows that epigenetic control of expression pathways, which
include MeCP2 and non-coding microRNAs, are required for normal dendrite development of
hippocampal neurons, and demonstrate how alterations in epigenetic and noncoding RNAmediated processes can result in morphological and phenotypic abnormalities that are a
fundamental characteristic MR, such as that seen in fragile X, autism, and Rett syndrome. The
first major discovery of this work is that MeCP2 epigenetically regulates a number of specific
miRNAs in adult brain-derived neural stem cells (NSCs) under both proliferating and neuronal
differentiating conditions. One of the miRNAs is miR-137. MeCP2 was found to bind directly to
the genomic region proximal to miR-137, and absence of MeCP2 binding to this region
correlated with an altered chromatin state and enriched miR-137 expression (Szulwach et al.,
2010). Additionally, this finding shows that miR-137 is significantly upregulated in the absence
of MeCP2 in the adult mouse brain and primary neurons (see APPENDIX A). The second major
discovery of this work is that miR-137 itself has a profound effect on the development of
dendritic structure and dendritic spine distribution in newborn neurons of the hippocampus and
in post-mitotic cultured neurons from mice. These data support the idea that miR-137 may exert
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its biological effects, at least in part, through its interaction with MIB1 (Smrt et al., 2010). The
overall model of this research is that epigenetic and non-coding RNA pathways, particularly the
crosstalk between these pathways (Smrt et al., 2010; Szulwach et al., 2010) influence the
morphogenesis of dendrites and dendritic spines. Thus, because MeCP2 can alter expression of
specific miRNAs, including miR-137, I propose that altered expression of miRNAs may
contribute to the dendrite and dendritic spine pathogenesis observed in Rett Syndrome (Figure
7.1 and 7.2).

Figure 7.1. A simple model based on my dissertation research (Smrt et al., 2010) showing how crosstalk between
epigenetic (MeCP2) and non-coding RNA (miR-137) pathways may converge on a protein coding gene (Mib1) to
influence the morphogenesis of dendrites and dendritic spines (Smrt et al., 2010). A more complex model is shown
in Figure 7.2.

Although these novel discoveries strengthen the link between epigenetic and non-coding
RNA pathways, much is still unknown about the diversity of epigenetic and non-coding RNA
molecules that may be interacting to shape the expression of developmentally relevant protein
coding genes. Furthermore, many of these pathway interactions may only play a functional role
in a specific cell type, or at a specific developmental period. It is important to realize the
complexity of epigenetic and non-coding RNA pathways during development. For instance, a
single epigenetic regulator such as MeCP2 can affect the expression of multiple miRNAs
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(Szulwach et al., 2010) along with the expression of coding genes, and miRNAs such as miR137 have multiple predicted targets (Figure 7.2). My dissertation research is only the “tip of the
iceberg” in terms of drawing a direct link between epigenetic and non-coding RNA pathways
and their role in dendritic development.
In the remainder of this chapter, I address some specific concerns and limitations
surrounding my research, and expand on some strategies I have used to address many of those
concerns. I also speculate on additional experimental procedures that may strengthen my
dissertation research and present alternative possibilities that may explain my findings. Finally, I
discuss the future directions of my research.
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Figure 7.2. Detailed overall model summarizing this dissertation research showing how crosstalk between
epigenetic (MeCP2) and non-coding RNA (miR-137) pathways may involve a complex series of pathways that
ultimately influence the morphogenesis of dendrites and dendritic spines (Smrt et al., 2010; Szulwach et al., 2010).
A. miR-137 expression is correlated with global changes in histone acetylation which could persist throughout
neurogenesis and affect miR-137 expression during maturation. Additionally, activity dependant phosphorylation of
MeCP2 can influence its association with DNA. B. MeCP2 modulates miR-137, but may also modulate the
expression of other miRNAs and unknown factors. C. miR-137 has been shown to regulate MIB1 expression, but it
may also regulate other factors important for neuronal maturation. D. MIB1, a ubiquitin ligase, may interact with
other molecules like EEA and cateninis. E. Molecules downstream of MIB1, EEA1, and catenins may interact with
synaptic molecules such as SDC1 (Smrt et al., 2007) and receptors such as NMDA and AMPA to influence dendritic
morphology and dendritic spine development. Red lines indicate pathways confirmed in this dissertation research,
blue lines indicate pathways confirmed in other papers, and grey lines are possible pathways that have yet to be
confirmed.
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7.2 Critical analysis of my dissertation research

7.2.1 Limitations and concerns surrounding cultured neurons
Both the reviewers of my manuscript (Smrt et al., 2010) and members of my dissertation
committee have raised concerns about cultured primary neurons as a model for
neurodevelopment. Although primary neurons dissociated from an embryonic brain and grown in
culture dishes are accepted as a valuable model in neuroscience to study the biological properties
of neurons (Goslin and Banker, 1989), cultured neurons have many inherent differences
compared to those neurons which function in a living brain. The primary concern regarding these
differences is how they may affect the conclusions drawn from experiments using neuronal
culture. One can imagine that if the procedure for isolating primary hippocampal neurons
involves stripping developing neurons of their normal chemical and physical contacts, they must
somehow be different.
This concern is certainly a “no brainer” (pun intended) as the conditions between in vitro
(dish) and in vivo (brain) are different in notable ways. Specifically, primary neurons are cultured
in a standardized culture medium which contains factors needed for metabolism and survival of
neurons in culture; however this rich medium could not fully recapitulate all of the factors found
in a specific brain microenvironment, which interacts with a specific group of neurons.
Formation of functional neural networks is a fundamental characteristic of brain development. In
culture, post-mitotic neurons are taken out of their native networks, and asked to form new
synapses and network connections. Although formation of synapses and networks are highly
characterized in cultured neurons, the number and complexity of networks in the standard culture
method could certainly not rival the brain. Another difference between cultured neurons and the
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brain is that cultured primary neurons suffer from increased degeneration over time. After about
3-4 weeks in culture, hippocampal neurons rapidly lose their synaptic connections and begin to
die. This is different from the living brain where many of our neurons must maintain synaptic
connectivity and continue to function for a lifetime. Changes in any of these variables may have
an impact on the outcome of in vitro experiments. For that reason, we favor in vivo experiments
to complement the compelling evidence we gather from primary neuronal culture.
In my study, I used both cortical and hippocampal neuronal cultures taking advantage of
the strength of both. As I mentioned in the manuscript, cortical culture yield more neurons with
higher purity of neurons (>90%), which allows for biochemical and molecular pathway analysis.
On the other hand, hippocampal neurons, generally containing >70% astrocytes, are more
suitable for neuronal maturation analysis. However, I am aware of the limitation of both culture
systems. Between cortical and hippocampal neuronal isolation, which are two common primary
culture methods that both share a nearly identical isolation protocol, cortical cultures can be
considered the most heterogeneous in terms of the variety of cell types cultured. For example,
cortical cultures contain all the cell types and brain regions of the neocortex. If the experimenter
is not careful during dissection, cortical cultures may even contain striatum, hippocampus, and
olfactory bulb neurons. However if the dissection is performed correctly, with a strict criteria for
removing the additional brain structured mentioned, the cortical preparation will still contain
neurons of various cortical regions, birthdates, neurochemical function, and epigenetic
background. Thus, it is important to determine how the variability, or heterogeneity, in cortical
cultures will impact the question that is being asked. One of the major benefits of hippocampal
cultures is that they are far more homogeneous than cortical cultures. Specifically, hippocampal
cultures of E17.5 mouse embryos contain primarily CA1 neurons, as the dentate gyrus has not
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formed at this early developmental time point. Although mouse hippocampal cultures isolated at
E17.5 are more homogenous than cortical cultures isolated at the same time, they are not devoid
of other cell types. Thus, I have made an effort to produce cultures that are enriched with
neurons, making cellular and biochemical analysis of neurons possible (See Appendix Figure
A.6). Despite the advantages of hippocampal cultures, they produce a lower yield of neuronal
product in terms of total number of neurons compared to isolated cortex. This can limit the
number of conditions that can be held in a single experiment. Many experiments (e.g. ChIP, WB,
etc) prefer a generous amount of starting product which may favor cortical preparations.

7.2.2 Limitations and concerns surrounding in vivo retroviral targeting
One effective way for me to study gene regulation in neuronal development is to
manipulate young neurons residing in the living brain. The method gaining popularity among
neurodevelopmental biologists, and heavily used in my thesis work, is the single-cell genetic
approach. This system makes use of recombinant retroviruses capable of specifically infecting
dividing cells in vivo. Although this method has tremendous advantages due to its ability to
deliver a transgene specifically to newborn cells in the DG, there is a caveat that should be
considered when using this method to perform morphological and phenotypic analysis of
differentiated neurons. Specifically, since retrovirus infects dividing cells, overexpression of
transgenes in dividing neuroprogenitors may affect initial neuronal differentiation, which might
affect subsequent neuronal maturation. One could speculate that ectopic gene expression under a
retroviral promoter during proliferation and differentiation of neuroprogenators may disrupt the
cell’s normal biochemical balance during that stage of neurogenesis and interfere with
subsequent stages in neuronal maturation. For example, when retroviruses are used to deliver a
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transgene (for example GFP, or miR-137) into a cell, the experimenter doesn’t have control over
the genomic location the transgene will be inserted. Although researchers suggest retrovirus can
select active chromatin sties for integration of their viral DNA (Coffin et al., 1990; Naldini et al.,
1996), these mechanisms are poorly understood and viral DNA integration into the genome can
sometimes lead to unstable mutations in the genome of the host cell(s) (Harbers et al., 1984;
Soriano et al., 1987). Another potential confound is that it is unknown if the retrovirus may cause
long-lasting changes in dividing or differentiating cells could impact the development of
maturing neurons. To address these limitations and confirm that retroviral delivery of miR-137
affects dendritic morphology during neuronal maturation, and not early stages of neurogenesis
such as proliferation or differentiation, I expressed miR-137 in post-mitotic hippocampal
neurons. The limitations I described above have not eliminated the use of retroviral-mediated
gene delivery to study neuronal maturation, but they are important to consider when thinking
about additional experiments that can validate your findings. In Future Directions section 7.4
below, I will discuss a specific molecular modification to the retroviral system that can be used
to circumvent the caveats I mentioned here.

7.3

Additional studies that could strengthen my dissertation research

7.3.1 Validation of MeCP2 target genes in neurons
In Smrt et al 2007, I showed a number of possible gene targets that were upregulated in
the absence of MeCP2. It is a common belief that identification of gene targets that are directly
or indirectly regulated by MeCP2 in neurons is an important effort in determining how MeCP2
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exerts it effect on gene expression in the brain (Smrt et al., 2007). Although my research
contained expression profiles of mRNAs that were differentially regulated in the hippocampus of
mice lacking MeCP2, we did not perform ChIP on a subset of those genes. Performing ChIP
would allow us to determine of MeCP2 directly regulated their expression, or if gene expression
regulation was an indirect consequence of altered MeCP2 expression. To follow up on genes
regulated by MeCP2, a gain or loss of function approach could be used to confirm if these genes
are important for specific developmental stages of the neuron, specifically dendrite and dendritic
spine development. If these MeCP2-regulated genes were found to be linked to dendritic
morphology, we would express them in the Mecp2 KO to attempt to rescue the mouse Mecp2
KO phenotype. Additionally, genes that were confirmed to be down-regulated in the absence of
MeCP2 may be pathway targets of my later miRNA studies. These studies could help identify
some the factors that are involved in the morphological phenotype observed in previous studies
(Smrt et al., 2007).

7.3.2 How MeCP2 regulates miR-137 in neurons
Unpublished data from my dissertation research project show that expression of miR-137
is upregulated in the absence of MeCP2 in neuronal cultures and cortical brain tissue (Appendix
Figure A.1). Although these data suggest a link between epigenetic and non-coding RNA
pathways, these data do not explain the epigenetic mechanism of how MeCP2 may function to
modulate the expression of non-coding RNAs, specifically miR-137. The data (unpublished,
Appendix Figure A.5) showed no enrichment of MeCP2 on genomic region surrounding miR137 both in mouse hippocampal cultures and mouse adult cortex. This suggests that although
miR-137 levels are elevated in the absence of MeCP2, MeCP2 may not directly regulate miR114

137 by direct genomic binding in post-mitotic neurons. In this section I will propose a number of
possibilities that may explain why elevated miR-137 levels are observed in the absence of
MeCP2.
In proliferating adult neural stem cells, elevated expression of miR-137 was found in the
absence of MeCP2 (Szulwach et al., 2010). To determine if MeCP2 directly interacts with
genomic regions proximal miR-137, MeCP2-specific ChIP followed by real-time PCR was
performed in aNSCs. It was found that elements just upstream of miR-137 were enriched 3-fold
suggesting MeCP2 has a direct association with regions proximal to miR-137. In aNSC, the
interaction of MeCP2 with miR-137 involves SOX2, an important transcriptional regulator
specifically expressed in stem cells but not in differentiated neurons. This data suggests that
MeCP2 is involved in establishing the chromatin state so that transcription can be coordinated in
stem cells by factors such as SOX2. It was found by Szulwach et al 2010 that Ezh2 is a
functional target of miR-137. EZH2 is a H3-K27 methytransferase and part of the Polycomb
group (PcG) of complexes that is related to the maintenance of the “bivalent chromatin state” of
stem cells. The “bivalent chromatin state” essentially “primes” genes for cell/tissue specific
expression, but holds them in check by opposing chromatin modifications (Boyer et al., 2006;
Lee et al., 2006). Regulation of Ezh2 by miR-137 may be important for establishing and
maintaining the bivalent chromatin state of stem cells, by keeping appropriate levels of H3-K27Tri-Me3. A decrease in EZH2 expression resulting from elevated miR-137 is correlated with a
global decrease in H3-K27-Tri-Me3 levels that can change the chromatin state of aNSCs
(Szulwach et al., 2010). These changes may persist throughout neurogenesis even when aNSCs
differentiate into neurons when Ezh2 is no longer expressed.
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I propose that reduced H3-K27-Tri-Me3 levels in differentiating KO NSCs leads to
increased expression of specific developmental genes, such as miR-137 in neurons. There are
several ways to test this hypothesis. To test if the amount of H3-K27-Tri-Me3 bound to miR-137
genomic region is altered in the absence of MeCP2, I could perform a H3-K27-Tri-M3e histonespecific ChIP in proliferating NSCs, differentiating NSCs and primary neurons lacking MeCP2
compared to WT controls. I will then determine whether exogenous MeCP2 or Ezh2 can rescue
the binding of H3-K27-Tri-M3e to the miR-137 genomic region using ChIP. These experiments
will show whether H3K27-Me3 levels are altered in KO neurons and whether it is result of
lacking MeCP2. Another possibility is that H3-K9-Ac, which is associated with transcription
activation, is increased in miR-137 genomic region of Mecp2 KO aNSCs and such increase may
persist into the neuronal lineage. It was found previously that H3-K9-Ac was increased
surrounding the miR-137 gene in proliferating aNSCs lacking MeCP2 (Szulwach et al., 2010).
Therefore, I could also use a histone-specific ChIP to determine if H3-K9-Ac is altered in
neuronal differentiating aNSCs lacking MeCP2 compared to WT controls. These data will help
us to determine if decreased MeCP2 and increased miR-137 expression early in development
may be related to altered establishment of the chromatin state leading to the altered miR-137
expression observed in neurons lacking MeCP2.
Alternate possibilities are that MeCP2 indirectly regulates miR-137 expression by
regulating an unknown factor (Figure 7.2). For instance, MeCP2 may maintain expression of
miR-137 by repressing a transcriptional activator of miR-137. Additionally, MeCP2 has been
shown to be a transcriptional activator for a small subset of genes. Thus, MeCP2 could activate a
repressor to maintain miR-137 expression. Another possibility based on recent literature showing
the role of MeCP2 in activity dependant gene regulation, is that MeCP2 may selectively regulate
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miR-137 in an activity dependant manner (See section 7.4.1 about activity-dependant
regulation). Thus, detection of genomic binding of MeCP2 may only be possibe under activated
conditions. In any of these testable scenarios, lack of MeCP2 would lead to increased miR-137
levels (Appendix Figure A.1).

7.3.3 Other potential targets of miR-137
Most miRNAs bind to their target 3’UTR with imperfect complementarity as they
function as translational repressors (Guo et al., 2010). This is in contrast to RNA interference
(RNAi), where RNAi is a sequence-specific gene silencing mechanism (Hannon, 2002) that uses
small interfering RNAs (siRNAs) to interact with target mRNAs. siRNAs and miRNAs are
similar with respect to their biogenesis, molecular characteristics, and functions (He and Hannon,
2004). As described in Chapter 2.4, both miRNAs and siRNAs are 21-25 nucleotides in length,
share the RNase-III processing enzyme, Dicer, and interact with the effector complex, RISC.
miRNAs and siRNAs seem to differ most noticeably in their origin and target recognition. First,
miRNA precursors are genetically encoded whereas siRNAs are formed from long dsRNAs that
can be generated from endogenous RNAs that can anneal to form dsRNA (Hannon, 2002).
Second, miRNAs bind to target 3’UTRs through imperfect complementarity, often at multiple
sites (Guo et al., 2010). In contrast, siRNA mostly binds only one site forming a perfect duplex
with the target. It seems that the similarities and differences between miRNA and siRNA have
been extensively explored; we have yet to identify all the miRNA-interacting complexes and to
understand the specific actions that distinguish miRNA and siRNA and their respective in vivo
targets. Thus, the small similarities and differences between these two regulatory mechanisms
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will certainly emerge as the precise mechanisms of individual non-coding RNAs and associated
protein complexes are revealed.
This introduction sets the stage for a major concern surrounding my research, which is
focused on the effect of a single miRNA on neurodevelopment when there are so many targets of
any single miRNA based on the non-complementary characteristics of miRNA targeting. Why
select miR-137 when there are a number of miRNAs expressed in developing neurons and quite
a few of them might be regulated by MeCP2? This question has been raised for a number of
reasons. Since the study of miRNA function in the brain is a novel pursuit in neuroscience,
scientific peers and critics are particularly interested in knowing more about how they can
optimize selection criteria and target validation. Fortunately, despite the fact that miRNAs are
only recently becoming a popular target for neurodevelopmental studies, researchers have long
been using molecular tools to detect RNAs. These tools, along with advances in high-throughput
microarray screening and popularization of bioinformatic databases have accelerated our ability
to examine miRNA expression in the brain, and enabled researchers to propose potential
mechanisms for miRNA function. I will first describe a somewhat standardized process for
identifying miRNA’s and their functional targets followed by how I identify miR-137 and its
target MIB1.
In my studies, we first looked at the expression of miRNAs using miRNA-specific
microarrays in brain tissue, post-mitotic neurons, undifferentiated neural stem cells, and neural
stem cells that are differentiated into neurons or astrocytes. This kind of sampling enabled us to
identify a subset of miRNAs that are enriched in cells derived from the neuronal lineage. This is
precisely how miR-137 became noticed as a neuronal enriched miRNA that may be important for
development. The next step is to assess the subset of miRNAs that have been revealed by the
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array. This selection process can be based on factors such as the degree of expression, or
relevance to development. When considering miRNAs that are relatively uncharacterized, one
may chose to study a miRNA based on its expression levels in a certain tissue or cell type.
However, with the increasing amount of literature on miRNA in the brain, researchers can now
chose miRNAs to study based on relevance to their research and potentially discover novel
mechanisms. For example, miR-137 was highly uncharacterized at the time we noticed it on
arrays, and was chosen based on its neuronal specific expression. Once the miRNA(s) have been
selected, their expression levels can be confirmed by qRT-PCR. The next step involves the
mining of reputable bioinformatic databases. The internet is populated with many miRNA
prediction databases (mentioned in Chapter 6) that use genetic sequences and mathematical
algorithms to generate a list of possible interactions between a mature miRNA and specific
sequences of the 3’UTR of a target gene. It has been reported that this method for target
prediction is very efficient. One may consider using defined selection criteria when choosing a
target. For example, a subset of potential miRNA targets can be chosen for further analysis based
on conservation, context score of target ‘‘seed sequences,’’ and known relevance to dendritic
morphogenesis and neuronal development. Next, it is a common practice in miRNA research to
take the subset of potential targets and validate them using luciferase assays. This assay is
designed to confirm that the miRNA binds to the 3’UTR of a target gene to regulate translation.
The 3’UTR of the potential target genes can be fused to a luciferase reporter, and cells of interest
can be co-tranfected with the reporter and miRNA(s) of interest. To further confirm that the
miRNA regulates translation of the target gene by binding the predicted “seed” region, many
researchers have modified the seed region on the 3’UTR of the target. Based on luciferase
activity data, identified targets can be further assayed using western blots. For example, one

119

would overexpress or knockdown miRNA in cells and assay protein expression of the target
gene. Overall, this process allows researchers to discover the expression profiles of miRNAs in a
tissue of interest, and then derive a one or more protein targets that play a role in the function of
the cell.
Previously, I used this process to show miR-137 regulates neuronal development by
translational regulation of MIB-1 (Smrt et al., 2010). However, during this process many other
miRNAs and potential miR-137 targets were identified. Other miRNAs identified during our
initial screening may also be important for neurodevelopment and dendritic morphogenesis.
Following up on additional miRNAs or miR-137 targets is considered a “lack of studies” because
it is likely that some of the other miRNAs may be related to the pathway I have identified, and
that additional miR-137 targets function to shape dendritic and spine development of the neuron.
However, although there may be many potential targets of miR-137, only a few are likely to be
true targets of miR-137 and have a function in neuronal maturation. For example, it was
criticized that I identified SHANK2 as a potential target of miR-137, but didn’t perform
additional experiments to confirm that gene as a target. SHANK2 is known to specifically play a
role in spine morphogenesis and function, and I found spine morphology was no different in
neurons overexpressing miR-137 compared to controls suggesting Shank2 is not a functional
target of miR-137. However, although SHANK2 is not a likely target for miR-137-mediated
dendritic maturation, it could potentially mediate miR-137 function in other neuronal
development aspects. In addition, some of the other potential miR-137 targets may also play a
role in dendrite morphogenesis to some extent. This additional information not only may shed
light on the role of miRNAs in neuronal maturation, but also can provide an additional
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dimension to the complexity of the miRNA regulatory pathway. Thus, these unexplored data I
have generated can be used to propose future experiments.

7.3.4 Cell type-specific and subcellular localization of miRNA
The combination of fluorescent in situ hybridization (FISH) and immunohistochemical
colocalization method is used by many researchers as a tool to characterize the cell type-specific
and subcellular localization of miRNAs and the proteins they potentially regulate. The major
technical limitation to this approach is obtaining antibodies and RNA probes that can each label
their target effectively when used together. It seems that specific combinations of antibodies and
probes can be challenging to optimize. Using FISH to characterize the subcellular localization of
miRNA may give clues to its function and could be used to help researchers identify a potential
miRNA pathway. For example when studying dendritic or spine development, it’s informative to
know if a specific miRNA is expressed in the dendrites, cell body, or nucleus. ISH combined
with immunohistochemistry could confirm that the miRNA and its proposed target are
colocalized within a cellular compartment. In the case of my dissertation research, the colocalization of miR-137 and MIB-1 in neurons could further support my model. In addition,
identification of where the interaction of miR-137 with MIB1 takes place would provide further
mechanistic insight to the relationship between miR-137 with MIB1. Is it in the dendrite, in the
spine, or in the cell body? Are they selectively colocalized proximal to translation machinery?
For example, I hypothesize that miR-137 and MIB1 localized in the dendrite near or in the
dendritic spine because it has been shown that translation of proteins important for synaptic
function take place locally at the dendrite and at the dendritic spine (Sutton and Schuman, 2005),
and miR-137 has been shown to be enriched in synaptic fractions (Lugli et al., 2008). I further
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speculate that this interaction of miR-137 and MIB1 takes place proximal to polysomes located
in the dendrites and dendritic spine. This hypothesis could be tested in neurons by using FISH
along with the appropriate probes. This additional information could show where this subcellular
interaction takes place, and add to the understanding of how miR-137 shapes dendritic
development through its interaction with MIB1.

7.3.5 Potential function of MIB1 in neuronal maturation
MIB1 is an ubiquitin ligase known to be important for neurogenesis and
neurodevelopment (Choe et al., 2007; Itoh et al., 2003; Ossipova et al., 2009). MIB1 is a E3
ubiquitin ligase and promotes ubiquitination and internalization of the Notch ligand Delta,
leading to Notch pathway activation. In mice, notch activation by MIB1-positive newborn
neurons and intermediate progenitors functions to ensure the maintenance of stem cell properties
of radial glia during neurodevelopment (Yoon et al., 2008). Although we know MIB1 is
important for neuronal maturation (Choe et al., 2007), the molecular mechanism(s) underlying
the effect of MIB1 on dendritic development are unclear. One proposed hypothesis is that the
effect of MIB1 on neurite outgrowth could be explained to some degree by the effect of MIB1 on
Notch signaling (Choe et al., 2007). Because Notch has been shown to reduce neurite
morphology, activation of Notch by MIB1 cannot explain my results as published in Smrt et al
2010. I have found that overexpression of MIB1 leads to increased dendrite complexity and
acute knockdown leads to reduced dendrite complexity. Choe and colleagues also recognized
that MIB1 may regulate neurite morphogenesis through pathways other than Notch. For
example, MIB1 was proposed to regulate neurite morphogenesis by its functional interaction
with p35/CDK5, where CDK5 activity can stimulate the degradation of MIB1, however it is not
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known if this interaction is transient because the majority MIB1 and p35/CDK5 are not localized
in the same compartment (Choe et al., 2007).
My research reports an increase of dendritic complexity when over expressing MIB1
while others have reported a decrease in dendritic complexity, however the importance of MIB1
in neuronal maturation is clearly demonstrated by both the other published literature and our data
(Choe et al., 2007; Smrt et al., 2010). The reason for this discrepancy is likely due to the celltype, and developmental time-point we used. For example, the data shown in Choe et al 2007
was mostly in cortical neurons, where transfection was performed and morphology was analyzed
at a time when neurons have made few synaptic connections, and at an earlier time than in my
studies. In my studies, hippocampal neurons were used, which are more homogeneous and can
become far more complex compared to cortical neurons, and additional morphological analysis
were used which included dendritic length, branch points, dendritic ends, and dendritic
complexity by sholl analysis. Although MIB1 is highly expressed in both embryos and adults,
one possibility is that the function of MIB1 may vary in cell/tissue specific manner and over a
developmental time course. There are multiple ways that MIB1 can regulate neuronal maturation
(Figure 7.2). For example, it was discovered that many other proteins that may interact with
MIB1 also have a dramatic effect neuronal morphology. One such protein is FAM, a mammalian
orthologue of the Drosophola protein fat facets. FAM is a deubiquitinating enzyme that can
remove ubiquitin tags from substrates. FAM/faf has been proposed to control vesicle trafficking
(Chen et al., 2003a), synaptic plasticity (Chen et al., 2002), and Notch signaling (Overstreet et
al., 2004). Expression of FAM/faf in neurons causes an increase of synaptic boutons in
neuromuscular junctions (DiAntonio et al., 2001). The interaction of ubiquitin ligases and
deubiquitinating enzymes is an important mechanism for modulation of the ubiquitination of
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protein targets (Nijman et al., 2005), and this interaction could play a underlying role in effect on
MIB1 on neuronal maturation in my dissertation research.
The ubiquitin pathway is best known for its role in marking target proteins for specific
proteolysis by proteasomes; however, the ubiquitin pathway may also be involved in regulating
the abundance of postsynaptic receptors (Burbea et al., 2002). Using affinity purification and
mass spectrometry, MIB1 was found to interact with membrane trafficking proteins such as early
endosomal antigen 1 (EEA1), Rab11-interacting proteins, and synaptosomal associated protein
of 25 kDa-like protein (SNAP25) (Choe et al., 2007). For example, knocking down EEA1 in
hippocampal slice cultures using EEA1 antibodies has been shown to increase AMPA, NMDA,
and kainite mediated excitatory post-synaptic currents, which may be due to impairment of
internalization of specific and glutamate receptors at the synapse (Selak et al., 2006), and EEA1
is colocalized with these receptors during synapse formation (Washbourne et al., 2004). Catenins
have also be suggested to interact with MIB1 by affinity purification (Choe et al., 2007), and it is
known that alpha-, beta- and delta-catenin are involved in synaptic function and dendritic
morphogenesis (Arikkath, 2009). Thus, the possible role of the E3 ubiquitin ligase MIB1 and its
interaction with trafficking proteins like EEA1 or catenins to shape neuronal maturation is
intriguing, albeit speculative. It is unknown what effect MIB1 may have on the function of its
proposed interactome such as EEA1 and catenins. Hence, I propose that MIB1 is involved in
dendritic patterning in neuronal development through its modification of postsynaptic or celladhesion molecules at the synapse. Further studies can be conducted in vitro to confirm the
physical and functional interaction of MIB1 with these other proteins. For example, affinity
chromatography and subsequent mass spectrometry has been used to identify MIB1 interacting
proteins, followed by affinity columns made of GST-MIB1 to isolate target proteins (Choe et al.,
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2007). To test if these molecules interact with MIB1 to shape dendritic morphology in neurons,
the proteins predicted to interact with MIB1 can be co-transfected with MIB1 in neurons to
determine if they can alter or rescue the effect of MIB1 on dendritic morphology. Understanding
this pathway may shed light on the molecular mechanism that leads to the results I see when
manipulating MIB1 expression, and the underlying neurodevelopmental disorders associated
with neuronal dendritic deficits.

7.4 Future directions of this project

I have made significant discoveries during my dissertation research that have led to
multiple publications in peer-reviewed scientific journals. The results of my work have also
generated many new questions and future directions that can be pursued by other scientists in our
laboratory and related scientific fields. These future directions are the focus of this section.

7.4.1 Activity-dependant epigenetic regulation (MeCP2) of miRNA
An important characteristic of MeCP2 is that its function is regulated in a neuronal
activity-dependent manner. For example, addition of potassium chloride (KCl) will depolarize
cultured neurons and lead to reduced association of MeCP2 with its known target promoter of
Bdnf, and also leads to an increase in Bdnf transcription (Chen et al., 2003b). The activitydependent function of MeCP2 is regulated by protein phosphorylation, which is known to be an
important posttranslational modification that can modulate the function of a protein by adding a
phosphate group to serine, tyrosine, or threonine residues. MeCP2 is predicted to be
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phosphorylated in at least 10 different sites and the the most studied sites are Serine 421 (S421)
and S80. MeCP2 can be phosphorylated at S421 and dephosphorylated at S80 under activitydependant conditions and is associated with promoter binding to methylated DNA. MeCP2 is
phosphorylated at S80 and dephosphorylated at S421 under resting conditions and such
phosphorylation inhibits binding methylated DNA (Chao and Zoghbi, 2009; Zhou et al., 2006).
Recently, it was found that mutations of specific phosphorylation sites on MeCP2, such as S80A,
can recapitulate the loss of function phenotype whereas a S421A/S424A double mutant displays
phenotypes observed in the gain of function model (Tao et al., 2009). This research demonstrates
the significance of posttranscriptional changes to MeCP2 and how transcriptional regulation by
MeCP2 can respond to neuronal activity. We know that MeCP2 S421 phosphorylation regulates
the activity dependant induction of Bdnf transcription (Zhou et al., 2006); however, much is
unknown about the role of activity-dependant phosphorylation of MeCP2 on the expression of
specific MeCP2-mediated genes. It was also shown that KCl treatment can induce miR-132
expression, which targets the Mecp2 3’UTR and inhibits its translation (Klein et al., 2007),
demonstrating an activity dependant link between MeCP2 and miRNA. Thus, I propose that
activity-dependant phosphorylation of MeCP2 may be a mechanism by which miRNA
expression is modulated in developing neurons. It is possible that direct MeCP2-dependant
epigenetic regulation of non-coding RNAs during neuronal development requires depolarization
of the cell, such as the depolarization of neurons induced by KCl in previous MeCP2 studies
(Chen et al., 2003b; Martinowich et al., 2003; Zhou et al., 2006). That is, MeCP2 may have an
activity-dependant role in regulating of non-coding RNA expression that we have not previously
explored. Activity dependant regulation of miR-137 by MeCP2 could explain why we see an
upregulation of miR-137 in the absence of MeCP2, yet MeCP2 does not appear to bind the
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region upstream of miR-137 using ChIP. A potential future experiment to explore this
mechanism is to stimulate neuronal cultures with KCL and determine if MeCP2 can bind to
genomic regions proximal to miR-137 and compare those results to non-stimulated cultures.

7.4.2 Synergistic effects of multiple miRNAs
The effect of multiple miRNAs on single gene targets and also multiple miRNAs on
multiple gene targets is an understudied area concerning miRNA functions in the brain. One aim
is to address the problem of complexity in the network of miRNA-mRNA interactions that may
play a role neurodevelopment. For example, a potential future experiment would first use
bioinformatics to identify multiple miRNAs that may converge on a single gene target to regulate
translation. For example, I previously showed that developing neurons express miR-137 and
miR-301, and a bioinformatic approach confirmed that are both predicted to bind the Mib1
3’UTR (Smrt et al., 2010). Interestingly, altered miR-301 and miR-137 levels are found in the
absence of MeCP2. The hypothesis for this potential future experiment is that both of these
miRNAs may function together to regulate the expression of MIB1 during the process of
neuronal development. However, the complexity of such an interaction should be considered
carefully. For example, do these miRNAs (137 and 301) interact with Mib1 in the same subcellular compartment, and at the same time during development? One possibility is that they both
work together, at the same time during neuronal maturation to regulate MIB1 protein expression.
An alternate possibility is that they work at different periods, or in different sub-cellular
compartments. For example, miR-137 is known to by enriched in the synaptic compartment
(Lugli et al., 2008), where it is speculated to play a regulatory role on local gene translation, but
perhaps miR-301 is has its maximum regulatory effect in a non-synaptic fraction of the cell. I
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speculate that such combinations of altered miRNA expression could contribute to the phenotype
of Rett syndrome, and could be the focus of a future direction. This “convergence” of multiple
miRNA’s on a gene target could then be expanded to look at the effect these multiple miRNAs
have on other targets related to neurodevelopment. Solving the complexity of these regulatory
networks will shed light on the mechanisms of developmental pathways, and help us to
understand the pathogenesis of diseases like Rett syndrome.

7.4.3 How MeCP2-regulated miRNAs may regulate synaptic function
In my previous work, I show that miR-137 overexressing neurons have morphological
abnormalities, including reduced dendritic complexity and spine density (Smrt et al., 2010). The
functional relevance of how a modest miR-137-mediated decreased dendritic complexity and
decreased spine density may affect the function of neurons and synapses remains to be explored.
Because the synapse is the locus of communication between neurons, one possibility is that
reductions in dendrite length, complexity, and spine density lead to fewer total synapses on the
neuron. A neuron with fewer synapses, all else being equal, could affect the capacity to which
that neuron responds to the surrounding circuitry. Specifically, fewer spines and smaller
dendrites could result in fewer synapses which would lead to reduced connectivity to
surrounding neurons. A modest change in dendritic complexity and spine density may be
detrimental to overall neuronal connectivity and function when considered in the context of an
entire neural network, such as the hippocampus.

However, I do not imply that a modest

morphological change alone can interfere with functional circuitry development and lead to
severe cognitive and motor impairment. It may be possible that changes in other molecular and
functional characteristics of the neuron lead to the phenotype I observe in neurons
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overexpressing miR-137. Specifically, it has been shown that there is a shift in the balance
between synaptic excitation and inhibition in Layer 5 pyridimal neurons in Mecp2-mutant mice
(Dani et al., 2005). Additionally, deficits in long-term potentiation (LTP) in cortical and
hippocampal synapses have been reported in Mecp2-mutant mice (Asaka et al., 2006; Moretti et
al., 2006). It has also been demonstrated that duplication or knock down of MeCP2 can lead to
altered glutamatergic synapse numbers in hippocampal cultures (Chao et al., 2007). Recently it
was shown that Mecp2-mutant mice have weaker excitatory synapses and fewer connections in
Layer 5 neurons (Dani and Nelson, 2009). Thus, these data suggest there is a relationship
between neural circuits and the RTT phenotype, and that MeCP2 expression is critical for the
proper formation and balance of excitatory and inhibitory synapses. It is possible that miR-137
may therefore alter the synaptic function and connectivity in hippocampal neurons. To determine
if overexpression of miR-137 leads to synaptic deficits similar to those seen in Mecp2-mutant
mice, a retrovirus carrying GFP and miR-137 can be injected into the mouse hippocampus as
described in Smrt et al 2010. Hippocampal slice cultures can be prepared from the brains of these
mice, and whole-cell recordings can be performed in GFP-expressing new dentate granule
neurons. Spontaneous action potential firing can be measured, which has been shown to be
significantly decreased in Mecp2-mutant mice (Dani et al., 2005). In addition spontaneous
excitatory and inhibitory synaptic currents can be measured in these slice cultures, as excitatory
synaptic charge has been found to be decreased and inhibitory synaptic charge has been found to
be decreased in Mecp2-mutant mice (Dani et al., 2005). Quantal release of individual
glutamatergic vesicles can be studied by looking at spontaneous mini excitatory postsynaptic
currents (mEPSCs) and individual GABA vesicles by spontaneous mini inhibitory postsynaptic
currents (mIPSCs), which have also been found to be modestly altered in Mecp2-mutant mice
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(Dani et al., 2005). These studies could help us understand how miR-137 may alter the synaptic
function in hippocampal neurons. However, electrophysiology methods alone may not tell the
complete story. It is possible that miR-137 may be important for the development of excitatory
and inhibitory synapse distribution. The effect of miR-137 on the formation of glutamatergic
synapses can be determined using immunohistochemisty in mouse cultured hippocampal
neurons. To do this, the localization of developmentally-regulated synaptic proteins that are
known to cluster at the synapse can be stained: 1) Excitatory post-synaptic proteins PSD95, and
NMDA and AMPA receptor subunits GluR2 and NR2b, 2) inhibitory synaptic post-synaptic
proteins GABA Receptor A, 3) excitatory pre-synaptic proteins scaffolding protein Bassoon, and
neurotransmitter transporters VGLUT1 and VGLUT2, and 4) the inhibitory pre-synaptic protein
GAD67. This study will determine if altering the expression of miR-137 leads to changes in the
distribution of excitatory and inhibitory synaptic proteins. Overall, these studies will help us to
understand how MeCP2 regulates miRNAs, such as miR-137, may affect synaptic function.
Additionally, these studies may associate the miR-137 pathway as an underlying mechanism that
leads to the mysterious altered balance between excitation and inhibition observed in Rett
syndrome research.

7.4.4 Studying in vivo miRNA functions using mouse genetics
Previously, I take a gain-of-function approach to study the effect of miR-137 on dendritic
and dendritic spine development (Smrt et al., 2010). However, we still don’t know the effect of
knocking out, or reducing miR-137 expression. Thus, a major future direction to my dissertation
research is to further characterize the importance of miR-137 in dendrite and dendritic spine
development. I hypothesize that knocking out miR-137 in vivo, will increase dendritic
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complexity, which is consistent with what I observed previously (Smrt et al., 2010) when I
knocked down miR-137 in vitro. To test this, a novel miR-137 conditional knockout must be
generated. These mice can be used to extrapolate meaningful information on the function of
miR-137 in neurodevelopment. We also don’t know the effects of manipulating miR-137
expression in different brain regions and at specific developmental periods. Because a novel
miR-137 conditional knockout or overexpressing mouse will possess the potential for conditional
loss or gain of miR-137 function, researchers can probe the effect of miR-137 at specific
developmental periods, or within specific brain regions. For example the conditional miR-137
mice could be crossbred with a mouse expressing CRE-ERT2 fusion protein under a
developmentally or tissue specific promoter, such that the effects of gain or loss of miR-137 can
be studied in a subset of cells when CRE-mediated recombination is induced by Tamoxifen
(Lagace et al., 2007). Additionally, conditional miR-137 knockout or overexpressing mice could
be crossbred with Mecp2 mutant mice, and functional or behavioral studies could be performed
without the invasive use of intracranial virus injection surgery. This proposal is one solution to
the limitations of in vitro culture system and in vivo retroviral injection I used in my previous
research.
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APPENDIX A:
SUPPLEMENTAL DATA
miR-137 is upregulated in MeCP2-deficient neurons

Relative miR-137 levels

A

E17 cortical neurons
3

Cortex, 8-week
2.0

Mean ± SEM
n=3
2

1

0

B
Relative miR-137 levels

A.1.

WT

1.5
1.0
0.5
0.0

MeCP2KO

Mean ± SEM
WT, n=2
KO, n=3

WT

MeCP2KO

Goal of the experiment: I have previously shown that MeCP2 deficiency leads to reduced
neuronal maturation in young neurons of postnatal brains; however gene expression analyses
yielded limited information about the potential downstream effector(s) (Smrt et al., 2010). The
goal of these experiments is to determine if miR-137 expression levels is changed in the absence
of MeCP2. To determine whether MeCP2 regulates neuronal maturation through noncoding
miRNAs, our collaborators obtained miRNAs expression profiles in NSC derived from young
adult Mecp2 KO and control littermate mice that were differentiated into neurons for 72 hours. A
subset of miRNAs, such as miR-137, miR-301, and miR-187, etc exhibited showed altered
expression in the absence of Mecp2 compared to WT controls (Szulwach et al., 2010). In these
experiments, I isolated all primary neurons and brain tissues and miR-137 levels were
determined by Keith Szulwach at the Jin lab.
Results: We looked at altered expression of a subset of miRNAs in adult brain tissue from both
wildtype and KO animals. Among the candidate miRNA’s displaying altered expression, miR137 exhibited increased expression in both E17 primary cultures and brain tissue of Mecp2 WT
and KO animals. (Figure A.1 A, B), suggesting that the expression of miR-137 is modulated by
MeCP2.
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A.2.

miR-137 is enriched in the dentate gyrus of the hippocampus
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miR-137/Synapsin

Goal of the experiment: It has been shown that miR-137 is expressed in the brain and enriched
at the synaptic compartment (Siegel et al., 2009; Smalheiser and Lugli, 2009). I rationed that if
miR-137 is a mediator of MeCP2, it should be expressed in neurons in the adult DG of adult
hippocampus which is affected by MeCP2 deficiency (Smrt et al., 2007). The goal of this
experiment is to determine if miR-137 is localized in the adult hippocampus. The brain tissues
were isolated and prepared for ISH by me at UNM. The tissue was then sent to Yale and ISH
was done by our collaborator and co-author Manov. Note that ISH in Figure A.2 was published
in my paper described in chapter 6 (Smrt et al., 2010).
In-situ hybridization: Following transcardial perfusion, brain tissue is equilibrated in 30%
sucrose, then embedded in OCT (Tissue Tek) and frozen in liquid nitrogen-cooled isopentane. 10
µm thick serial cryosections were cut in the sagittal plane on a Leica CM3050S cryomicrotome
and stored at -20C until hybridization could begin. In situ hybridization was carried out as
outlined previously with a few modifications (Obernosterer et al., 2007). Following tissue
processing, slides are air-dried, then fixed in 4% PFA and washed in DEPC-treated PBS. Slides
were then acetylated (590ml DEPC water, 8ml triethanolamine, 1050 µl 37% HCl and 1.5 ml
acetic anhydride), washed in PBS, treated with Proteinase K (5 µg/ml) and washed again. Slides
were then prehybridized (50% formamide, 5X SSC, 5X Denhardt’s, 200µg/ml yeast RNA, 500
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µg/ml salmon sperm DNA, 0.4g Roche blocking reagent and 1.75 ml DEPC water) for 4-8 hours
at RT. For hybridization 0.1 µl of LNA DIG- or FITC-labeled probe was added to the
hybridization buffer (same as prehybdrization buffer but with 500 µl 10% CHAPS, 100 µl 20%
Tween and 1.15ml DEPC water) and applied to the tissue at 50-60C overnight (~20C below the
predicted melting temperature (Tm) of probe:miRNA). Following hybridization, slides were
washed in 5X and 0.2X SSC at 60C, followed by buffer B1 (0.1M Tris pH 7.5/0.15M NaCl) at
RT. Sections were then blocked in 10% FCS in B1 and probed with anti-DIG/FITC-HRP
antibodies as well as anti-synapsin and anti-neurofilament H. Following incubation in primary
antibodies, slides were washed in B1 and then equilibrated in buffer B3 (0.1M Tris pH 9.5/0.1M
NaCl/50Mm MgCl2) for 10 minutes. Developer solution (100mg/ml NBT, 50 mg/ ml BCIP, 24
mg/ml levamisol and 10% Tween in B3) was then added to the tissue for ~4hours RT. The
reaction was stopped with washes in PBT, and sections were then probed with dye-coupled
secondary antibodies. Following final washing steps, slides were mounted in Aquamount and
visualized using confocal microscopy (UNMHSC Fluorescence Microscopy Shared Resource).
Results: Hybridization with the miR-137-specific probe showed an enrichment of miR-137
within the DG and molecular layer of the hippocampus compared to the miR-1, an miRNA that
is expressed at low levels in CNS (Figure A.2 A,B). In the molecular layer, miR-137 expression
is overlap with the expression of the synaptic protein synapsin. This data, along with previous
reports from other labs suggests miR-137 my play a functional role in the connectivity of
neurons in the hippocampus, and may be particularly important for developing neurons in the
hippocampus.

A.3.

Characterization of Mecp2-siRNA

Goal of the experiment: To determine which Mecp2 siRNA is the most effective for knocking
down expression of MeCP2.
Cells: 293 cells were cultured in 6cm dishes, and transfected using a CaCl2 transfection method
which results in ~100% infection efficiency. The cells were collected for protein analysis
(western blot).
DNA constructs: Mecp2 expression vector in pCDNA3 was a gift from Dr Qiang Chang (Univ
Wisconsin Madison), Mecp2 shRNA (co-express eGFP) expression vector was purchased from
SABioscience and one of the four shRNAs was selected based on in vitro efficacy assays.
Results: M1-4 are four constructs purchased from SABiosciences. This data demonstrates M1 is
more effective.
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MeCP2 and mir137 rescue (morphology data)
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Goal of the experiment: I hypothesized that MeCP2-regulated miR-137 modulates neuronal
dendritic development through MIB1. If this is correct, both MeCP2 and MIB1 would be capable
of rescuing the dendritic developmental deficits resulting from miR-137 overexpression. The
rescue of MIB1 has been published and is described in Chapter 6. The rescue by MeCP2 has not
been published and is exclusively described here.
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Methods: The methods for cell culture, transfection, and DNA are described previously (Chapter
6). Mecp2 expression vector in pCDNA3 was a gift from Dr Qiang Chang (Univ Wisconsin
Madison), Mecp2 shRNA (co-express eGFP) expression vector was purchased from
SABioscience and one of the four shRNAs was selected based on in vitro efficacy assays.
Results: First, I demonstrated that overexpression of MeCP2 in neurons led to an increase in
dendritic length of 32% (n = 4, p < 0.01), as well as increased dendritic complexity (F(1,42) =
7.439, p = 0.009) (Figure A.4 A,B), consistent with previous findings (Jugloff et al., 2005).
Next, I explored whether MeCP2 could rescue the miR-137-induced deficits in dendritic
development. To this end, Mecp2 expression plasmid was cotransfected with synthetic miR-137
RNA. My data show that MeCP2 could rescue the miR-137-mediated reduction both in dendritic
length (n = 4, 1% difference between MeCP2+miR137 and control, 33% difference between
MeCP2+miR137 and miR-137) (Figure A.4 A) and in dendritic complexity (F(1,36) = 18.15, p
< 0.001) (Figure A.4 C). Figures D-F are already published and described in Chapter 6.
Finally, I investigated whether MIB1 could rescue MeCP2 deficiency-induced deficits in
dendritic development. To confirm that MeCP2 expression levels were important for dendritic
development in my model system, I knocked down endogenous MeCP2 in cultured neurons
using RNAi (Supplemental Figure S6.6). I found that acute knockdown of MeCP2 led to a 39%
reduction in dendritic length (n = 8, p < 0.0001) and a significant decrease in dendritic
complexity (F(1,37) = 9.707, p = 0.004) in hippocampal neurons compared with control RNAi
(Figure A.4 G, H). I then showed that MIB1 expression could indeed rescue the Mecp2 RNAiinduced reduction both in dendritic length (n = 3, 1% difference between Mib1+RNAi and
control, 38% difference between Mib1+RNAi and Mecp2 RNAi) (Figure A.4 G) and in
dendritic complexity (F(1,36) = 11.83, p = 0.002) (Figure A.4 H).
Thus, my data suggests that miR-137, which is a potential downstream effector of
MeCP2, regulates dendritic morphogenesis in developing neurons, at least in part, by
translational regulation of MIB1 (Figure A.4 I).

A.5.

MeCP2/mir-137 ChIP assay in adult brain and cultured post-mitotic
neurons
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Goal of the experiment: To determine if MeCP2 directly interacts with genomic regions
proximal to miR-137, our collaborators and I performed MeCP2-specific chromatin
immunoprecipitation (ChIP) followed by real-time quantitative PCR across a 7 kb region
surrounding miR-137 that included most of the highly conserved upstream sequences. I isolated
chromatin from mouse brains and primary neurons and sent these samples to collaborator Keith
Szulwach and Peng Jin at Emory to finish ChIP.
Isolation of chromatin from mouse brains or neurons: The ChIP methods are previously
described in a paper I co-authored (Szulwach et al., 2010). For cultured neurons, E17 cortex was
used. For P0-P2 pups, a litter was obtained from a Het Mecp2 mom and chromatin was isolated
from each brain separately. For adult mouse brain, dissected hippocampi and cortex from Mecp2
WT or KO animals were separated and chromatin was isolated. Each animal is considered n=1, a
total of n=3 or greater are presented in the data. Note, the ChIP was performed for all samples
(including both published aNSCs, and unpublished neurons and brain tissue) at the same time.
Results: Immunoprecipitation of chromatin chemically crosslinked to DNA in primary cortical
neurons using two different MeCP2-specific antibodies demonstrated non-significant enrichment
of MeCP2, compared to IgG, in the genomic regions proximal to miR-137 (Figure A.5 A).
Additional ChIP assays were performed on developing brains (Postnatal day 2) and adult brain
regions (hippocampus and cortex), and again found no enrichment of MeCP2 in this genomic
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regions (Figure A.5 B-D). Therefore, increased expression of miR-137 in the absence of MeCP2
may not be due to direct binding of MeCP2 to miR-137.

A.6.

Characterization of neuronal cultures

A.

B.

Goal of the experiment: To determine the characteristics and optimize the conditions of
primary neuronal culture. For example, what is the percentage of neurons with respect to total
cells that make up a standard neuronal culture? At what timepoint is the percentage of neurons
the highest? Finally, does AraC enrich the percentage of neurons? Defining these parameters
enables me to produce an enriched neuronal population which serves as a model system to
conduct extensive biochemical analysis of neurons.
Cells: Cortical neurons from wildtype E15 fetal mice were grown as dispersed mixed cell
cultures, as established by the Wilson lab (Washbourne et al., 2002). Cortical neurons were fixed
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and stained for NeuN (neuronal marker) and dapi (nuclear marker) at 2, 4, 6, and 9 days in
culture. Stereology was used unbiased sampling and quantification of total cell and neuronal cell
counts. For araC treatment, fresh araC was added to the neuron media (10ug/mL) for 48 hours,
then the media was changed to non-araC containing media.
Results: Early timpoints (DIV2) yield the highest percentage of neurons (Figure A.6 A).
Additionally, although araC enriches the neuronal population (Figure A.6 A), it also kills a large
amount of total cells including neurons (Figure A.6 B).
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B.1. ABSTRACT
Mutations and altered expression of the x-linked MeCP2 protein leads to Rett’s syndrome
one of the Autistic Spectrum Disorders (ASDs). MeCP2 deregulation has also been found in
autism. Most RTT patients are females who are mosaic in the MeCP2 deficiency due to random
X Chromosome Inactivation (XCI). Given the critical function of MeCP2 in postnatal brain
development and its clear link to autism, it is important to determine whether MeCP2 mutation
affects XCI. Our data suggests that neurons expressing WT MeCP2 in Mecp2 heterozygote
females have a survival advantage over mutant neurons. To determine whether MeCP2 affects
XCI, we developed a novel Mecp2 mosaic mouse model, in which one X chromosome expresses
WT Mecp2 and also expresses GFP while the mutant X chromosome does not. Due to random
XCI, the female mosaic mice have both WT (GFP+) and mutant (GFP-) Mecp2 neurons that can
be distinguished by GFP fluorescence. To characterize XCI skewing in our newly generated
mouse model, we evaluated the HET mosaic mice at three separate time points: 3 months, 6
months, and 9 months after birth. Using this mouse model, we have determined that MeCP2
deficiency leads to reduced neuronal survival rather than skewed XCI in Mecp2 heterozygote
mice. Given the important function of MeCP2 in postnatal brain development understanding how
Mecp2 mutation affects XCI skewing in neurons will likely provide critical insight in
understanding the etiology of Rett syndrome.
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B.2. INTRODUCTION
ASDs, including autism, Asperger disorder, Rett syndrome (RTT), childhood
disintegrative disorder, and pervasive developmental disorder not otherwise specified, affect one
in 166 children in the US. Among ASDs, only RTT has been clearly linked to a known gene, Xlinked MECP2 gene (Amir et al., 1999). MECP2 mutations and reduced expression of MeCP2
protein have also been found in autistic patients (Samaco et al., 2004). These data suggest that
MeCP2 deficiency not only is responsible for classic RTT, but is also involved in the etiology of
autism. Autism affects more boys than girls, with male to female ratio about 4 to 1 (Volkmar et
al., 1993). This gender difference, together with the discovery of X Chromosome rearrangements
in autistic patients (Ishikawa-Brush et al., 1997; Rao et al., 1994; Thomas et al., 1999) suggests
the involvement of genes on the X Chromosome. It is our premises that by studying the function
of X-linked MeCP2 in neurodevelopment, we will gain critical knowledge in not only RTT but
also the more complex autism.
RTT is primarily caused by mutations in the X-linked MECP2 gene encoding a methyl
CpG binding protein that binds methylated DNA and repress gene transcription. Most RTT
patients are females who are heterozygote and mosaic in the MeCP2 deficiency due to random X
Chromosome inactivation. Mammalian female cells inactivate one of the two X Chromosomes,
and the genes on the inactive X Chromosome, with a few exceptions, are not expressed. X
Chromosome inactivation occurs during early embryonic development, and it is generally
irreversible (Plath et al., 2002). While some studies found skewed X Chromosome inactivation
(one X Chromosome is more active than the other X) in Mecp2 heterozygote females
(Braunschweig et al., 2004; Young and Zoghbi, 2004), another study does not fully support this
notion(Metcalf et al., 2006). Skewed X Chromosome inactivation has been shown in both autism
(Talebizadeh et al., 2005) and X Chromosome linked mental retardation (Plenge et al., 2002).
Given the important function of MeCP2 in postnatal brain development and reduced MeCP2
expression is frequently found in autistic brains (Samaco et al., 2005), it is important to
determine whether MeCP2 mutation affect X Chromosome inactivation pattern and whether
neurons expressing abnormally lower levels of MeCP2 have negative effect on other neurons.
Mecp2 mutant mice have provided valuable models in understanding the function of
MeCP2 in postnatal neuronal development, however most RTT patients are heterozygote females
and male RTT patients generally die in early infancy. In contrast to the dosage compensation
mechanism in Drosophila and C. elegans, mammalian female cells inactivate one of the two X
Chromosomes, and the genes on the inactive X Chromosomes, with a few exceptions, are not
expressed (Plath et al., 2002). X Chromosome inactivation occurs before the completion of
gastrulation during early embryonic development, and it is generally random and irreversible
(Plath et al., 2002). Several groups have shown that both human and mouse Mecp2 heterozygote
females are mosaic in the Mecp2 mutation and exhibit a uniform distribution of mutant cells.
However, there is a preferential inactivation of the mutant allele in more than 60% heterozygote
females, with only 20-40% cells expressing mutant MeCP2 (Braunschweig et al., 2004; Young
and Zoghbi, 2004). The severity of neurological deficits in both human and mice is partially
dependant on the X Chromosome inactivation patterns (Braunschweig et al., 2004; Young and
Zoghbi, 2004). How do heterozygote brains with more than half of their neurons expressing
functional MeCP2 have such severe neurological deficits? Young et al has demonstrated that
there is a survival advantage for neurons expressing the wild type Mecp2 allele compared to
those expressing the mutant allele, suggesting that the skewed ratio of mutant Mecp2 expressing
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neurons versus wild type Mecp2 expressing neurons could be due to the survival disadvantage of
mutant neurons (Young and Zoghbi, 2004). However, the problem is further complicated by the
findings that first, no significant neuronal death has been found in RTT brains (Armstrong,
2002), and second, in RTT patients or Mecp2 mutant mice, MeCP2 protein expression levels in
wild type Mecp2 expressing neurons are lower than that of wild type cells of normal brains
(Braunschweig et al., 2004). These observations suggest that MeCP2 mutation in heterozygote
females not only affects the development of neurons expressing the mutant allele but also
neurons expressing the wild type allele. Given the important function of MeCP2 in postnatal
brain development and reduced MeCP2 expression is frequently found in autistic brains (Samaco
et al., 2005), it is important to determine whether MeCP2 mutation affects X Chromosome
inactivation patterns and whether neurons expressing abnormally lower levels of MeCP2 have a
negative effect on other neurons. Our MeCP2 heterozygote females containing both normal and
mutated neurons in the same brains provide a unique model for us to understand how neuronneuron interactions regulate neuronal maturation and brain function. Neuronal maturation is a
complex process that is regulated by many genetic and epigenetic factors and is significantly
influenced by inter-cellular signaling between neurons and between neurons and glia (Waites et
al., 2005; Webb et al., 2001). It is during this major postnatal maturation period that RTT
manifests itself. Recent studies suggest that RTT may result from a defect in synaptogenesis
(Belichenko et al., 1997b; Cohen et al., 2003; Kishi and Macklis, 2004; Matarazzo et al., 2004).
MeCP2 expression is correlated with neuronal maturation, with an increase in protein levels
immediately before and during synapse formation and reaching its highest level in mature
neurons (Balmer et al., 2003; Jung et al., 2003; Shahbazian et al., 2002b). Both RTT patients and
Mecp2 mutant mice have excess immature neurons in the olfactory epithelium, and reduced
transition of immature neurons into mature neurons (Matarazzo et al., 2004). RTT patients have
underdeveloped neuronal axons and dendrites (Armstrong, 1997; Armstrong et al., 1995;
Kaufmann et al., 1997). Using retrovirus-based in vivo neuron labeling, we have demonstrated
that newly matured neurons in Mecp2 mutant mice develop fewer synaptic spines (Smrt et al.,
2007). Since each neuron interacts with many other neurons, intercellular signaling, including
neuron-neuron and neuron-glia interaction, is critical for both development and function (Waites
et al., 2005; Webb et al., 2001). To date, most MeCP2 studies focus on the intrinsic properties of
MeCP2 in cells. In order to have a complete picture of how postnatal neural development is
regulated by MeCP2, it is critical and essential to know whether and how Mecp2 mutation affects
the function of surrounding wt-Mecp2 expressing neurons that share the microenvironment
and/or form interactions with mutant neurons in a mosaic Mecp2 system.
In this study, we show no difference in the percentage of MeCP2 expressing neurons at 3
months after birth. However at 6 and 9 months, the percentage of MeCP2/GFP positive neurons
is significantly altered in the experimental mosaic mouse compared to the GFP control female
mouse.

B.3. MATERIALS AND METHODS
Animals
All animal procedures were performed according to protocols approved by the University
of New Mexico Animal Care and Use Committee. The Mecp2 KO mice (Mecp2tm1.1Jae) used in
this study were created by deleting exons 3 containing the MBD domain of Mecp2 (Chen et al.,
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2001b). These mice have been bred over 40 generations on to ICR background. They start to
show neurological symptoms between 5 and 7 weeks of age and die before 10 weeks of age. The
mosaic mouse line was created by cross breeding Tg-GFPx mice from the Jackson labs with
Mecp2+/- female mice. By crossing the WT male (Tg-GFP+/Mecp2+) with a Mecp2 heterozygous
female (Mecp2+/-), some of the female mosaic offspring will be heterozygous for GFP and
MeCP2 (Tg-GFP+/-/Mecp2+/-). Specifically, these mosaic offspring express the WT Mecp2 gene
and Gfp on one x-chromosome and no Gfp and no Mecp2 on the other (See Figure B.1A). For
histological analyses, mice were euthanized by intraperitoneal injection of sodium pentobarbital.
Mice were then perfused with saline followed by 4% PFA. Brains were dissected out, post-fixed
overnight in 4% PFA, and then equilibrated in 30% sucrose. Forty-micrometer brain sections
were generated.

A

B

% of dentate gyrus GFP+ cells
in GFPX HET female mouse

% of total

100
75
50
25
0

GFP+ cells

Figure B.1. Breeding strategy and quantification of GFP+ cells. A. Breeding diagram showing how the mosaic
mouse model is generated. B. 50% of cells express GFP in the dentate gyrus of the hippocampus in this X-linked
GFP mouse model. To quantify, roughly 100 cells from a single z-plane (n=4) were analyzed for GFP
expression using ImageJ software. A One-sample t-test confirms the actual mean (47.35 +/- 2.33, P=0.32) is not
different from the expected mean of 50%.

Immunohistochemistry:
Immunostaining was conducted according to previous works (Barkho et al., 2008; Silber
et al., 2008; Smrt et al., 2007; Zhao et al., 2003). Mouse Neun (Chemicon 1:5000) and MeCP2
Chicken (Emory, 1:5000). The secondary antibodies used were AF488 (Molecular Probes,
1:500) to amplify the endogenous GFP, Cy3 (donkey anti-mouse, 1:500, Sigma), and Mouse
AF647 (Molecular Probes, 1:500). After the primary and secondary antibodies were rinsed the
sections were then stained with Dapi and mounted on glass slides using DABCO for
coverslipping. The DABCO helps to prevent fading from microscope exposure.
Confocal microscopy and quantification:
Images of brain sections were taken using a 63x/1.4 Oil DIC Plan-apochronial lens (Zeiss
LSM510META Confocal Microscope). The proportions of GFP/MeCP2expressing neurons
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were counted using the computer program Metamorph. The images obtained from confocal
microscopy were merged and 3 concurrent frames were chosen based upon image quality. These
3 frames were then stamped with a 600x600 box. The number of Neun+ cells were then counted
and recorded followed by the total number of GFP expressing cells. The counts were done as
previously described (Zhao et al. 2003).
Statistical analysis
All statistical analyses were performed using unpaired, two-tailed, Student’s t-test. The
data bars and error bars indicate mean ± standard error mean. (s.e.m).

B.4. RESULTS
GFP+/- control mice express GFP in 50% of cells in the hippocampus
To determine if female Tg-GFPx mice, which are heterozygous for the X-linked GFP
gene, can faithfully demonstrate random X-Chromosome inactivation in neurons, we quantified
the percentage of GFP expressing neurons. Specifically, expression of GFP in neurons was
determined by counting the number of neurons that are GFP-positive (GFP+NeuN+) over the
total number of neurons (NeuN+) in the dentate gyrus. We show that approximately 50% of
neurons express GFP in the dentate gyrus of the hippocampus in this X-linked GFP mouse model
(Figure B.1B). This data suggests that control heterozygous Tg-GFPx mice in our model undergo
random X-Chromosome inactivation in the hippocampus, consistent with previous data that was
conducted in other anatomical regions (Hadjantonakis Non-invasive sexing of preimplantation
stage mammalian embryos 1998).
To determine if our control GFP mosaic female (Tg-GFP+/-/Mecp2+/+) mice expressed
GFP in neurons and astrocytes of the cortex and hippocampus, we stained brain tissue sections
with antibodies against early and late neuronal markers, and astrocytes. Using confocal
microscopy, we found that brain tissue was mosaic for GFP expression, and that all three
markers could be found to be colocalized with GFP (Figure B.2 A-C)
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Figure B.2. Tissue staining showing the co-localization of GFP with other astrocytic/neuronal markers in the
brain. A. GFP+ neuron colocalized with NeuN in the cortex. B. GFP+ early neuron colocalized with DCX in the
hippocampus. C. GFP+ cell colocalized with S100B in the hippocampus.

GFP-positive neurons express MeCP2 in the Mecp2 mosaic mouse model
To determine if neurons in the Mecp2+/- mice have a survival deficit, we generated a
novel Mecp2 mouse model by crossing a Mecp2+/- female with a Tg-GFPx male mouse (Figure
B.1A). The resulting progeny include males which are Mecp2 WT or Mecp2 KO, females which
are Gfp+/- and Mecp2+/+ (Tg-GFP+/-/Mecp2+/+: used as controls), and females which are GFP+/and Mecp2+/- (Tg-GFP+/-/Mecp2+/-) experimental condition, also referred to in this paper as the
“mosaic mouse model”). The expression of GFP in all the female progeny is mosaic, in which
cells expressing GFP indicate that the active X-chromosome contains the Gfp gene. Cells that are
negative for GFP indicate the X-chromosome containing GFP is silenced. In the Tg-GFP+//Mecp2+/- mosaic mice, the GFP protein expression is found to be linked to wild-type MeCP2 in
all neurons of the dentate gyrus (Figure B.3B-C). These results indicate that wild-type MeCP2
and GFP are located on the same X-chromosome in the mosaic model and GFP is consistently
expressed in conjunction with MeCP2 in adult animals. This design allows us to genotype
MeCP2 expressing cells through GFP fluorescence.
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Figure B.3. Tissue staining showing the colocalization of MeCP2 and GFP in the dendate gyrus (DG) of the
hippocampus. A. Illustration showing a representative coronal section of the mouse brain. The location of the
DG is indicated by a square. B. Comparison of the mosaic mouse (GFPX/MeCP2) and the control (TgGFPX).
Arrowhead: Cells positive for both MeCP2 and GFP. Arrow: Cells negative for MeCP2 and GFP. C.
Quantification of cells colocalized with MeCP2 and GFP in the mosaic mouse and the TgGFPX control. In the
mosaic mouse, it is expected that all MeCP2+ cells are also GFP+.
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MeCP2 expression varies in heterozygous neurons over time
In order to characterize XCI skewing in our newly generated mouse model, we evaluated
the HET mosaic mice at three separate time points: 3 months, 6 months, and 9 months after birth.
At 3 months, our data show that the percentage of neurons expressing both MeCP2 and GFP in
the hippocampus are the same for both the GFP+/-/Mecp2+/- mosaic mice and the GFP+/-/Mecp2+/+
control mice (Figure B.4A). At 6 months, the percentage of neurons expressing both MeCP2 and
GFP has significantly decreased in the experimental mosaic mouse compared to the GFP control
female mouse (Figure B.4B). However at 9 months, the overall MeCP2/GFP positive neurons is
significantly higher in the experimental mosaic mouse than in the GFP control female mouse
(Figure B.4C).
To extend our characterization of XCI skewing in the brain, we next looked in the cortex
of our mosaic mouse model. At 3, 6, and 9 months, there is no significant difference in the
number of GFP/MeCP2 positive neurons between the experimental and control conditions
(Figure B.4D-F). These data suggest that there is genetic skewing in the hippocampus of the
MeCP2 mosaic mice that favor to the WT allele at late adult developmental time points;
however, there is no effect of X-chromosome skewing in the cortex.
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Figure B.4. Quantification of the percentage of GFP+ neurons in the hippocampus and cortex. A-C. The
percentage of GFP+ neurons in the hippocampus relative to the total number of neurons analyzed. D-F. The
percentage of GFP+ neurons in the cortex relative to the total number of neurons analyzed. G. A color line graph
describing the same data shown in A-F.

Survival of neurons in TgGFP-X/Mecp2 mosaic mice is not affected by GFP expression
To confirm GFP alone does not play a role in the genetic skewing, we observe the
hippocampus at the later time points, we found that the number of GFP/MeCP2 positive neurons
in the experimental mosaic mouse model are no different than the number of MeCP2 positive
neurons in Mecp2 heterozygous female mice that do not co-express GFP (Figures B.5A,B). This
suggests that XCI in the adult Mecp2 mosaic mouse is similar to the traditional non-GFP
expressing Mecp2 heterozygous mice.
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Figure B.5. Comparison of GFP+ and GFP- Mecp2 heterozygous mice. A. The percentage of GFP+ neurons (for
Mecp2+/+/TgGFP+/- and Mecp2+/-/TgGFP+/-) and MeCP2+ neurons (for Mecp2+/+/TgGFP-/-) in the hippocampus of
3mo old mice relative to the total number of neurons analyzed. B. The percentage of GFP+ neurons (for
Mecp2+/+/TgGFP+/- and Mecp2+/-/TgGFP+/-) and MeCP2+ neurons (for Mecp2+/+/TgGFP-/-) in the hippocampus of
6mo old mice relative to the total number of neurons analyzed

B.5. DISCUSSION
By the creation and analysis of a novel mosaic mouse, we have discovered that Xchromosome inactivation is skewed in favor of the normal Mecp2 allele over time. However,
our data found from our three month time point suggests that skewing does not take place during
the primary X-chromosome inactivation early in the mouse female’s development. The fact that
the level of skewing is actually in favor of the mutant allele at the 6 month time point indicated
that the mutant MeCP2 expressing neurons may have a negative effect on their WT neighbors,
though overtime this is corrected by a higher proliferation of the WT neurons. At the 9 month
time point however there was a significantly higher proportion of WT neurons in the
hippocampus, suggesting there is skewing occurring in the hippocampus, which is consistent
with previous reports of XCI in Mecp2 hereozygous females (Braunschweig et al., 2004).
Studies using Mecp2 mutant mice have greatly advanced our knowledge of RTT
pathogenesis, however, most RTT patients are heterozygous females and are mosaic for the
MeCP2 mutation. Mecp2 mosaic female mice, containing neurons both with and without
mutation of MeCP2, can be distinguished by GFP fluorescence (Fig B.3), providing a unique
model to study how neuron-neuron interactions regulate neuronal maturation and function, and
how deficits of a subpopulation of neurons may contribute to autism spectrum disorders. We
anticipate the results of this study will set the stage for further mechanistic investigations that
will significantly sharpen our understanding of the pathogenesis of RTT. For example, if
mutations in Mecp2 affect the development and function of wild type MeCP2 expressing neurons
in the same brain region, blocking the negative effects of mutant neurons on wild type MeCP2
expressing neurons or supplying wild type neurons with the factors that are limited in
heterozygote brains may ultimately lead to stopping or reversing the progression of neurological
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deficits in RTT females. In summary, X-chromosome skewing may play an important role in the
severity presented by Rett syndrome patients. Therefore better understanding of XCI in Rett
Syndrome may provide valuable insight into the development of the hippocampus and provide
researchers with answers for the cognitive pathogenesis of RTT.
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